

# CITATION REPORT

List of articles citing

## Effects of intensive glucose lowering in type 2 diabetes

DOI: 10.1056/nejmoa0802743

New England Journal of Medicine, 2008, 358, 2545-59.

**Source:** <https://exaly.com/paper-pdf/43951825/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2273	Study Design. 16-17		
2272	Drugs used in diabetes mellitus. 83-92		
2271	REVIEWS. <b>2001</b> , XLVI, 151-152		
2270	Hopes, disillusion and more hopes from vitamin C. <b>2004</b> , 61, 209-19		60
2269	The ABC transporter structure and mechanism: perspectives on recent research. <b>2004</b> , 61, 682-99		406
2268	Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage. <b>2008</b> , 9, 275-87		22
2267	HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. <b>2008</b> , 51, 2197-204		60
2266	Differenzierte Insulintherapie des Typ-2-Diabetes. <b>2008</b> , 4, 516-524		2
2265	Führt eine normoglykämische Einstellung zu einer erhöhten kardiovaskulären Mortalität?. <b>2008</b> , 4, 448-450		
2264	Rosiglitazone and cardiovascular risk. <b>2008</b> , 10, 398-404		8
2263	Does the method of obtaining glycemic control influence cardiovascular outcomes?. <b>2008</b> , 8, 341-4		
2262	Cardiometabolic risk management in type 2 diabetes and obesity. <b>2008</b> , 8, 345-52		6
2261	Practical strategies to normalize hyperglycemia without undue hypoglycemia in type 2 diabetes mellitus. <b>2008</b> , 8, 375-82		2
2260	Management of type 2 diabetes in patients with heart failure. <b>2008</b> , 10, 465-75		5
2259	Diabetes in the elderly. <b>2008</b> , 2, 382-389		1
2258	Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen. <b>2008</b> , 2, 417-429		
2257	Improved survival in both men and women with diabetes between 1980 and 2004--a cohort study in Sweden. <b>2008</b> , 7, 32		37

2256	Institute of Diabetes for Older People: surviving a sweet old age. <b>2008</b> , 25, 221-222	1
2255	Advances in diabetes care?. <b>2008</b> , 25, 258-260	1
2254	What's new for the DPP-4 inhibitors?. <b>2008</b> , 25, 342-344	
2253	Newer agents for blood glucose control in type 2 diabetes: the NICE draft proposals. <b>2008</b> , 25, 353-354	
2252	A sweet summer for drug-eluting stents in patients with diabetes mellitus. <b>2008</b> , 72, 610-1	
2251	The cardiovascular safety of rosiglitazone. <b>2008</b> , 7, 367-76	26
2250	NICE and type 2 diabetes – does the pinky get their vote?. <b>2008</b> , 19, 6-8	
2249	SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. <b>2008</b> , 10, 1128-9; author reply 1129-30	12
2248	Impact of the UKPDS--an overview. <b>2008</b> , 25 Suppl 2, 2-8	23
2247	Estimated average glucose (eAG): fit for purpose?. <b>2008</b> , 25, 899-901	3
2246	Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. <b>2008</b> , 25, 1295-301	62
2245	Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT). <b>2008</b> , 66, 169-72	0
2244	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <b>2008</b> , 102, 1K-34K	280
2243	Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management. <b>2008</b> , 9, S8-S16	7
2242	Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS. <b>2008</b> , 11, 230-6	2
2241	ASH position paper: treatment of hypertension in patients with diabetes-an update. <b>2008</b> , 10, 707-13; discussion 714-5	43
2240	The glycemia-cardiovascular disease hypothesis. <b>2008</b> , 1, 185-6	
2239	Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. <b>2008</b> , 10, 419-39	96

2238	New drugs for type 2 diabetes mellitus: what is their place in therapy?. <b>2008</b> , 68, 2131-62		82
2237	Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. <b>2008</b> , 68, 2387-409		41
2236	Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study. <b>2008</b> , 28, 501-7		11
2235	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2560-72	59.2	5250
2234	10-year follow-up of intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1577-89	59.2	5246
2233	Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?. <b>2008</b> , 52, 2206-9		22
2232	Silent myocardial ischaemia. To screen or not to screen? That is. <b>2008</b> , 101, 509-11		2
2231	Stroke prevention: modifying risk factors. <b>2008</b> , 2, 287-303		70
2230	Contrôler lâHyperglycémie basale et postprandiale pour rduire le risque cardiovasculaire : comment et jusquâà?. <b>2008</b> , 2, S142-S148		
2229	Insulinothérapie, poids, composition corporelle. <b>2008</b> , 2, S189-S193		1
2228	Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. <b>2008</b> , 83, 1373-1381		37
2227	Treatment of hyperlipidaemia with fenofibrate and related fibrates. <b>2008</b> , 17, 1599-614		45
2226	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. <b>2008</b> , 156, 1074-9		17
2225	Does HbA1c represent a valid index for tight control of glucose in type 1 diabetes?. <b>2008</b> , 82, e23-4		3
2224	Shopping for basal insulin on the coffee aisle: Lots of choices for lots of tastes. <b>2008</b> , 3, 146-149		
2223	The ever-expanding universe. <b>2008</b> , 3, 204-207		
2222	LâInsulinothérapie du diabétique de type 2: quelques points ^retenir?. <b>2008</b> , 2, S209-S212		
2221	Insulinothérapie chez le sujet g. <b>2008</b> , 2, S168-S172		1

2220	Insulinothérapie et prévention des complications cardiovasculaires : quel rationnel?. <b>2008</b> , 2, S204-S208	
2219	Plaidoyer pour l'insuline basale dans le traitement du diabète de type 2. <b>2008</b> , 2, S153-S157	
2218	Intensification de l'insulinothérapie quand l'insuline basale ne suffit plus dans le diabète de type 2 : la stratégie Basal Plus. <b>2008</b> , 2, S158-S163	1
2217	Prise en charge d'une hyperglycémie au cours d'un infarctus du myocarde. <b>2008</b> , 2008, 26-28	
2216	Diabetes as a 'cardiovascular disease equivalent': implications for treatment. <b>2008</b> , 5, 682-3	5
2215	The role of incretins in glucose homeostasis and diabetes treatment. <b>2008</b> , 60, 470-512	552
2214	Approach to the patient with prediabetes. <b>2008</b> , 93, 3259-65	52
2213	Tight glycaemic control in the intensive care unit: pitfalls in the testing of the concept. <b>2008</b> , 12, 187	3
2212	Does carbamylated hemoglobin still affect the analysis of HbA(1c) in uremic and hyperglycemic patients?. <b>2008</b> , 46, 1791-2	8
2211	Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. <b>2008</b> , 300, 2180-1	10
2210	Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. <b>2009</b> , 95, 1-3	5
2209	Opportunities for enhancing the FDA guidance on pharmacovigilance. <b>2008</b> , 300, 952-4	11
2208	The conflict between complex systems and reductionism. <b>2008</b> , 300, 1580-1	64
2207	Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. <b>2008</b> , 300, 2134-41	554
2206	The Paradox of Glycemic Control and Cardiovascular Complications: Sorting Out the Data. <b>2008</b> , 21, 150-152	1
2205	Minimizing hypoglycemia while maintaining glycemic control in diabetes. <b>2008</b> , 57, 3177-83	31
2204	Glycemic management of type 2 diabetes: how tight is right and how to get there. <b>2008</b> , 168, 2064-6	7
2203	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. <b>2008</b> , 179, 920-6	30

2202	Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. <b>2008</b> , 9, 2857-65		6
2201	Echocardiographic epidemiology—an emerging tool for early diagnosis, studying pathophysiology, predicting prognosis, and testing treatments. <b>2009</b> , 30, 642-4		
2200	National trends in treatment of type 2 diabetes mellitus, 1994-2007. <b>2008</b> , 168, 2088-94		170
2199	Redefining quality—implications of recent clinical trials. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2537-92	59.2	62
2198	The barrier of hypoglycemia in diabetes. <b>2008</b> , 57, 3169-76		512
2197	Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. <b>2008</b> , 21, 177-189		8
2196	Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. <b>2008</b> , 31, 1672-8		176
2195	Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. <b>2008</b> , 31, 2294-300		24
2194	Intensive glycemic control in the ACCORD and ADVANCE trials. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2630-3	59.2	292
2193	The safety of rosiglitazone in the treatment of type 2 diabetes. <b>2008</b> , 7, 579-85		15
2192	Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. <b>2008</b> , 300, 2742-53		278
2191	Glycaemic memory. <b>2008</b> , 8, 242-247		11
2190	Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?. <b>2008</b> , 300, 2051-3		15
2189	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <b>2008</b> , 5, 319-35		192
2188	Glycemic control in diabetes: a tale of three studies. <b>2008</b> , 31, 1913-9		37
2187	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. <b>2008</b> , 5, 216-8		35
2186	UKPDS and the legacy effect. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1618-20	59.2	175
2185	Intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1519; author reply 1520-1	59.2	4

2184	Glycemic targets and cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2633-5	59.2	58
2183	Assessing the cardiovascular safety of diabetes therapies. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1092-5	59.2	88
2182	Wo stehen wir? âBlutzuckersenkung zur Reduktion des kardiovaskulären Risikos. <b>2008</b> , 6, 105-112		
2181	Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. <b>2008</b> , 24, 2651-61		17
2180	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. <b>2008</b> , 24, 3009-22		9
2179	The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. <b>2008</b> , 17, 250-9		5
2178	Intensive Control of Blood Sugar (HbA1c 2008, 100, 1249-1250		
2177	Whither 'Rational' Use of Drugs?. <b>2008</b> , 38, 89-91		4
2176	Keeping up with the Evidence, Trials and Journals. <b>2008</b> , 38, 91-91		
2175	Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. <b>2008</b> , 149, 549-59		65
2174	Children's Commissioner. <b>2008</b> , 58, 729		
2173	Managing hyperglycaemia. <b>2008</b> , 58, 729; authore reply 729-30		
2172	Normalization of glucose in the intensive care unit: does one size really fit all?. <b>2008</b> , 36, 2448-9		5
2171	Therapy and clinical trials: glycaemia and prevention of macroangiopathy in type 2 diabetes. <b>2008</b> , 19, 629-30		
2170	Treating diabetes in the elderly: what is the impact for cardiovascular health?. <b>2008</b> , 4, 333-335		
2169	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. <b>2008</b> , 23, 502-11		36
2168	Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. <b>2008</b> , 26, 2096-100		2
2167	Does tight glycemic control increase the risk of death?. <b>2008</b> , 108, 31		

2166	Does Tight Glycemic Control Increase the Risk of Death?. <b>2008</b> , 108, 31	
2165	. <b>2008</b> ,	
2164	Mission: halt diabetes momentum and stop growing epidemic. <b>2008</b> , 121, 2115-2118	0
2163	Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes. <b>2008</b> , 58, 531-3	5
2162	Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. <b>2008</b> , 14, 639-43	6
2161	Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. <b>2008</b> ,	
2160	Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. <b>2008</b> , 58, 405-11	10
2159	Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent studies of intensive glycemic control. <b>2008</b> , 14, 791-5	2
2158	Intensive Glycemic Control and Macrovascular Disease in Type 2 Diabetes - A Report on the 44th Annual EASD Meeting, Rome, Italy, September 2008. <b>2008</b> , 5, 180-3	3
2157	Does Intensive Glycemic Control Reduce Cardiovascular Complications in Type 2 Diabetes?. <b>2008</b> , 43, 705-708	
2156	Contemporary management of type 2 diabetes: blood glucose-lowering therapies and glycaemic targets. <b>2008</b> , 189, 246-8	0
2155	Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. <b>2009</b> , 191, 339-44	51
2154	Low drug doses may improve outcomes in chronic disease. <b>2009</b> , 191, 511-3	15
2153	Insulin glulisine in the management of diabetes. <b>2009</b> , Volume 2, 111-115	2
2152	Risk management in the treatment of type 2 diabetes with pioglitazone. <b>2009</b> , Volume 2, 51-60	
2151	Safety and efficacy of rosiglitazone in the elderly diabetic patient. <b>2009</b> , 5, 389-95	12
2150	ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes. <b>2009</b> , 150, JC3-8	
2149	Still looking for health outcomes in all the wrong places? Misinterpreted observational evidence, medication adherence promotion, and value-based insurance design. <b>2009</b> , 15, 501-7	6



2148	[Glycemic control in type 2 diabetic patients in public and private healthcare service]. <b>2009</b> , 53, 733-40	10
2147	Doen arterial coronria e diabetes: do tratamento farmacolgico aos procedimentos de revasculariza. <b>2009</b> , 17, 398-413	3
2146	Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. <b>2009</b> , 5, 683-98	9
2145	Contrle glycmique intensif et ´diabte de ´type 2 : rsultats des tudes dintervention rcentes (ADVANCE, VA Diabetes Trial et ´ACCORD). <b>2009</b> , 21, 015-022	
2144	ACP Journal Club. What does it take to put an ugly fact through the heart of a beautiful hypothesis?. <b>2009</b> , 150, JC3-2, JC3-3	11
2143	Fixed combination of repaglinide and metformin in the management of type 2 diabetes. <b>2009</b> , Volume 2, 101-109	4
2142	Redefining the role of thiazolidinediones in the management of type 2 diabetes. <b>2009</b> , 5, 141-51	42
2141	Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. <b>2009</b> , 1, CMT.S2370	
2140	Nonadherence, clinical inertia, or therapeutic inertia?. <b>2009</b> , 15, 690-5	36
2139	Common risk factors and prevention. 89-104	
2138	Editorial: What have we lost in the wake of the rosiglitazone controversy?. <b>2009</b> , 15, 273-4	
2137	Economic and clinical impact of inpatient diabetic hypoglycemia. <b>2009</b> , 15, 302-12	59
2136	[Type 2 diabetes among elderly people]. <b>2009</b> , 66, 707-11	1
2135	[Management of ischemic heart disease in the elderly]. <b>2009</b> , 46, 391-4	1
2134	Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. <b>2009</b> , 5, 859-71	22
2133	[Macrovascular diabetic complications: clinical characteristics, diagnosis and management]. <b>2009</b> , 53, 698-708	7
2132	Diabte de ´type 2: prise en ´charge efficace du ´risque vasculaire. <b>2009</b> , 21, 409-415	
2131	The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. <b>2009</b> , 4, e4412	50

2130	Rosiglitazone and myocardial infarction in patients previously prescribed metformin. <b>2009</b> , 4, e6080	16
2129	Controle glicêmico em terapia intensiva 2009: sem sustos e sem surpresas. <b>2009</b> , 21,	0
2128	Secondary prevention. 272-282	
2127	The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. <b>2009</b> , 6, 6-12	21
2126	Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review. <b>2009</b> , 5, 225-31	
2125	. <b>2009</b> ,	6
2124	Type 2 diabetes: lifestyle changes and drug treatment. <b>2009</b> , 11, 237-41	2
2123	Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. <b>2009</b> , 25, 65-75	73
2122	Addressing the need to tailor treatment to the spectrum of type 2 diabetes: new perspectives. <b>2009</b> , 11, 267-74	1
2121	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. <b>2009</b> , 25, 2631-41	16
2120	Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. <b>2009</b> , 32, 1880-6	193
2119	Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status. <b>2009</b> , 27, 147-148	1
2118	Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé. <b>2009</b> , 7, 79-81	1
2117	The prescription of insulin pen devices versus syringes for older people with diabetes. <b>2009</b> , 11, 439-42	12
2116	DURABILITY of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. <b>2009</b> , 32, 1007-13	103
2115	Rosiglitazone in Canada: experience in clinical practice. <b>2009</b> , 5, 441-8	1
2114	Toward optimal health: current approaches to standards of care for diabetes in women. Interview by Jodi R. Godfrey. <b>2009</b> , 18, 605-10	
2113	A randomized trial of therapies for type 2 diabetes and coronary artery disease. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2503-15	59.2 1304

2112	Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. <b>2009</b> , 120, 212-20	189
2111	Shifting the disease management paradigm from glucose: what are the cons?. <b>2009</b> , 32 Suppl 2, S353-6	
2110	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Woo and Eizirik. <b>2009</b> , 32, e37-e38	4
2109	The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. <b>2009</b> , 3, 3-11	34
2108	Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. <b>2009</b> , 3, 743-7	24
2107	C. elegans as model for the study of high glucose- mediated life span reduction. <b>2009</b> , 58, 2450-6	206
2106	Mortality and glycemic targets in the intensive care unit: another paradigm shift?. <b>2009</b> , 58, 1469-70	3
2105	Changing the treatment paradigm for type 2 diabetes. <b>2009</b> , 32 Suppl 2, S217-22	27
2104	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <b>2009</b> , 32, 187-92	500
2103	Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. <b>2009</b> , 24, 2866-71	80
2102	Fetuses of obese mothers develop insulin resistance in utero. <b>2009</b> , 32, 1076-80	481
2101	Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. <b>2009</b> , 7, 1349-61	12
2100	Hypertension and diabetes: should we treat early surrogates? What are the cons?. <b>2009</b> , 32 Suppl 2, S290-3	2
2099	Oxford International Programme in Evidence-Based Health Care. <b>2009</b> , 14, 69-69	7
2098	A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial. <b>2009</b> , 11 Suppl 2, S53-61	5
2097	Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): dilemmas in clinical practice. <b>2009</b> , 32 Suppl 2, S149-50	1
2096	Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. <b>2009</b> , 32, 1237-43	100
2095	Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. <b>2009</b> , 22, 46-51	128

2094	Antidiabetic agents and cardiovascular risk in type 2 diabetes. <b>2009</b> , 5, 500-6	20
2093	Blood glucose in acute stroke. <b>2009</b> , 9, 409-19	11
2092	Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months. <b>2009</b> , 11, 427-30	13
2091	Personalized pharmacotherapy for Type 2 diabetes mellitus. <b>2009</b> , 6, 417-422	10
2090	Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes. <b>2009</b> , 25, 24-36	
2089	Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target?. <b>2009</b> , 94, 3163-70	196
2088	Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. <b>2009</b> , 32, 221-6	314
2087	Defining the importance of daily glycemic control and implications for type 2 diabetes management. <b>2009</b> , 121, 82-93	11
2086	Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes. <b>2009</b> , 9, 44-52	2
2085	Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). <b>2009</b> , 32, 971-6	61
2084	The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. <b>2009</b> , 6, 53-5	26
2083	Disruption of the Nitric Oxide Signaling System in Diabetes. <b>2009</b> , 35-59	
2082	Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting. <b>2009</b> , 22, 241-246	18
2081	New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. <b>2009</b> , 35, 731-4, 738-40, 742-4 passim	7
2080	Recent clinical trials in diabetes – implications for managing older patients. <b>2009</b> , 19, 25-33	
2079	The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. <b>2009</b> , 120, 2529-40	198
2078	Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. <b>2009</b> , 6, 7-14	62
2077	Progress in diabetes research--what's next. <b>2009</b> , 301, 1599-601	7

2076	Transparency standards for diabetes performance measures. <b>2009</b> , 301, 210-2	14
2075	Variation in event rates in trials of patients with type 2 diabetes. <b>2009</b> , 302, 1698-700	9
2074	Does strict glucose control improve outcome?. <b>2009</b> , 103, 331-4	4
2073	Initiating and Titrating Insulin in Patients With Type 2 Diabetes. <b>2009</b> , 27, 72-76	7
2072	Insulin therapy for type 2 diabetes. <b>2009</b> , 32 Suppl 2, S253-9	105
2071	Coronary artery calcium: a clue to the enigma of tight glycemic control and cardiovascular disease?. <b>2009</b> , 58, 2448-9	2
2070	Intensive insulin therapy in the intensive care unit. <b>2009</b> , 180, 799-800	37
2069	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <b>2009</b> , 119, 351-7	265
2068	Is quality of care only instrumental?. <b>2009</b> , 169, 417-8; author reply 418	
2067	Is Quality of Care Only Instrumental?âReply. <b>2009</b> , 169, 415	
2066	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. <b>2009</b> , 6, 283-7	12
2065	Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. <b>2009</b> , 7, 541-9	6
2064	The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. <b>2009</b> , 169, 150-4	25
2063	Reply: Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective. <b>2009</b> , 43, 392-393	
2062	Erratum. <b>2009</b> , 9, 97-97	
2061	Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. <b>2009</b> , 9, 177-185	1
2060	Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. <b>2009</b> , 3, 964-70	36
2059	An overview of preoperative glucose evaluation, management, and perioperative impact. <b>2009</b> , 3, 1261-9	30

2058	Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. <b>2009</b> , 58, 2642-8	136
2057	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al. <b>2009</b> , 32, e34; author reply e35-6	8
2056	Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al. <b>2009</b> , 32, e90-1; author reply e92-3	12
2055	Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. <b>2009</b> , 32 Suppl 2, S322-5	42
2054	A summary of the ADVANCE Trial. <b>2009</b> , 32 Suppl 2, S357-61	66
2053	U-500 Insulin: When More With Less Yields Success. <b>2009</b> , 22, 116-122	13
2052	The EASD/ADA consensus: trick or treat?. <b>2009</b> , 6, 5-6	1
2051	Update of secondary stroke prevention. <b>2009</b> , 24, 1718-24	10
2050	Pregnancy glycaemia to vascular risk: nonglycaemic diabetes?. <b>2009</b> , 181, 361-2	
2049	Dysglycaemia and cardiovascular risk in the general population. <b>2009</b> , 119, 773-5	18
2048	Diabetes: vascular or neurodegenerative: an epidemiologic perspective. <b>2009</b> , 40, S53-5	24
2047	Tight glycaemic control and cardiovascular disease in type 2 diabetes. <b>2009</b> , 70, 31-2, 34	
2046	Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. <b>2009</b> , 11, E4-E8	1
2045	The value of early detection of type 2 diabetes. <b>2009</b> , 16, 95-9	23
2044	Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. <b>2009</b> , 30, 1301-4	4
2043	Trends in medication use among US adults with diabetes mellitus: glycaemic control at the expense of controlling cardiovascular risk factors. <b>2009</b> , 169, 1718-20	50
2042	Trials review: cardiovascular outcome with intensive glycaemic control and implications for patients with type 2 diabetes. <b>2009</b> , 121, 31-41	1
2041	Implementing treatment guidelines for type 2 diabetes in primary care. <b>2009</b> , 121, 125-38	2

2040	Implications of new diabetes treatment trials: should current clinical practice be altered?. <b>2009</b> , 121, 67-72		2
2039	Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. <b>2009</b> , 180, 1310-6		14
2038	Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. <b>2009</b> , 180, 919-26		15
2037	Cardiovascular risk and glycemic control. <b>2009</b> , 180, 907-8		4
2036	Pharmacoepidemiology of insulin initiation in diabetes care. <b>2009</b> , 180, 1287-8		1
2035	Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. <b>2009</b> , 5, 8-9		1
2034	Genes, diabetes and cardiovascular risk prediction. <b>2009</b> , 5, 192-3		
2033	Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. <b>2009</b> , 9, 69-74		1
2032	La maitrise des complications du diabete: une question de sucre. <b>2009</b> , 181, E106-E107		1
2031	Glucose control and vascular complications in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2031; author reply 2032	59.2	7
2030	A1C: recommendations, debates, and questions. <b>2009</b> , 32, e141-7		43
2029	Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?. <b>2009</b> , 5, 78-9		1
2028	Diabetes: HOME reveals new data on a cornerstone of treatment. <b>2009</b> , 5, 478-9		1
2027	Glucose control in the ICU--how tight is too tight?. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1346-9	59.2	149
2026	Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. <b>2009</b> , 41, 116-22		15
2025	Normnahe Blutzuckerkontrolle oder HbA1c . <b>2009</b> , 4, 29-31		
2024	[The value of incretin based therapies]. <b>2009</b> , 134, 1062-6		0
2023	Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. <b>2009</b> , 117, 522-57		74

2022	Glucose normalization and outcomes in patients with acute myocardial infarction. <b>2009</b> , 169, 438-46	88
2021	The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. <b>2009</b> , 121, 5-6	
2020	Beyond glycemic control: treating the entire type 2 diabetes disorder. <b>2009</b> , 121, 68-81	19
2019	The role of colesevelam HCl in type 2 diabetes mellitus therapy. <b>2009</b> , 121, 19-24	3
2018	Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. <b>2009</b> , 5, 138-9	1
2017	Controlling the complications of diabetes: it's about the sugar. <b>2009</b> , 181, 357, E106-7	1
2016	Glucose blood levels as a therapeutic target in acute ischaemic stroke setting. <b>2009</b> , 9, 1261-77	3
2015	[Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. <b>2009</b> , 134, 949-54	7
2014	Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. <b>2009</b> , 41, 123-31	33
2013	Experimentelle Untersuchungen und klinische Evidenz der Insulinpumpentherapie (CSII). <b>2009</b> , 4, 390-397	5
2012	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. <b>2009</b> , 5, 270-5	8
2011	Elevated HbA1c level: a risk factor for cardiovascular disease mortality in patients with chronic heart failure?. <b>2009</b> , 5, 130-1	4
2010	Secondary Stroke Prevention &ndash; Medical Treatment. <b>2009</b> , 144-159	
2009	Implications of recent clinical trials on pay-for-performance. <b>2009</b> , 66, 864-7	7
2008	The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. <b>2009</b> , 6, e1000058	1227
2007	GHb level and subsequent mortality among adults in the U.S. <b>2009</b> , 32, 1440-6	47
2006	Motor vehicle crashes in diabetic patients with tight glycemic control: a population-based case control analysis. <b>2009</b> , 6, e1000192	30
2005	Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. <b>2009</b> , 24, 2286-7	1



2004	Transplantation in type 1 diabetes. <b>2009</b> , 24, 2026-9	9
2003	Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. <b>2009</b> , 58, 360-6	153
2002	Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. <b>2009</b> , 95, 917-23	41
2001	Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. <b>2009</b> , 297, E685-94	36
2000	Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. <b>2009</b> , 119, 1728-35	424
1999	Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. <b>2009</b> , 32, 2068-74	184
1998	Benefits of tight blood pressure control to prevent diabetes complications were not sustained. <b>2009</b> , 14, 9-10	
1997	Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. <b>2009</b> , 58, 1229-36	399
1996	Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?. <b>2009</b> , 22, 686-97	18
1995	Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. <b>2009</b> , 6, 416-29	5
1994	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. <b>2009</b> , 76, 705-16	75
1993	What does it take to put an ugly fact through the heart of a beautiful hypothesis?. <b>2009</b> , 14, 68-9	5
1992	Diabetes P4P: a view from near and far. <b>2009</b> , 9, 96-97	
1991	How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. <b>2009</b> , 21, 327-35	16
1990	Secondary prevention of stroke. <b>2009</b> , 7, 1103-15	17
1989	Therapy: Intensive glucose control in the ICU: is sugar nice?. <b>2009</b> , 5, 473-4	10
1988	Redefining the diagnosis of diabetes using glycated hemoglobin. <b>2009</b> , 32, 1344-5	29
1987	Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years. <b>2009</b> , 14, 9-10	3

1986	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. <b>2009</b> , 121, 94-107	68
1985	Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. <b>2009</b> , 339, b4324	27
1984	An Update of Recent Trials with Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes. <b>2009</b> , 25, 235-243	1
1983	Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke. <b>2009</b> , 10, 1883-94	9
1982	Cardiovascular benefit of intensive glucose control: approaching closure. <b>2009</b> , 9, 175-176	
1981	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <b>2009</b> , 24, 1663-71	245
1980	Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. <b>2009</b> , 32, 1577-82	52
1979	Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. <b>2009</b> , 14, 73	
1978	Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. <b>2009</b> , 32 Suppl 2, S260-5	23
1977	Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. <b>2009</b> , 25, 1029-35	22
1976	Effects of a high-fat, low- versus high-glycemic index diet: retardation of insulin resistance involves adipose tissue modulation. <b>2009</b> , 23, 1092-101	36
1975	The diabetes mellitus medication choice decision aid: a randomized trial. <b>2009</b> , 169, 1560-8	212
1974	The Role of Diabetes Educators in the Medical Home. <b>2009</b> , 22, 124-126	1
1973	Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. <b>2009</b> , 302, 1186-94	85
1972	Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. <b>2009</b> , 6, 507-513	1
1971	Interdialytic weight gain in diabetic haemodialysis patients and diabetic control as assessed by glycated haemoglobin. <b>2009</b> , 113, c33-7	25
1970	Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. <b>2009</b> , 32 Suppl 2, S337-41	13
1969	Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. <b>2009</b> , 32 Suppl 2, S342-8	24

1968	The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. <b>2009</b> , 22, 179-193		
1967	What the headline giveth, the critique often taketh away: The "News and headlines" feature of EvidenceUpdates. <b>2009</b> , 14, 69-69		
1966	The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice. <b>2009</b> , 32 Suppl 2, S326-30		18
1965	Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer?. <b>2009</b> , 32, 521-2		38
1964	Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. <b>2009</b> , 161, 1-9		14
1963	Target for glycemic control: concentrating on glucose. <b>2009</b> , 32 Suppl 2, S199-204		39
1962	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <b>2009</b> , 27, 2121-58		1004
1961	Prevalence of daily hyperglycemia in obese type 2 diabetic men compared with that in lean and obese normoglycemic men: effect of consumption of a sucrose-containing beverage. <b>2009</b> , 90, 511-8		12
1960	Arguments for and against the role of glucose variability in the development of diabetes complications. <b>2009</b> , 3, 649-55		27
1959	Statin-induced diabetes: will it change clinical practice?. <b>2009</b> , 32, 1941-3		8
1958	Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. <b>2009</b> , 58, 701-9		50
1957	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 27, 4-16		18
1956	Review: intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes. <b>2009</b> , 14, 167		
1955	Community pharmacist-provided extended diabetes care. <b>2009</b> , 43, 882-9		59
1954	Intensive versus conventional glucose control in critically ill patients. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1283-97	59.2	5107
1953	Perioperative and critical illness dysglycemia--controlling the iceberg. <b>2009</b> , 3, 1288-91		3
1952	To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. <b>2009</b> , 14, 34-7		1
1951	Glucose control in type 2 diabetes: still worthwhile and worth pursuing. <b>2009</b> , 301, 1590-2		9

1950	Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors: The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Trial: Response to Abbatecola and Paolisso. <b>2009</b> , 32, e103-e103	4
1949	Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. <b>2009</b> , 301, 1547-55	547
1948	Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. <b>2009</b> , 94, 4810-9	187
1947	Clinically significant disagreement between mean blood glucose and estimated average glucose in two populations: implications for diabetes management. <b>2009</b> , 3, 1128-35	14
1946	Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. <b>2009</b> , 58, 989-94	18
1945	The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. <b>2009</b> , 25, 657-67	31
1944	Erratum. <b>2009</b> , 25, 667	1
1943	Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. <b>2009</b> , 155, 668-72.e1-3	278
1942	The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. <b>2009</b> , 19, 94-9	10
1941	The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. <b>2009</b> , 9, 136	71
1940	Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. <b>2009</b> , 9, 24	70
1939	A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. <b>2009</b> , 29, 1280-8	10
1938	Diabetes control and cardiovascular risk, Part II: Intensive glucose control--UKPDS follow-up. <b>2009</b> , 12, 51-8	1
1937	Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. <b>2009</b> , 11, S40-S47	0
1936	KDIGO clinical practice guideline for the care of kidney transplant recipients. <b>2009</b> , 9 Suppl 3, S1-155	937
1935	Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. <b>2009</b> , 6, 1719-1728	56
1934	Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. <b>2009</b> , 31, 245-59	17
1933	A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. <b>2009</b> , 31, 2472-88	81

1932	Clinical benefits of tight glycaemic control: effect on the kidney. <b>2009</b> , 23, 431-9	6
1931	Clinical benefits of tight glycaemic control: focus on the intensive care unit. <b>2009</b> , 23, 421-9	25
1930	Impact of admission blood glucose on outcomes of nondiabetic patients with acute ST-elevation myocardial infarction (from the German Acute Coronary Syndromes [ACOS] Registry). <b>2009</b> , 103, 583-7	23
1929	Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. <b>2009</b> , 104, 41-5	44
1928	Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. <b>2009</b> , 104, 910-6	16
1927	The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. <b>2009</b> , 602, 448-54	29
1926	More is not always better: intensive glycemic control in type 2 diabetes. <b>2009</b> , 53, 12-5	1
1925	Analysis on blood glucose excursions in well-controlled patients with type 2 diabetes mellitus. <b>2009</b> , 24, 92-98	1
1924	Temas de actualidad en hipertensi3n arterial y diabetes. <b>2009</b> , 9, 14-27	
1923	¿Qu3 sucede tras el control estricto inicial de la presi3n arterial en los pacientes diab3ticos tipo 2? Seguimiento a largo plazo de los pacientes del estudio UKPDS. <b>2009</b> , 16, 322	
1922	¿Conseguiremos reducir las complicaciones macrovasculares en un paciente con diabetes mellitus tipo 2 de larga evoluci3n y un buen control de la hemoglobina glucosilada?. <b>2009</b> , 16, 467	
1921	Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. <b>2009</b> , 25, 224-31	12
1920	Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. <b>2009</b> , 25, 393-402	63
1919	Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. <b>2009</b> , 335, 165-89	203
1918	Exercise therapy in type 2 diabetes. <b>2009</b> , 46, 263-78	82
1917	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. <b>2009</b> , 46, 173-81	19
1916	[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus]. <b>2009</b> , 121, 473-82	1
1915	Scherp instellen DM2 kost meer dan het oplevert. <b>2009</b> , 52, 316-316	3

1914	How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. <b>2009</b> , 23, 403-8	9
1913	Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke. <b>2009</b> , 11, 201-11	1
1912	Cardiovascular disease is prevented over the long term by better blood glucose control. <b>2009</b> , 3, 33-34	
1911	Cardiovascular risk-benefit ratio of thiazolidinediones. <b>2009</b> , 3, 42-50	2
1910	Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus. <b>2009</b> , 3, 71-77	
1909	Evolving concepts of cardiovascular disease prevention in older adults. <b>2009</b> , 3, 366-373	
1908	ACCORD, ADVANCE und VADT – Paradigmenwechsel in der Diabetologie?. <b>2009</b> , 4, 196-199	
1907	Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. <b>2009</b> , 11, 281-8	13
1906	Serum glucose control in diabetic patients with cardiovascular disease: should we be less aggressive?. <b>2009</b> , 11, 384-90	3
1905	Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. <b>2009</b> , 11, 258-63	20
1904	Preventing cardiovascular disease in type 2 diabetes: where do things stand with glycemic control? Part two. <b>2009</b> , 9, 9-10	
1903	Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. <b>2009</b> , 9, 18-25	25
1902	The "legacy effect" associated with intensive glucose control in patients with type 2 diabetes. <b>2009</b> , 9, 63-4	
1901	Diabetes and cardiovascular disease: the role of glycemic control. <b>2009</b> , 9, 65-72	9
1900	Potential of glucose-lowering drugs to reduce cardiovascular events. <b>2009</b> , 9, 87-94	2
1899	Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction. <b>2009</b> , 9, 223-8	2
1898	Glycemic control and cardiovascular disease in chronic kidney disease. <b>2009</b> , 9, 243-8	9
1897	What is the best treatment for prediabetes?. <b>2009</b> , 9, 335-41	5

1896	When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?. <b>2009</b> , 9, 325-8	1
1895	Management of diabetes in dialysis patients. <b>2009</b> , 9, 466-72	9
1894	Pharmacologic management of patients with both heart failure and diabetes. <b>2009</b> , 6, 126-32	3
1893	The role of incretins in cardiovascular control. <b>2009</b> , 11, 18-22	21
1892	All things considered-including glucose control in the ICU. <b>2009</b> , 11, 383-4	1
1891	Insulintherapie bei Intensivpatienten. <b>2009</b> , 5, 219-229	1
1890	Diabetes und Niere âUpdate 2009. <b>2009</b> , 5, 190-199	
1889	Update Typ-2-Diabetes anhand ausgewalter aktueller Publikationen. <b>2009</b> , 5, 177-189	
1888	Kardiale Arrhythmie und nachtliche Hypoglykmie bei Patienten mit einem Diabetes mellitus Typ 1. <b>2009</b> , 5, 122-123	
1887	Schlaganfall-Primrprvention bei Diabetespatienten. <b>2009</b> , 5, 611-619	
1886	Schlaganfallsekundrprvention bei Diabetespatienten. <b>2009</b> , 5, 620-627	
1885	Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. <b>2009</b> , 19, 1077-83	78
1884	Soluble forms of RAGE in internal medicine. <b>2009</b> , 4, 389-401	143
1883	Key priorities in managing glucose control in older people with diabetes. <b>2009</b> , 13, 685-91	32
1882	Journal Club. <b>2009</b> , 104, 567-577	
1881	[Pancreas and islet transplantation]. <b>2009</b> , 50, 536-49	
1880	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 52, 17-30	541
1879	Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 52, 552-3; author reply 554-5	21

1878	Medical management of hyperglycaemia in type 2 diabetes mellitus. Reply to Woo V [letter] and Eizirik DL [letter]. <b>2009</b> , 52, 554-555	2
1877	Megatrials in type 2 diabetes. From excitement to frustration?. <b>2009</b> , 52, 1219-26	102
1876	Rosiglitazone: to be or not to be?. <b>2009</b> , 52, 1448-50	1
1875	Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. <b>2009</b> , 52, 1434-41	19
1874	Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. <b>2009</b> , 52, 1479-95	181
1873	Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. <b>2009</b> , 52, 1990-2000	86
1872	Intensive glucose control and macrovascular outcomes in type 2 diabetes. <b>2009</b> , 52, 2288-98	854
1871	[ESC/EASD joint guidelines on diabetes and cardiovascular diseases]. <b>2009</b> , 34, 21-9	3
1870	Insulin glargine and cancer: cause and effect unproven. <b>2009</b> , 26, 256-257	3
1869	Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. <b>2009</b> , 18, 973-6	52
1868	DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. <b>2009</b> , 9, 13	1
1867	The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. <b>2009</b> , 9, 19	37
1866	Seven mistakes and potential solutions in epidemiology, including a call for a World Council of Epidemiology and Causality. <b>2009</b> , 6, 6	13
1865	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. <b>2009</b> , 4, 41	36
1864	Management of progressive type 2 diabetes: role of insulin therapy. <b>2009</b> , 3, 5	1
1863	Metabolic diseases and associated complications: sex and gender matter!. <b>2009</b> , 39, 631-48	96
1862	Complexity and health--yesterday's traditions, tomorrow's future. <b>2009</b> , 15, 543-8	41
1861	What can complexity do for diabetes management? Linking theory to practice. <b>2009</b> , 15, 761-5	17



1860	Is there a downside to customizing care? Implications of general and patient-specific treatment strategies. <b>2009</b> , 15, 1171-6	3
1859	The value, qualification, and regulatory use of surrogate end points in drug development. <b>2009</b> , 86, 32-43	48
1858	Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?. <b>2009</b> , 23, 997-1003	15
1857	Getting away from glucose: stop sugarcoating diabetes. <b>2009</b> , 15, 372-3	7
1856	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. <b>2009</b> , 8, 417-29	245
1855	Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. <b>2009</b> , 8, 361-7	34
1854	Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. <b>2009</b> , 63, 656-66	12
1853	Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. <b>2009</b> , 63, 912-29	30
1852	Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. <b>2009</b> , 63, 903-11	3
1851	Storms, tea cups and the adverse effects of statins. <b>2009</b> , 63, 1268-70	3
1850	Dietary cholesterol and other nutritional considerations in people with diabetes. <b>2009</b> , 63, 15-21, 44-51	7
1849	Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. <b>2009</b> , 63, 1354-68	3
1848	Le cholestfol alimentaire et autres considfations nutritionnelles chez les personnes atteintes de diabte. <b>2009</b> , 63, 44-51	1
1847	Type 2 diabetes and HbA1c goal: time for individualised therapy. <b>2009</b> , 63, 1408-9	
1846	Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. <b>2009</b> , 63, 1421-5	45
1845	Where now for insulin glargine--a time for pragmatic medicine?. <b>2009</b> , 63, 1413-5	1
1844	Insulin intensification--the rationale and the target. <b>2009</b> , 63, 1-5	8
1843	Patterns of glycaemic control in Australian primary care (NEFRON 8). <b>2009</b> , 39, 512-8	20

1842	Mortality in diabetic patients undergoing non-cardiac surgery: a 7-year follow-up study. <b>2009</b> , 53, 749-58	20
1841	Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. <b>2009</b> , 11, 315-22	24
1840	Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. <b>2009</b> , 11, 379-86	47
1839	Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. <b>2009</b> , 11, 157-66	231
1838	The role of pioglitazone in modifying the atherogenic lipoprotein profile. <b>2009</b> , 11, 742-56	22
1837	Earlier triple therapy with pioglitazone in patients with type 2 diabetes. <b>2009</b> , 11, 844-54	20
1836	Restaging insulin therapy for patients with type 2 diabetes. <b>2009</b> , 11 Suppl 5, 1-5	14
1835	Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. <b>2009</b> , 11, 1153-62	128
1834	Longitudinal studies of time-dependent changes in both bladder and erectile function after streptozotocin-induced diabetes in Fischer 344 male rats. <b>2009</b> , 104, 1292-300	24
1833	Ethnic variation in the correlation between random serum glucose concentration and glycated haemoglobin. <b>2009</b> , 26, 128-33	31
1832	Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. <b>2009</b> , 26, 409-15	8
1831	Impact of high-fat /low-carbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in Type 2 diabetes. <b>2009</b> , 26, 589-95	20
1830	Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes. <b>2009</b> , 26, 974-80	30
1829	Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). <b>2009</b> , 26, 1033-9	33
1828	Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. <b>2009</b> , 26, 1147-55	21
1827	Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. <b>2009</b> , 26, 1255-61	23
1826	Which people with Type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. <b>2009</b> , 26, 1269-76	34
1825	Intensified multifactorial treatment of patients with Type 2 diabetes: what can be achieved and does it pay off?. <b>2009</b> , 1, 83-9	4

1824	What is the evidence base for the randomized controlled trial?. <b>2009</b> , 1, 73-5	1
1823	Recent cardiovascular trials: what are the drivers of benefit and adverse effect?. <b>2009</b> , 1, 227-9	0
1822	Treatment with metformin is protective against limitations in instrumental activities of daily living in older subjects with type 2 diabetes mellitus. <b>2009</b> , 57, 562-4	6
1821	Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. <b>2009</b> , 57, 2011-9	64
1820	Ethical considerations in cardiovascular prevention. <b>2009</b> , 23, 669-73	3
1819	CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. <b>2009</b> , 23, 675-9	19
1818	Insulin Glargine: a review 8 years after its introduction. <b>2009</b> , 10, 705-18	33
1817	The "glucose pentagon": assessing glycaemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles. <b>2009</b> , 11, 399-409	25
1816	Balancing risk and benefit with oral hypoglycemic drugs. <b>2009</b> , 76, 234-43	26
1815	Glycemic targets for patients with type 2 diabetes mellitus. <b>2009</b> , 76, 227-33	6
1814	Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. <b>2009</b> , 25, 1605-13	65
1813	Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. <b>2009</b> , 94, 709-28	701
1812	Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycaemic control. <b>2009</b> , 15, 540-59	692
1811	Anti-inflammatory diets for obesity and diabetes. <b>2009</b> , 28 Suppl, 482S-491S	18
1810	Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. <b>2009</b> , 25, 1273-84	26
1809	The assessment of glycaemic variability and its impact on diabetes-related complications: an overview. <b>2009</b> , 11, 623-33	55
1808	The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. <b>2009</b> , 13, R67	72
1807	Pancreatic network control of glucagon secretion and counterregulation. <b>2009</b> , 467, 547-581	9

1806	Frequency of hypoglycemia and its significance in chronic kidney disease. <b>2009</b> , 4, 1121-7	269
1805	Glycemic control and cardiovascular events in diabetic hemodialysis patients. <b>2009</b> , 120, 2421-8	88
1804	Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. <b>2009</b> , 119, 3244-62	263
1803	Hypertension, diabetes, and elevated cholesterol among insured and uninsured U.S. adults. <b>2009</b> , 28, w1151-9	52
1802	A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. <b>2009</b> , 35, 168-77	65
1801	Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. <b>2009</b> , 35, 372-7	82
1800	Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. <b>2009</b> , 35, 425-30	6
1799	Preventing diabetic complications: a primary care perspective. <b>2009</b> , 84, 107-16	22
1798	Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <b>2009</b> , 86, 74-81	23
1797	Glucoregulation in type 2 diabetes: the lower the better? Glycosylated HbA1c of 6.5% seems to be the limit. <b>2009</b> , 20, 232-5	1
1796	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. <b>2009</b> , 20 Suppl 2, S329-39	33
1795	Integrative medicine and patient-centered care. <b>2009</b> , 5, 277-89	169
1794	Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. <b>2009</b> , 19, 365-77	78
1793	Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. <b>2009</b> , 19, 604-12	140
1792	The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. <b>2009</b> , 19, 596-603	31
1791	Extent of glycemic control in type 2 diabetes mellitus: close, but no cigar. <b>2009</b> , 19, 593-5	1
1790	[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?]. <b>2009</b> , 30, 1001-3	
1789	Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. <b>2009</b> , 297, 112-26	39

1788	[Primary and secondary prevention of stroke: a guideline]. <b>2009</b> , 133, 754-62	8
1787	Clinical trial design and evidence-based outcomes in the study of liver diseases. <b>2009</b> , 50, 817-26	10
1786	The normalization heuristic: an untested hypothesis that may misguide medical decisions. <b>2009</b> , 72, 745-8	8
1785	Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. <b>2009</b> , 72, 610	1
1784	Season of birth: a potential influential factor for quality of life. <b>2009</b> , 72, 609-10	1
1783	Role of the primary care physician in stroke prevention. Introduction. <b>2009</b> , 122, S1-6	0
1782	Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. <b>2009</b> , 122, S37-50	92
1781	Geriatric pharmacotherapy updates. <b>2009</b> , 7, 186-195	
1780	Pharmacologic management of the older patient with type 2 diabetes mellitus. <b>2009</b> , 7, 324-42	57
1779	[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation]. <b>2009</b> , 41, 463.e1-463.e24	1
1778	Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. <b>2009</b> , 32, 361-6	71
1777	Intensive glycemc control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <b>2009</b> , 53, 222-204	272
1776	Cardiac resynchronization therapy: are modern myths preventing appropriate use?. <b>2009</b> , 53, 608-611	40
1775	Defining the role of basal and prandial insulin for optimal glycemc control. <b>2009</b> , 53, S21-7	8
1774	Comparative effectiveness research: the view from the NHLBI. <b>2009</b> , 53, 1084-6	17
1773	End points for clinical trials in acute heart failure syndromes. <b>2009</b> , 53, 2248-58	84
1772	Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. <b>2009</b> , 54, 422-8	144
1771	Aiming for the best control of glycemc in patients with heart failure and type 2 diabetes the "sweet spot". <b>2009</b> , 54, 429-31	6

1770	Dysglycemia and acute myocardial infarction: the role of echocardiography. <b>2009</b> , 2, 600-3		
1769	Diabetic cardiomyopathy--a distinct disease?. <b>2009</b> , 23, 347-60		53
1768	Diabetes and acute coronary syndromes. <b>2009</b> , 23, 305-16		14
1767	Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). <b>2009</b> , 23, 479-86		149
1766	The new rosiglitazone story: its place today in type 2 diabetes management. <b>2009</b> , 3, 57-9		
1765	Rosiglitazone. <b>2009</b> , 3, 123-4		1
1764	Hypoglycaemia: an overview. <b>2009</b> , 3, 131-9		50
1763	Free fatty acids are associated with pulse pressure in women, but not men, with type 1 diabetes mellitus. <b>2009</b> , 58, 1215-21		6
1762	Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. <b>2009</b> , 209, 279-302		11
1761	De los algoritmos a la práctica clínica en el manejo óptimo del paciente diabético. <b>2009</b> , 209, 18-27		
1760	Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. <b>2009</b> , 25, 2239-49		13
1759	Three-year efficacy of complex insulin regimens in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1736-47	59.2	522
1758	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. <b>2009</b> , 75, 1272-1277		227
1757	Present recommendations in type 2 diabetes treatment. <b>2009</b> , 56S4, 46-49		1
1756	Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. <b>2009</b> , 26, 157-180		2
1755	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2009</b> , 32, 193-203		2432
1754	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <b>2009</b> , 18, 308-47		186
1753	Revisiting clinical trials on glycemic control and cardiovascular risk. <b>2009</b> , 1, 12		2

1752	Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. <b>2009</b> , 1, 22		12
1751	Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes. <b>2009</b> , 1, 27		47
1750	Epigenetics: a molecular link between environmental factors and type 2 diabetes. <b>2009</b> , 58, 2718-25		439
1749	Stroke and Diabetes Mellitus. <b>2009</b> , 183-218		1
1748	Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. <b>2009</b> , 94, 410-5		293
1747	Dapagliflozin: an emerging treatment option in type 2 diabetes. <b>2009</b> , 18, 327-34		11
1746	Cardiovascular Endocrinology. <b>2009</b> ,		2
1745	Glucose control and vascular complications in veterans with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 129-39	59.2	3424
1744	Diabetes and atherosclerosis: is there a role for hyperglycemia?. <b>2009</b> , 50 Suppl, S335-9		132
1743	Treatment blood pressure targets for hypertension. <b>2009</b> , CD004349		97
1742	From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. <b>2009</b> , 25, 671-81		65
1741	Glycemic control in type 2 diabetes: time for an evidence-based about-face?. <b>2009</b> , 150, 803-8		108
1740	Development of CRITERIA to assess appropriate Medication use among Elderly complex patients (CRIME) project: rationale and methodology. <b>2009</b> , 26 Suppl 1, 3-13		29
1739	Équilibre glycémique et morbidimortalité cardiovasculaire : apport des études 2008. <b>2009</b> , 70, e1-e8		1
1738	Standards of medical care in diabetes--2009. <b>2009</b> , 32 Suppl 1, S13-61		1378
1737	Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. <b>2009</b> , 15, 750-62		4
1736	A pilot study of glycosylated hemoglobin levels in periodontitis cases and healthy controls. <b>2009</b> , 80, 1057-61		35
1735	Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. <b>2009</b> , 32, 1137-42		75

1734	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <b>2009</b> , 7, 85-93	1
1733	Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. <b>2009</b> , 4, 111-118	1
1732	Management of Type 2 diabetes: Treating targets and strategies. <b>2009</b> , 51, 5-9	2
1731	Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound. <b>2009</b> , 18, 1365-73	1
1730	Metabolic effects of manidipine. <b>2009</b> , 9, 163-76	11
1729	Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. <b>2009</b> , 87, 37-50	9
1728	Comment: Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome. <b>2009</b> , 43, 393-4	4
1727	Changes in levels of haemoglobin A1c during the first 6 years after diagnosis of clinical type 2 diabetes. <b>2009</b> , 69, 851-7	7
1726	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <b>2009</b> , 25, 1931-40	9
1725	The glycemic index: physiological significance. <b>2009</b> , 28 Suppl, 439S-445S	59
1724	Insulin resistance is a cellular antioxidant defense mechanism. <b>2009</b> , 106, 17787-92	362
1723	Toward optimal health: a renewed look at stroke in women. Interview by Jodi R. Godfrey. <b>2009</b> , 18, 13-8	3
1722	Acupressure therapy inhibits the development of diabetic complications in Chinese patients with type 2 diabetes. <b>2009</b> , 15, 1027-32	8
1721	Quality measurement in diabetes care. <b>2009</b> , 12, 265-71	10
1720	Surrogate markers in clinical trials--challenges and opportunities. <b>2009</b> , 206, 8-16	42
1719	Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke. <b>2009</b> , 5, 149-53	1
1718	Treatment of hypertension in patients with diabetes-an update. <b>2009</b> , 3, 150-5	10
1717	A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. <b>2009</b> , 16, 446-56	248



1716	Case study responses. <b>2009</b> , 4, 124-125	
1715	Appropriate, timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. <b>2009</b> , 4, 144-157	4
1714	Guà Europea de Prevenci3 Cardiovascular en la Pràctica Clànica. Adaptaci3 espa8la del CEIPC 2008. <b>2009</b> , 35, 66-85	1
1713	Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes. <b>2009</b> , 35, 564-8	14
1712	Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?. <b>2009</b> , 86 Suppl 1, S22-5	11
1711	How to interpret results of the HEART2D trial?. <b>2009</b> , 86 Suppl 1, S53-6	1
1710	Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. <b>2009</b> , 86 Suppl 1, S57-62	36
1709	Response to "Rosiglitazone no longer recommended". <b>2009</b> , 373, 544	1
1708	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <b>2009</b> , 373, 1765-72	1015
1707	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. <b>2009</b> , 373, 1780-8	223
1706	Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. <b>2009</b> , 374, 126-35	178
1705	Hyperglycaemia and coronary heart disease: the meta picture. <b>2009</b> , 373, 1737-8	9
1704	Intensive glucose control and cardiovascular outcomes. <b>2009</b> , 374, 522-3; author reply 524	1
1703	Intensive glucose control and cardiovascular outcomes. <b>2009</b> , 374, 523-4; author reply 524	0
1702	Guà Europea de Prevenci3 Cardiovascular en la Pràctica Clànica. Adaptaci3 espa8la del CEIPC 2008. <b>2009</b> , 21, 124-150	3
1701	[Advances in hypertension and diabetes]. <b>2009</b> , 62 Suppl 1, 14-27	0
1700	Macrovascular Complications of Diabetes Mellitus. <b>2009</b> , 22, 135-148	6
1699	Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy. <b>2009</b> , 27, 199-215	6

1698	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. <b>2009</b> , 256, 1603-19	43
1697	Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. <b>2009</b> , 339, b4731	325
1696	Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. <b>2009</b> , 84, 741-757	88
1695	Influence du contrôle glyémique du diabétique de type 2 sur les complications cardiovasculaires : une apparente contradiction. <b>2009</b> , 3, 527-533	4
1694	Glycaemic control and cardiovascular morbi-mortality: the contribution of the 2008 studies. <b>2009</b> , 70, 48-54	7
1693	Cardiovascular disease in women. <b>2009</b> , 36, 73-102, viii	5
1692	Incrétines et diabète, une petite révolution conceptuelle et thérapeutique (3) L'effet incrétine, un nouveau concept thérapeutique. <b>2009</b> , 2009, 26-27	
1691	Quelle est la nouvelle donne pour soigner les patients diabétiques de type 2?. <b>2009</b> , 3, 141-146	1
1690	Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. <b>2009</b> , 84, 34-36	7
1689	Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. <b>2009</b> , 84, 38-42	21
1688	Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis. <b>2009</b> , 5, 4-10	13
1687	Réflexions pour de nouvelles recommandations de traitement médicamenteux du diabète de type 2 après post-UKPDS, ACCORD, VADT, ADVANCE. <b>2009</b> , 3, 147-150	
1686	Diabetes and cardiovascular disease prevention in older adults. <b>2009</b> , 25, 607-41, vii-viii	34
1685	Drug treatment of hypertension in older hypertensives. <b>2009</b> , 25, 235-44	8
1684	Memory complaints and dementia. <b>2009</b> , 93, 389-406, ix	4
1683	Diabetic nephropathy in the elderly. <b>2009</b> , 25, 373-89	7
1682	Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. <b>2009</b> , 32, 381-6	281
1681	Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. <b>2009</b> , 6 Suppl 1, 86-108	32

1680	Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. <b>2009</b> , 5, 225-41	41
1679	Current Opinion in Anaesthesiology. Current world literature. <b>2009</b> , 22, 822-7	
1678	Blood glucose control in critically ill patients: The impact of diabetes. <b>2009</b> , 37, 382-383	3
1677	Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. <b>2009</b> , 37, 2536-44	101
1676	Impact of glycemetic treatment choices on cardiovascular complications in type 2 diabetes. <b>2009</b> , 17, 165-75	20
1675	Evidence for a lower target blood pressure for people with heart disease. <b>2009</b> , 24, 318-24	9
1674	Strategies to enhance cardiovascular disease prevention in patients with diabetes. <b>2009</b> , 24, 461-7	3
1673	Latin American guidelines on hypertension. Latin American Expert Group. <b>2009</b> , 27, 905-22	71
1672	Signs of improvement: diabetes update 2009. <b>2009</b> , 34, 12-22, quiz 23	1
1671	A multimodal strategy based on pay-per-performance to improve quality of care of family practitioners in Argentina. <b>2009</b> , 32, 103-14	11
1670	Therapy and clinical trials: glycaemic control and cardiovascular disease. <b>2009</b> , 20, 530-1	
1669	Perioperative management of ambulatory surgical patients with diabetes mellitus. <b>2009</b> , 22, 718-24	37
1668	An algorithm for the care of type 2 diabetes. <b>2009</b> , 8, 156-65	3
1667	Current Opinion in Clinical Nutrition and Metabolic Care. Current world literature. <b>2009</b> , 12, 444-65	1
1666	Current therapeutic drugs for type 2 diabetes, still useful after 50 years?. <b>2009</b> , 108, 1727-30	4
1665	Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. <b>2009</b> , 87, 1031-6	100
1664	Current world literature. <b>2009</b> , 24, 496-508	
1663	Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. <b>2009</b> , 18, 539-45	49

1662	The effect of antidiabetic drugs on genes regulating lipid metabolism. <b>2009</b> , 20, 10-6	2
1661	Diabetes and cardiovascular disease: new perspectives. <b>2009</b> , 20, 145-6	
1660	Providing cardiovascular benefits with safe diabetes therapy. <b>2009</b> , 6, 455-457	
1659	Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. <b>2009</b> , 27, S19-23	9
1658	Trials of cardiovascular risk factor management in type 2 diabetes. <b>2009</b> , 24, 288-94	4
1657	Clinical trials: evidence based and clinically relevant or not?. <b>2009</b> , 22, 68-70	
1656	Does normalization of blood glucose reduce the rate of cardiovascular events?. <b>2009</b> , 6, 459-461	
1655	Diabetes and cardiovascular disease: time for individualized risk reduction. <b>2009</b> , 6, 451-453	
1654	Translating clinical guidelines into clinical practice: role of the pharmacist in type 2 diabetes management. <b>2009</b> , 49, e152-62	5
1653	Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. <b>2009</b> , 15, 326-34	20
1652	5) Countermeasures of Diabetic Vascular Complication and Future Prospects. From the Viewpoint of Study on Japan Diabetes Outcome Intervention Trial (J-DOIT). <b>2009</b> , 98, 2231-2240	
1651	[Progress in therapy for diabetes mellitus--intensified insulin therapy]. <b>2009</b> , 98, 750-5	
1650	[Recent topics in the Japan Diabetes Outcome Intervention Trial]. <b>2009</b> , 98, 824-33	1
1649	The role of glycemia management in the prevention of cardiovascular disease--starting over?. <b>2009</b> , 151, 888-9	4
1648	Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. <b>2009</b> , 151, 854-60	119
1647	The net value of health care for patients with type 2 diabetes, 1997 to 2005. <b>2009</b> , 151, 386-93	20
1646	Registries, databases, and electronic health records in ambulatory care. <b>2009</b> , 35, 247	2
1645	Linking diabetes and atherosclerosis. <b>2009</b> , 4, 603-624	6

1644	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. <b>2009</b> , 2009, 6-7	
1643	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. <b>2009</b> , 2009, 76-77	
1642	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. <b>2009</b> , 2009, 525-527	
1641	Effects of Intensive Glucose Lowering in Type 2 Diabetes. <b>2009</b> , 2009, 38-40	
1640	Prise en charge thérapeutique du diabète de type 2. <b>2009</b> , 4, 1-7	
1639	Lipoprotein glycation in atherogenesis. <b>2009</b> , 4, 781-790	8
1638	Cardiovascular disease and intensive glucose lowering in type 2 diabetes. <b>2009</b> , 102, 293-6	4
1637	Effects of insulin resistance on endothelial progenitor cells and vascular repair. <b>2009</b> , 117, 173-90	58
1636	PPARgamma and its ligands: therapeutic implications in cardiovascular disease. <b>2009</b> , 116, 205-18	99
1635	Diabetic cardiomyopathy. <b>2009</b> , 116, 741-60	123
1634	Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. <b>2009</b> , 59, 43-8	59
1633	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <b>2009</b> ,	3
1632	Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. <b>2009</b> , 169, 1403-10	42
1631	Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. <b>2009</b> , 6, 515-529	
1630	Multidisciplinary approach for the treatment of diabetes in the elderly. <b>2009</b> , 5, 207-216	4
1629	Systematic review: glucose control and cardiovascular disease in type 2 diabetes. <b>2009</b> , 151, 394-403	249
1628	Clinical and economic impact of a diabetes clinical pharmacy service program in a university and primary care-based collaboration model. <b>2009</b> , 49, 200-8	25
1627	Diabetes and peripheral vascular disease. <b>2009</b> , 109, 587-94	43

1626	Is patient activation associated with future health outcomes and healthcare utilization among patients with diabetes?. <b>2009</b> , 32, 320-7	163
1625	Visceral adipose tissue and atherosclerosis. <b>2009</b> , 7, 169-79	52
1624	Setting glycaemic targets in patients with type 2 diabetes. Where to now?. <b>2009</b> , 14, 125-128	1
1623	Targeting MCP-1 to reduce vascular complications of obesity. <b>2009</b> , 4, 164-76	13
1622	New insights into myocardial glucose metabolism: surviving under stress. <b>2009</b> , 12, 424-30	15
1621	Effects of Intensive Glucose Lowering in Type 2 Diabetes. <b>2009</b> , 2009, 3-5	
1620	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <b>2009</b> , 2009, 2-3	0
1619	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <b>2009</b> , 2009, 5-6	1
1618	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. <b>2009</b> , 2009, 111-113	
1617	Fibrates and microvascular complications in diabetes--insight from the FIELD study. <b>2009</b> , 15, 537-52	57
1616	Actions of selected cardiovascular hormones on arterial stiffness and wave reflections. <b>2009</b> , 15, 304-20	19
1615	Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. <b>2009</b> , 27, S3-8	22
1614	Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial. <b>2010</b> , 3, 565-7	9
1613	Glucose control is associated with patient survival in diabetic patients after renal transplantation. <b>2010</b> , 89, 612-9	21
1612	Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?. <b>2010</b> , 59, 1129-31	58
1611	Quality Improvement: Simple But Hard. <b>2010</b> , 28, 1-3	0
1610	What changes we may expect in 2010 hypertension diagnosis and management: Insights from the European update document. <b>2010</b> , 8, 788-91	1
1609	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. <b>2010</b> , 2010, 37-40	1

1608 Effects of Intensive Glucose Lowering in Type 2 Diabetes. **2010**, 2010, 462-464

1607 The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. **2010**, 5, 89-95

22

1606 Incretin-Based Therapies in Patients with Type 2 Diabetes. **2010**, 5, 75-85

1605 Diabetes, obesity, and heart failure: the new pandemic. **2010**, 6, 20-6

5

1604 Diabetesstudien im Überblick – Intensive Blutzuckersenkung von Vorteil?. **2010**, 8, 22-31

1603 Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. **2010**, 2010, 22-24

1602 Diagnosing diabetes with A1C: implications and considerations for measurement and surrogate markers. **2010**, 35, 16-23; quiz 23-4

2

1601 Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3'-untranslated region of the PAI-1 gene and its pharmacologic implications. **2010**, 21, 144-50

9

1600 Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. **2010**, 21, 8-14

7

1599 Diabetic Nephropathy: Eye on the Targets. **2010**, 3, 12

1598 Diabetes mellitus and the importance of self-care. **2010**, 25, 93-8

32

1597 Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. **2010**, 19, 425-31

42

1596 Current Opinion in Lipidology. Current world literature. **2010**, 21, 84-8

1595 Longitudinal differences in glycemic control by race/ethnicity among veterans with type 2 diabetes. **2010**, 48, 527-33

31

1594 Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. **2010**, 48, S9-16

35

1593 Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. **2010**, 5, 495-505

3

1592 Glycemic control in the intensive care unit. **2010**, 152, 65-6

1591 Combination of serum adiponectin level and metabolic syndrome is closely associated with coronary artery disease in Japanese subjects with good glycemic control. **2010**, 49, 721-7

10

- 1590 2) Treatment Strategies for Preventing Atherosclerosis in Patients with Diabetes Mellitus.. **2010**, 99, 447-453
- 1589 Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis. **2010**, 152, 64; author reply 65 1
- 1588 Tailoring treatment to risk in type 2 diabetes. **2010**, 60, 158-60 1
- 1587 Goals for HbA1c need to be individualized based on clinical judgment, instead of third party recommendations. **2010**, 103, 854-5
- 1586 Spoons systematically bias dosing of liquid medicine. **2010**, 152, 66-7 11
- 1585 Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis. **2010**, 152, 65; author reply 65 1
- 1584 Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis. **2010**, 152, 64; author reply 65
- 1583 Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. **2010**, 103, 911-6 14
- 1582 Managing type 2 diabetes in the primary care setting: beyond glucocentricity. **2010**, 340, 133-43 4
- 1581 Praktische Tipps zum Finden der individuell besten Option. **2010**, 4, 27-33
- 1580 The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). **2010**, 60, 172-5 31
- 1579 Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. **2010**, 74, 779-85 10
- 1578 Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog. **2010**, 3, 65-80 3
- 1577 Diabetes Drugs: Present and Emerging. **2010**, 1-38 2
- 1576 Near infrared spectroscopy (NIRS) should not be standard of care for postoperative management. **2010**, 13, 51-4 48
- 1575 De behandeling van diabetes: stap voor stap. **2010**, 26, 17-24
- 1574 Insulin therapy for type 2 diabetes: what does the 4T trial tell us?. **2010**, 21, 7-9
- 1573 Weight management in type 2 diabetes mellitus. **2010**, 77, 533-48 12



1572	How to use an article about quality improvement. <b>2010</b> , 304, 2279-87	94
1571	Diabetic cardiomyopathy--to take a long story serious. <b>2010</b> , 35, 161-8	14
1570	Blood glucose control and coronary heart disease. <b>2010</b> , 35, 148-59	5
1569	[Comparison of risk factors and guideline oriented prevention and therapy of diabetic retinopathy between type 2 diabetes patients undergoing laser therapy and type 2 diabetes outpatients]. <b>2010</b> , 105, 772-8	0
1568	The time has come for incretins, a long time coming. <b>2010</b> , 88, 319-21	
1567	Duration of diabetes, glucose control and cardiovascular risk. <b>2010</b> , 53, 214-5	6
1566	Using individual patient data in meta-analyses of glucose-lowering studies. <b>2010</b> , 53, 216-7	2
1565	Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. <b>2010</b> , 53, 840-9	77
1564	Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. <b>2010</b> , 53, 1190-8	85
1563	Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. <b>2010</b> , 53, 1258-69	72
1562	The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. <b>2010</b> , 53, 1552-61	106
1561	Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction--a nationwide study. <b>2010</b> , 53, 1612-9	35
1560	Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. <b>2010</b> , 53, 1856-66	10
1559	Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited. <b>2010</b> , 53, 2105-11	4
1558	Intensified glucose lowering in type 2 diabetes: time for a reappraisal. <b>2010</b> , 53, 2079-85	102
1557	Guidelines: we'll always need them, we sometimes dislike them, and we have to make them better. <b>2010</b> , 53, 2280-4	7
1556	Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. <b>2010</b> , 99, 337-44	4
1555	Endothelial dysfunction in diabetes: multiple targets for treatment. <b>2010</b> , 459, 977-94	79

1554	Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. <b>2010</b> , 160, 8-19	48
1553	Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. <b>2010</b> , 47 Suppl 1, 7-11	5
1552	Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. <b>2010</b> , 47 Suppl 1, 169-75	26
1551	Ein âffeffirliches Duoâff2010, 13, 32-43	
1550	The evolving place of incretin-based therapies in type 2 diabetes. <b>2010</b> , 25, 1207-17	25
1549	Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?. <b>2010</b> , 27, 321-33	43
1548	Engaging and empowering patients to manage their type 2 diabetes, Part II: Initiatives for success. <b>2010</b> , 27, 665-80	14
1547	Incretin therapy for type 2 diabetes mellitus. <b>2010</b> , 27, 881-94	1
1546	Risk stratification in diabetes: not all patients or perfusion defects are the same. <b>2010</b> , 17, 990-2	
1545	Verwarring rond scherp instellen DM2. <b>2010</b> , 53, 277-278	
1544	Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. <b>2010</b> , 14, 3-4	5
1543	Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study. <b>2010</b> , 1, 35-41	1
1542	Therapieziele beim geriatrischen Patienten. <b>2010</b> , 6, 551-559	3
1541	Therapie mit oralen Antidiabetika und/oder Insulin im hffieren Alter?. <b>2010</b> , 6, 560-569	2
1540	Intensivierte Blutdruckeinstellung bei Typ-II-Diabetes. <b>2010</b> , 5, 236-238	
1539	Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk. <b>2010</b> , 4, 159-164	1
1538	Intensive-Therapy Glycemic Control Fails to Prevent Vascular Complications in Veterans with Type 2 Diabetes Mellitus. <b>2010</b> , 4, 248-250	
1537	Diabetes in the Elderly. <b>2010</b> , 4, 347-353	

1536	"Dead in bed": a tragic complication of type 1 diabetes mellitus. <b>2010</b> , 179, 585-7	6
1535	A cardiologist's view of hypoglycemia. <b>2010</b> , 12, 88-95	4
1534	Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. <b>2010</b> , 12, 432-9	61
1533	Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome?. <b>2010</b> , 12, 140-6	8
1532	Challenges and approaches to managing type 2 diabetes mellitus. <b>2010</b> , 10, 7-9	3
1531	Does choice of antidiabetes therapy influence macrovascular outcomes?. <b>2010</b> , 10, 24-31	2
1530	Multifactorial intervention to reduce cardiovascular events in type 2 diabetes. <b>2010</b> , 10, 16-23	16
1529	Relationship of coronary angiographic findings to choice of antidiabetic medication. <b>2010</b> , 10, 1-3	
1528	Lessons learned from glycemia control studies. <b>2010</b> , 10, 133-8	6
1527	Update on the safety of thiazolidinediones. <b>2010</b> , 10, 116-23	1
1526	Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary?. <b>2010</b> , 10, 506-11	30
1525	Insulin sensitizers and heart failure: an engine flooded with fuel. <b>2010</b> , 12, 399-401	3
1524	The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. <b>2010</b> , 25, 141-6	105
1523	Update in new medications for primary care. <b>2010</b> , 25, 261-9	1
1522	Primary care of the renal transplant patient. <b>2010</b> , 25, 731-40	11
1521	Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE). <b>2010</b> , 25, 962-8	113
1520	Bad medicine: there is a lot wrong with diabetes care in the United States. <b>2010</b> , 34, 2-12	
1519	Secondary prevention strategies for coronary heart disease. <b>2010</b> , 29, 8-24	20

1518	Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. <b>2010</b> , 11, 21-30	21
1517	Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. <b>2010</b> , 11, 61-74	388
1516	Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. <b>2010</b> , 11, 75-86	52
1515	Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. <b>2010</b> , 11, 87-94	8
1514	Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. <b>2010</b> , 55, 426-30	22
1513	Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. <b>2010</b> , 55, 875-84	53
1512	KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. <b>2010</b> , 56, 189-218	57
1511	HbA1c en los pacientes diabéticos tipo 2: ¿cuál ha de ser el objetivo?. <b>2010</b> , 17, 351-352	0
1510	No debe ser distinto el valor objetivo de la presión arterial sistólica en los pacientes diabéticos. Resultados del estudio ACCORD. <b>2010</b> , 17, 727	
1509	Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. <b>2010</b> , 59, 1365-71	17
1508	Reducing cardiovascular risk in type 2 diabetes mellitus. <b>2010</b> , 38, 632-637	
1507	Glycaemic management of type 2 diabetes. <b>2010</b> , 38, 618-625	1
1506	Hypoglycaemia in diabetes. <b>2010</b> , 38, 671-675	3
1505	Glycaemic control in type 2 diabetes: targets and new therapies. <b>2010</b> , 125, 328-61	130
1504	Therapeutic advances in myocardial microvascular resistance: unravelling the enigma. <b>2010</b> , 127, 131-47	23
1503	Hyperglycemia and neurodevelopmental outcomes in infants with congenital heart disease. <b>2010</b> , 29, 107-111	
1502	Translating evidence into practice: a shared priority in public health?. <b>2010</b> , 70, 1492-500	25
1501	Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. <b>2010</b> , 20, 90-5	108

1500	Cardiovascular risk assessment--from individual risk prediction to estimation of global risk and change in risk in the population. <b>2010</b> , 8, 29	46
1499	Outcomes in diabetic versus nondiabetic patients who present with acute myocardial infarction and are treated with drug-eluting stents. <b>2010</b> , 105, 819-25	11
1498	Effect of baseline glycemic level on long-term cardiovascular outcomes after coronary revascularization therapy in patients with type 2 diabetes mellitus treated with hypoglycemic agents. <b>2010</b> , 105, 960-6	8
1497	Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus. <b>2010</b> , 105, 1090-4	15
1496	[Weight change, cardiometabolic risk and the impact of antidiabetic medications in type 2 diabetic patients]. <b>2010</b> , 59, 214-20	
1495	The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. <b>2010</b> , 32, 973-83	46
1494	Carbonylation of myosin heavy chains in rat heart during diabetes. <b>2010</b> , 80, 205-17	30
1493	Glycemic memory associated epigenetic changes. <b>2010</b> , 80, 1853-9	73
1492	The challenge of undiagnosed pre-diabetes, diabetes and associated cardiovascular disease. <b>2010</b> , 2, 43-46	17
1491	Glucose and surgical sepsis: a study of underlying immunologic mechanisms. <b>2010</b> , 210, 966-74	17
1490	[What has changed in the therapeutic strategy for type 2 diabetes mellitus?]. <b>2010</b> , 210 Suppl 1, 18-25	
1489	[Diagnosis and management of type 2 diabetes]. <b>2010</b> , 42 Suppl 1, 2-8	2
1488	Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. <b>2010</b> , 12, 973-82	10
1487	Increasing derangement of glucose homeostasis is associated with increased arterial stiffness in patients with diabetes, impaired fasting glucose and normal controls. <b>2010</b> , 26, 365-70	32
1486	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. <b>2010</b> , 26, 239-44	90
1485	Efficacy of Diabetinolân glycemic control in insulin resistant hamsters and subjects with impaired fasting glucose â pilot study. <b>2010</b> , 2, 171-178	10
1484	Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. <b>2010</b> , 9, 14	25
1483	Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. <b>2010</b> , 9, 15	7

1482	Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry. <b>2010</b> , 9, 22	12
1481	The Chronic CARE for diAbeTes study (CARAT): a cluster randomized controlled trial. <b>2010</b> , 9, 23	21
1480	Metabolic memory: a vascular perspective. <b>2010</b> , 9, 51	40
1479	Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. <b>2010</b> , 9, 52	29
1478	Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. <b>2010</b> , 9, 53	21
1477	Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. <b>2010</b> , 9, 63	61
1476	Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. <b>2010</b> , 9, 89	25
1475	Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. <b>2010</b> , 11, 16	68
1474	[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. <b>2010</b> , 39, 114-8	1
1473	Glycaemic outcomes following discharge from an intermediate care diabetes clinic. <b>2010</b> , 27, 53-54	3
1472	“New therapies for type 2 diabetes have added little to improve glycaemic control compared to conventional therapies” <b>2010</b> , 27, 72-74	
1471	Recurrent atrial fibrillation and prolonged QTc interval precipitated by severe hypoglycaemia. <b>2010</b> , 27, 120-121	
1470	Half full, half empty, or negative? Results of recent clinical trials. <b>2010</b> , 27, 174-175	
1469	Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. <b>2010</b> , 19, 1108-12	13
1468	Continuously evolving management concepts for diabetic CKD and ESRD. <b>2010</b> , 23, 134-9	2
1467	Management of the diabetic patient with advanced chronic kidney disease. <b>2010</b> , 23, 140-7	14
1466	Glycemic control and burnt-out diabetes in ESRD. <b>2010</b> , 23, 148-56	71
1465	Diabetes mellitus in older adults: time for an overtreatment quality indicator. <b>2010</b> , 58, 2244-5	5

1464	"Speed dating" as a technique to efficiently align mentees and mentors in a geriatrics training program. <b>2010</b> , 58, 2245-6	9
1463	Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. <b>2010</b> , 13, 196-208	42
1462	Persistence patterns with oral antidiabetes drug treatment in newly treated patients--a population-based study. <b>2010</b> , 13, 820-8	35
1461	Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. <b>2010</b> , 64, 295-304	55
1460	Self-monitoring of blood glucose. <b>2010</b> , 64, 1-10	26
1459	Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. <b>2010</b> , 64, 1121-9	62
1458	Benefits and risks around glycaemic control in diabetes: where are we now?. <b>2010</b> , 64, 1001-3	1
1457	Preventing diabetes complications: are we too glucocentric?. <b>2010</b> , 64, 1024-7	7
1456	Clinical experience with liraglutide. <b>2010</b> , 64, 44-8	4
1455	The glucose triad and its role in comprehensive glycaemic control: current status, future management. <b>2010</b> , 64, 1705-11	52
1454	Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. <b>2010</b> , 268, 75-82	6
1453	New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <b>2010</b> , 268, 471-82	116
1452	Glycemia and cardiovascular diseases in type 2 diabetes. <b>2010</b> , 268, 468-70	3
1451	Long-term successful weight loss improves vascular endothelial function in severely obese individuals. <b>2010</b> , 18, 754-9	60
1450	Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. <b>2010</b> , 88, 197-203	27
1449	Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. <b>2010</b> , 24, 1-6	37
1448	Journal of Diabetes NEWS. <b>2010</b> , 2, 9-15	
1447	The Avandia debate: an unhappy conclusion. <b>2010</b> , 2, 221-2	2

1446 Diabetes News. **2010**, 2, 227

1445	Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. <b>2010</b> , 12, 1-11	36
1444	Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. <b>2010</b> , 12, 124-32	10
1443	Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. <b>2010</b> , 12, 47-53	91
1442	Oral insulin - a review of current status. <b>2010</b> , 12, 179-85	95
1441	Benefits of moderate weight loss in patients with type 2 diabetes. <b>2010</b> , 12, 186-94	44
1440	Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. <b>2010</b> , 12, 115-23	77
1439	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. <b>2010</b> , 12, 267-87	63
1438	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. <b>2010</b> , 12, 384-92	106
1437	Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. <b>2010</b> , 12, 431-6	28
1436	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. <b>2010</b> , 12, 474-84	21
1435	The effect of intensive glycaemic control on cardiovascular outcomes. <b>2010</b> , 12, 641-7	14
1434	Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. <b>2010</b> , 12, 485-94	145
1433	Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. <b>2010</b> , 12, 865-70	19
1432	Screening for type 2 diabetes: an update of the evidence. <b>2010</b> , 12, 838-44	36
1431	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <b>2010</b> , 12, 929-40	20
1430	Measurements of medication adherence in diabetic patients with poorly controlled HbA(1c). <b>2010</b> , 27, 210-6	61
1429	Insulin initiation in Type 2 diabetes: the implications of the 4-T study. <b>2010</b> , 27, 1-3	7



1428	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. <b>2010</b> , 27, 175-80	33
1427	Low-dose thiazide diuretics in and around diabetes--definitely yes, and how do they compare with other interventions?. <b>2010</b> , 27, 127-9	2
1426	For debate. Glucose variability and diabetes complication risk: we need to know the answer. <b>2010</b> , 27, 868-71	40
1425	Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. <b>2010</b> , 27, 354-9	37
1424	Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. <b>2010</b> , 27, 303-8	2
1423	Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. <b>2010</b> , 27, 1024-32	125
1422	Hypoglycaemia increases aldosterone in a dose-dependent fashion. <b>2010</b> , 27, 1250-5	7
1421	Review: metformin: potential benefits and use in chronic kidney disease. <b>2010</b> , 15, 412-8	46
1420	An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. <b>2010</b> , 40, 286-92	45
1419	Surrogate end-points in clinical practice: are we providing worse care?. <b>2010</b> , 40, 395-8	4
1418	Diabetes:. 75-82	
1417	Intensive insulin therapy during cardiovascular surgery. <b>2010</b> , 57, 191-204	16
1416	Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. <b>2010</b> , 6, 17-26	1
1415	The Experience of Hypoglycaemia and Strategies Used For its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review. <b>2010</b> , 8, 1-21	
1414	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. <b>2010</b> , Volume 3, 227-242	3
1413	S14-4. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes. <b>2010</b> , 41, 99S-100S	
1412	Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. <b>2010</b> , Volume 3, 197-213	3
1411	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. <b>2010</b> , Volume 3, 243-252	3

1410	Implications of UKPDS evidence. <b>2010</b> , 21, 140-144	1
1409	Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes. <b>2010</b> , 6, 31-40	1
1408	Insulin therapy in critically ill patients. <b>2010</b> , 6, 1089-101	11
1407	Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. <b>2010</b> , 6, 145-55	59
1406	Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. <b>2010</b> , 8, 1-4	3
1405	Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus. <b>2010</b> , Volume 3, 49-53	2
1404	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <b>2010</b> , Volume 3, 155-163	16
1403	Diabetic microvascular complications: possible targets for improved macrovascular outcomes. <b>2011</b> , 4, 1-15	6
1402	Guas Latinoamericanas de Hipertensi3 Arterial. <b>2010</b> , 29,	5
1401	Molecular mechanisms of hyperglycemia and cardiovascular-related events in critically ill patients: rationale for the clinical benefits of insulin therapy. <b>2010</b> , 2, 281-8	1
1400	Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. <b>2010</b> , Volume 3, 387-394	2
1399	Regulation of glucose control in people with type 2 diabetes: a review and consensus. <b>2010</b> , 34, 16-20	
1398	Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. <b>2010</b> , 104, 1085-8	18
1397	Gender-Specific Aspects of Selected Coronary Heart Disease Risk Factors. <b>2010</b> , 162-174	5
1396	Coding guidelines for continuous glucose monitoring. <b>2010</b> , 16, 151-4	6
1395	Computerized physician order entry- based hyperglycemia inpatient protocol and glycemic outcomes: The CPOE-HIP study. <b>2010</b> , 16, 389-97	23
1394	Comments on the AACE/ACE statement on glycemic control for patients with type 2 diabetes mellitus. <b>2010</b> , 16, 130-1; author reply 131-2	1
1393	Abstracts of the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. April 21-25, 2010. Boston, Massachusetts, USA. <b>2010</b> , 16 Suppl 2, 1-49	1

1392	Complications and Management of Chronic Kidney Disease. <b>2010</b> , 145-163	1
1391	Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. <b>2010</b> , 6, 189-97	13
1390	Relationship among glycated albumin, hemoglobin A1c, and daily blood glucose profile in diabetic patients on chronic hemodialysis. <b>2010</b> , 43, 433-441	1
1389	A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. <b>2010</b> , 2, CMT.S3489	
1388	'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. <b>2010</b> , 69, 629-30	46
1387	Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. <b>2010</b> , 42, 19-35	20
1386	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. <b>2010</b> , 7, 119-30	38
1385	Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. <b>2010</b> , 59, 1074-81	23
1384	Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. <b>2010</b> , 7, 289-95	30
1383	Review: Does hypoglycaemia cause cardiovascular events?. <b>2010</b> , 10, 5-13	9
1382	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. <b>2010</b> , 121, 1868-77	94
1381	Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <b>2010</b> , 33, 798-803	20
1380	Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. <b>2010</b> , 33, 695-700	39
1379	The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. <b>2010</b> , 44, 1196-206	13
1378	Glucose supply and insulin demand dynamics of antidiabetic agents. <b>2010</b> , 4, 365-81	3
1377	Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. <b>2010</b> , 33, 983-90	331
1376	Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. <b>2010</b> , 67, 798-805	20
1375	Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <b>2010</b> , 33, 1578-84	342

1374	Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. <b>2010</b> , 33, 1591-7	137
1373	Cardiovascular risk and prevention in diabetes mellitus. <b>2010</b> , 10, 495-9	5
1372	Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <b>2010</b> , 122, 847-9	44
1371	ACCORD(ing) to a trialist. <b>2010</b> , 122, 841-3	4
1370	Strategies for the development of new PPAR agonists in diabetes. <b>2010</b> , 17 Suppl 1, S32-7	3
1369	Point: postprandial glucose levels are a clinically important treatment target. <b>2010</b> , 33, 1905-7	37
1368	Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. <b>2010</b> , 33, 116-20	16
1367	Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. <b>2010</b> , 33, 526-31	64
1366	A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. <b>2010</b> , 122, 16-27	179
1365	Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: the J-ACCESS 2 investigation. <b>2010</b> , 33, 2320-6	28
1364	Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture. <b>2010</b> , 121, 940-5	5
1363	More Intensive Glycemic Control Reduces Nonfatal Myocardial Infarction But Not All-Cause Mortality. <b>2010</b> , 28, 87-88	
1362	Secular trends in treatment and control of type 2 diabetes in an American Indian population: a 30-year longitudinal study. <b>2010</b> , 33, 2383-9	10
1361	Counterpoint: postprandial glucose levels are not a clinically important treatment target. <b>2010</b> , 33, 1908-10	7
1360	Hypoglycaemia: a limiting factor. <b>2010</b> , 10, 2-4	4
1359	Hypoglycaemia in patients with type 2 diabetes: minimising the risk. <b>2010</b> , 10, 35-41	3
1358	Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation. <b>2010</b> , 5, 2373-9	65
1357	Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. <b>2010</b> , 3, 236-42	27

1356	Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <b>2010</b> , 122, 844-6	72
1355	Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. <b>2010</b> , 59, 1063-73	228
1354	Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues. <b>2010</b> , 33, 2722-4	32
1353	Focusing on outcomes in Circulation: Cardiovascular Quality and Outcomes. <b>2010</b> , 3, 332-4	1
1352	Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. <b>2010</b> , 121, 1176-87	71
1351	Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. <b>2010</b> , 122, 2201-11	54
1350	Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. <b>2010</b> , 121, 2071-8	24
1349	Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. <b>2010</b> , 10, 178-182	9
1348	Trends in diabetes medication use and prevalence of geriatric syndromes in older Mexican Americans from 1993/1994 to 2004/2005. <b>2010</b> , 44, 1376-83	10
1347	Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. <b>2010</b> , 285, 26861-26868	52
1346	Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group. <b>2010</b> , 7, 322-32	26
1345	Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. <b>2010</b> , 1212, 29-40	18
1344	Association between admission hypoglycaemia and in-hospital and 3-year mortality in older patients with acute myocardial infarction. <b>2010</b> , 96, 1444-50	29
1343	Diabetes and heart failure in patients with coronary disease: separating markers from mediators. <b>2010</b> , 33, 2120-2	5
1342	Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. <b>2010</b> , 33, 1153-8	79
1341	Hemoglobin A1c in hemodialysis patients: should one size fit all?. <b>2010</b> , 5, 1539-41	15
1340	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. <b>2010</b> , 5, 811-826	20
1339	Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. <b>2010</b> , 5, 1595-601	68

1338	Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. <b>2010</b> , 14, 1-248	99
1337	Surgical interventions to correct metabolic disorders. <b>2010</b> , 10, 143-147	1
1336	Effect of trajectories of glycemc control on mortality in type 2 diabetes: a semiparametric joint modeling approach. <b>2010</b> , 171, 1090-8	21
1335	Prevention and Treatment of Diabetic Nephropathy. <b>2010</b> , 377-384	
1334	Medical Management of the Kidney Transplant Recipient: Cardiovascular Disease and Other Issues. <b>2010</b> , 1189-1199	
1333	Nuts, metabolic syndrome and diabetes. <b>2010</b> , 104, 465-73	88
1332	Kidney Transplantation: A Guide to the Care of Kidney Transplant Recipients. <b>2010</b> ,	1
1331	Diabetes and the Brain. <b>2010</b> ,	3
1330	Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. <b>2010</b> , 19, 167-75	38
1329	Residual microvascular risk in diabetes: unmet needs and future directions. <b>2010</b> , 6, 19-25	75
1328	Glucose lowering and cardiovascular disease: what do we know and what should we do?. <b>2010</b> , 17 Suppl 1, S25-31	10
1327	Clinical care guidelines: too much of a good thing?. <b>2010</b> , 33, 2716-8	1
1326	Prediabetes: the importance of early identification and intervention. <b>2010</b> , 122, 129-43	35
1325	Toward an outcomes-based health care system: a view from the United Kingdom. <b>2010</b> , 304, 2407-8	10
1324	Risk of diabetes and cardiovascular disease: best to return back to the basics: comment on "Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus". <b>2010</b> , 170, 1575-7	4
1323	Non-LDL-related dyslipidaemia and coronary risk: a case-control study. <b>2010</b> , 7, 204-12	15
1322	Managing medications in clinically complex elders: "There's got to be a happy medium". <b>2010</b> , 304, 1592-601	219
1321	After cardiac surgery, how does nutrition fit in with risk factors?. <b>2010</b> , 34, 163-8	3

1320	Serum resistin: physiology, pathophysiology and implications for heart failure. <b>2010</b> , 4, 445-52	11
1319	Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?. <b>2010</b> , 12, 1156-8	1
1318	3rd Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 7-8, 2010, London, UK. <b>2010</b> , 12, 859-72	2
1317	Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. <b>2010</b> , 12, 627-33	49
1316	Oral Antidiabetic Agents. <b>2010</b> , 452-477	2
1315	The role of bile acid sequestrants in the management of type 2 diabetes mellitus. <b>2010</b> , 8 Suppl 1, S15-21	4
1314	Lifestyle changes are related to reductions in depression in persons with elevated coronary risk factors. <b>2010</b> , 25, 1077-100	20
1313	Meeting targets in type 2 diabetes care contributing to good glycaemic control. A cross-sectional study from a primary care setting in Estonia. <b>2010</b> , 16, 85-91	12
1312	ACCORD glycemia results continue to puzzle. <b>2010</b> , 33, 1149-50	9
1311	Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease. <b>2010</b> , 11, 33-9	2
1310	ABC de la nefropatà diabètica: UNA guà pràctica para el mèdico general. <b>2010</b> , 21, 579-583	
1309	Novel therapeutics and targets for the treatment of diabetes. <b>2010</b> , 3, 209-29	16
1308	The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. <b>2010</b> , 12, 11-24	29
1307	Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model. <b>2010</b> , 4, 382-90	
1306	Glucose information for tight glycemic control: different methods with different challenges. <b>2010</b> , 4, 1269-75	3
1305	Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. <b>2010</b> , 9, 675-81	59
1304	Point: Intensive glycemic control and mortality in ACCORD--a chance finding?. <b>2010</b> , 33, 2719-21	17
1303	Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). <b>2010</b> , 33, 2558-60	7

1302	The law of diminishing returns in clinical medicine: how much risk reduction is enough?. <b>2010</b> , 23, 371-5	23
1301	The enigma of glucose and cardiovascular disease. <b>2010</b> , 96, 649-51	3
1300	Clinical analysis of elderly patients with elderly-onset type 2 diabetes mellitus in China: assessment of appropriate therapy. <b>2010</b> , 38, 1134-41	12
1299	Platelet abnormalities in diabetes mellitus. <b>2010</b> , 7, 251-9	138
1298	Diabetes mellitus en el paciente con enfermedad renal avanzada. <b>2010</b> , 21, 585-594	0
1297	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. <b>2010</b> , 26, 365-75	11
1296	Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <b>2010</b> , 33, 721-7	126
1295	Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. <b>2010</b> , 25, 2044-7	26
1294	Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1575-85	59.2 2411
1293	Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial. <b>2010</b> , 33, 478-84	144
1292	Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. <b>2010</b> , 42, 305-15	26
1291	Insulin Initiation During a 20-Minute Office Visit: Part 2: Making It Happen. <b>2010</b> , 23, 260-266	
1290	The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. <b>2010</b> , 31, 25-51	111
1289	Cardiovascular clinical trials in patients with diabetes mellitus: lessons from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study. <b>2010</b> , 121, 2453-5	4
1288	Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation. <b>2010</b> , 4, 717-22	5
1287	Simulated physician learning program improves glucose control in adults with diabetes. <b>2010</b> , 33, 1727-33	17
1286	Neuropathy: the crystal ball for cardiovascular disease?. <b>2010</b> , 33, 1688-90	61
1285	Translating "Nondiabetic" A1C levels to clinical practice: the art of medicine. <b>2010</b> , 59, 1868-9	2



1284	Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. <b>2010</b> , 59, 1349-57	36
1283	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. <b>2010</b> , 122, 52-60	16
1282	Pioglitazone and mechanisms of CV protection. <b>2010</b> , 103, 213-28	18
1281	A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. <b>2010</b> , 3, 221-2	
1280	The growing importance of diabetes screening. <b>2010</b> , 33, 1695-7	16
1279	Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics. <b>2010</b> , 30, 8-10	12
1278	Glycemic control in diabetes. <b>2010</b> , 25, 232-3	2
1277	Hypoglycemia, diabetes, and cardiovascular events. <b>2010</b> , 33, 1389-94	296
1276	Use of sensors in the treatment and follow-up of patients with diabetes mellitus. <b>2010</b> , 10, 7404-20	11
1275	Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. <b>2010</b> , 298, F125-32	50
1274	Blood pressure control in chronic kidney disease: is less really more?. <b>2010</b> , 21, 1086-92	69
1273	Can we reduce the cardiovascular risk in peritoneal dialysis patients?. <b>2010</b> , 20, 59-67	13
1272	Rostroventrolateral medullary neurons modulate glucose homeostasis in the rat. <b>2010</b> , 299, E802-7	49
1271	Using Electronic Health Records to Improve Outpatient Diabetes Care: Preface. <b>2010</b> , 23, 146-148	1
1270	Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor. <b>2010</b> , 122, 185-8	3
1269	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2010</b> , 122, e584-636	451
1268	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. <b>2010</b> , 340, b4909	672
1267	Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients. <b>2010</b> , 116, 48-50	7

1266	Risk-factor medicine: an industry out of control?. <b>2010</b> , 117, 64-7	4
1265	Targeting hyperphosphatemia: truth or dare. <b>2010</b> , 77, 256-7; author reply 257	1
1264	Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. <b>2010</b> , 31, 1159-62	11
1263	Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographed coronary patients. <b>2010</b> , 31, 1583-90	32
1262	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. <b>2010</b> , 31, 1677-1681	46
1261	Hypoglycemia-induced blood pressure elevation in patients with diabetes. <b>2010</b> , 170, 829-31	23
1260	Palliative care and type II diabetes: A need for new guidelines?. <b>2010</b> , 27, 444-5	15
1259	Metabolic syndrome, peripheral vascular disease and coronary artery disease: A concise review. <b>2010</b> , 19, e96-9	12
1258	Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a German multicenter analysis on 9294 patients. <b>2010</b> , 118, 490-5	3
1257	What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification. <b>2010</b> , 41, S35-8	15
1256	Die großen Diabetesstudien â€Fazit fïr die Praxis â€HbA1câ€the lower the better?. <b>2010</b> , 8, 32-37	
1255	Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. <b>2010</b> , 26, 163-75	18
1254	Approach to the patient with type 2 diabetes and progressive kidney disease. <b>2010</b> , 95, 3103-10	21
1253	Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. <b>2010</b> , 122, 172-83	7
1252	Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. <b>2010</b> , S15-21	5
1251	Diabetes: Low HbA1c levels and mortality in type 2 diabetes mellitus. <b>2010</b> , 6, 359-60	1
1250	Insulin regimens in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 959; author reply 960	59.2 1
1249	Biventricular pacing. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 956-7; author reply 958-9	59.2 2

1248	Reevaluating erythropoiesis-stimulating agents. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1742; author reply 1743-4	59.2	4
1247	ACCORD and Risk-Factor Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1628-36	59.2	48
1246	Effects of medical therapies on retinopathy progression in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 233-44	59.2	859
1245	Overcoming challenges in Type 2 diabetes management to improve patient outcomes. <b>2010</b> , 5, 741-751		1
1244	Diabetes: intensive glucose-lowering therapy-weighing up the evidence. <b>2010</b> , 6, 9-10		
1243	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. <b>2010</b> , 340, b5444		313
1242	Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. <b>2010</b> , 340, c103		20
1241	Cardiovascular disease and glyceic treatment. <b>2010</b> , 33, e134-9		4
1240	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. <b>2010</b> , 78, 726-36		36
1239	Therapie bei Patienten mit Typ-2-Diabetes â Von der tztlichen Verpflichtung einer normnahen Stoffwechseleinstellung. <b>2010</b> , 8, 72-76		
1238	Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. <b>2010</b> , 5, 234-44		19
1237	Blutzuckerkontrolle und Hypoglykämierisiko bei der Behandlung des Typ-2-Diabetes mit dem neuen GLP-1-Rezeptoragonisten Liraglutid. <b>2010</b> , 5, 287-292		
1236	Diabetes und Schlaganfall â Eine schwierige Beziehung, akut, wie im Langzeitbereich. <b>2010</b> , 37, 136-147		0
1235	Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. <b>2010</b> , 95, 5289-95		86
1234	Evidence-based management of carotid artery disease. <b>2010</b> , 19, e21-4		4
1233	Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. <b>2010</b> , 181, 507-13		335
1232	Contemporary management of patients with Type 2 diabetes. <b>2010</b> , 8, 767-70		
1231	Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. <b>2010</b> , 122, 7-15		90

1230	Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. <b>2010</b> , 122, 61-70	10
1229	Coagulation and fibrinolysis in diabetes. <b>2010</b> , 7, 260-73	144
1228	IMPROVEâobservational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus. <b>2010</b> , 5, 507-516	5
1227	Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. <b>2010</b> , 26, 9-15	13
1226	Pramlintide for diabetes mellitus. <b>2010</b> ,	
1225	Analyse critique du consensus ADA/EASD 2009 : âBack to the past and lost in translationâCritical analysis of the 2009 ADA/EASD consensus statement: Back to the past and lost in translation. <b>2010</b> , 4, 191-196	1
1224	Lower blood pressure goals in high-risk cardiovascular patients: are they defensible?. <b>2010</b> , 28, 447-52	2
1223	Capteurs de glucose et mesure continue du glucose. <b>2010</b> , 4, 157-168	7
1222	Diabetes, cardiovascular risk and nephropathy. <b>2010</b> , 28, 467-75	24
1221	Consensus ADA/EASD 2009 : lâlgorithme pour le traitement mdical du diabte de type 2 est utile !: The 2009 ADA/EASD consensus: The algorithm for the treatment of type 2 diabetes is useful!. <b>2010</b> , 4, 181-190	1
1220	Traitement du diabte de type 2 : il est temps de regarder lâEvidence Based Medicine en face !. <b>2010</b> , 4, 718-720	2
1219	Respuesta del Dr. Marcos Lahera Vargas. <b>2010</b> , 26, 366-369	
1218	Regarder lâEvidence Based Medicine en face ? OUI, mais de plus prs !. <b>2010</b> , 4, 721-724	1
1217	Lâintrt dmontr des statines chez les patients diabtiques de type 2. <b>2010</b> , 4, 75-78	0
1216	Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. <b>2010</b> , 28, 497-516	6
1215	Gestione terapeutica del diabete di tipo 2. <b>2010</b> , 12, 1-7	
1214	Effets cardiovasculaires du GLP-1 : des donnes exprimentales aux consquences thrapeutiques des incrtinomimtiques. <b>2010</b> , 4, 407-417	1
1213	The Cost of Diabetes: A Game Changer. <b>2010</b> , 34, 16-18	3

1212 Respuesta del Dr. Manuel Delgado Gñez. **2010**, 26, 440-444

1211 Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications. **2010**, 71, 505-10

2

1210 Maladie coronaire du diabétique. **2010**, 2010, 23-28

1209 Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. **2010**, 26, 331-338

24

1208 Defining and achieving treatment success in patients with type 2 diabetes mellitus. **2010**, 85, S50-9

29

1207 Self-monitoring of Blood Glucose in Individuals with Type 2 Diabetes Not Using Insulin: Commentary. **2010**, 34, 19-23

4

1206 Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. **2010**, 85, S15-26

20

1205 Respuesta del Dr. Juan Jos<sup>o</sup>Chillar<sup>o</sup> Jord<sup>o</sup>. **2010**, 26, 265-267

1204 Medication issues in older individuals with CKD. **2010**, 17, 320-8

11

1203 Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *New England Journal of Medicine*, **2010**, 362, 800-11

59.2 1045

1202 Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. **2010**, 6, 332-41

90

1201 Retinopathy progression in type 2 diabetes. *New England Journal of Medicine*, **2010**, 363, 2172-3; author reply 2173-4

59.2 9

1200 Effects of combination lipid therapy in type 2 diabetes mellitus. *New England Journal of Medicine*, **2010**, 362, 1563-74

59.2 1940

1199 Severe hypoglycemia and risks of vascular events and death. *New England Journal of Medicine*, **2010**, 363, 1410-8

59.2 1058

1198 Intensive glyceic control and cardiovascular disease: an update. **2010**, 7, 369-75

125

1197 Basic Study Design. **2010**, 67-96

1

1196 Proinflammatory and prothrombotic effects of hypoglycemia. **2010**, 33, 1686-7

60

1195 [Cardiovascular risk factor control in a population with longstanding diabetes attending endocrinology departments]. **2010**, 57, 472-8

13

1194	Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. <b>2010</b> , 55, 283-93	144
1193	Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. <b>2010</b> , 55, 1348-58	79
1192	Pre-clinical diastolic dysfunction in diabetic patients: where do we go from here?. <b>2010</b> , 55, 306-8	8
1191	Stroke prevention and treatment. <b>2010</b> , 56, 683-91	79
1190	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. <b>2010</b> , 55, 1885-94	47
1189	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2010</b> , 56, e50-103	976
1188	After acute coronary syndrome, diabetic patients with peripheral vascular disease remain at high risk of cardiovascular events despite secondary prevention measures. <b>2010</b> , 103, 97-105	9
1187	Sulphonyurea as a cause of severe hypoglycaemia in the community. <b>2010</b> , 4, 61-3	10
1186	Obesity and diabetes: the links and common approaches. <b>2010</b> , 4, 105-12	25
1185	Diabetes, related conditions, and dementia. <b>2010</b> , 299, 35-8	61
1184	Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. <b>2010</b> , 70, 489-512	75
1183	Alogliptin: a review of its use in the management of type 2 diabetes mellitus. <b>2010</b> , 70, 2051-72	46
1182	Current approaches to the management of diabetic retinopathy and diabetic macular oedema. <b>2010</b> , 70, 2171-200	25
1181	Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. <b>2010</b> , 70, 2229-45	41
1180	Wetenschapsdag. <b>2010</b> , 53, 298-298	
1179	Stagnant in cardiovascular prevention: alarming trends and persistent socioeconomic obstacles. <b>2010</b> , 63, 1340-8	2
1178	Quality of life on trial. <b>2010</b> , 1, 45-50	1
1177	Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. <b>2010</b> , 44, 791-9	34

1176	Comanagement of elderly patients with type 2 diabetes: better adherence to ADA guidelines?. <b>2010</b> , 2, 160-164	1
1175	Multicentre evaluation of the Tosoh HbA1c G8 analyser. <b>2010</b> , 48, 365-71	26
1174	Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. <b>2010</b> , 33, 1529-35	159
1173	Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). <b>2010</b> , 95, 2163-71	50
1172	Terapia del diabete di tipo 2: obiettivi glicemici in relazione al tipo di paziente. <b>2010</b> , 11, 254-259	
1171	The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. <b>2010</b> , 14, 1333-42	28
1170	Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. <b>2010</b> , 33, 2217-24	538
1169	Tagatose: from a sweetener to a new diabetic medication?. <b>2010</b> , 19, 285-94	40
1168	Perioperative insulin dosing in diabetic patients undergoing outpatient upper extremity surgery. <b>2010</b> , 35, 320-1	3
1167	[Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure]. <b>2010</b> , 134, 596-9	2
1166	[Residual vascular risk: recommendations of the Spanish Initiative for the Reduction of Residual Risk]. <b>2010</b> , 135, 165-71	5
1165	[Biomedical research, the market, clinicians, safety and corporate social responsibility post-phase III: maintaining confidence]. <b>2010</b> , 25, 169-72	
1164	Diabetic cardiomyopathy. <b>2010</b> , 16, 971-9	91
1163	Efficacy and safety of an insulin infusion protocol during and after cardiac surgery. <b>2010</b> , 36, 71-8	17
1162	Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. <b>2010</b> , 36, 86-7	
1161	It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. <b>2010</b> , 36, 91-6	23
1160	Are elderly patients with diabetes being overtreated in French long-term-care homes?. <b>2010</b> , 36, 272-7	38
1159	A randomized study comparing isotope and echocardiography stress testing in the screening of silent myocardial ischaemia in type 2 diabetic patients. <b>2010</b> , 36, 463-9	11

1158	Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. <b>2010</b> , 87, 228-32	5
1157	International Diabetes Federation: An update of the evidence concerning the prevention of type 2 diabetes. <b>2010</b> , 87, 143-9	34
1156	Hemoglobin A1c in predicting progression to diabetes. <b>2010</b> , 87, 126-31	23
1155	The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. <b>2010</b> , 89, 1-9	36
1154	Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America. <b>2010</b> , 88, 7-13	18
1153	Correlation between glucose fluctuations and carotid intima-media thickness in type 2 diabetes. <b>2010</b> , 90, 95-9	29
1152	The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. <b>2010</b> , 89, 126-33	31
1151	The cardiorenal syndrome in diabetes mellitus. <b>2010</b> , 89, 201-8	32
1150	DPP-4 inhibitors: what may be the clinical differentiators?. <b>2010</b> , 90, 131-40	77
1149	Update of cerebral vascular disease: issues for the primary care physician. <b>2010</b> , 56, 40-71	10
1148	Does glycated hemoglobin have clinical significance in ischemic stroke patients?. <b>2010</b> , 112, 98-102	11
1147	Managing cardiovascular risk factors: trial evidence in women. <b>2010</b> , 20, 445-50	8
1146	Glucohemoglobina HbA1c. Primera parte: conocerla. <b>2010</b> , 36, 82-88	2
1145	Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. <b>2010</b> , 159, 90-7	8
1144	The relationship between retinal microvascular abnormalities and coronary heart disease: a review. <b>2010</b> , 123, 374.e1-7	60
1143	Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. <b>2010</b> , 123, 374.e 9 -18	45
1142	Glycemic control and complications in type 2 diabetes mellitus. <b>2010</b> , 123, S3-11	201
1141	Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. <b>2010</b> , 123, S12-8	44



1140 Dislipemia aterogénica: una llamada de atención sobre su papel en el riesgo residual. **2010**, 22, 162-166

1139 Transforming mental healthcare in the Veterans Health Administration: a model for measuring performance to improve access, quality, and outcomes. **2010**, 32, 33-42; quiz 42-3 10

1138 The diabetic CKD patient--a major cardiovascular challenge. **2010**, 36 Suppl 1, 34-46 12

1137 In search of the holy grail? The quest to reduce macrovascular disease in type 2 diabetes mellitus. **2010**, 5, 2-6

1136 Hospital hypoglycemia: From observation to action. **2010**, 5, 16-36 10

1135 Tratamiento de la diabetes de tipo 2. **2010**, 14, 1-7

1134 Diabetes and cardiovascular mortality: from epidemiologic data to clinical trial evidence. **2010**, 73, 459-61

1133 Treat early, treat appropriately. **2010**, 4 Suppl 1, S3-10 1

1132 Practical guidance to insulin management. **2010**, 4 Suppl 1, S43-56 12

1131 Epigenetic phenomena linked to diabetic complications. **2010**, 6, 665-75 170

1130 [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?]. **2010**, 135 Suppl 2, 2-5 1

1129 [Assessment of glycemic control: new insights into the evaluation of the diabetic patient]. **2010**, 135 Suppl 2, 15-9 1

1128 [Safety and tolerability of oral antidiabetes drugs in the treatment of type 2 diabetes mellitus]. **2010**, 135 Suppl 2, 20-6 0

1127 Treatment of hypertension in patients with diabetes--an update. **2010**, 4, 62-7 11

1126 Rosiglitazone, thiazolidinediones and atherosclerosis. **2010**, 211, 384-5 5

1125 [Therapeutic behavior to follow in the following clinical case: treatment of type 2 diabetes]. **2010**, 210, 23-7 0

1124 Añadir insulina de acción lenta. Dr. J.A. Martín Oterino. **2010**, 210, 26-27

1123 [Progress in hypertension and diabetes mellitus]. **2010**, 63 Suppl 1, 101-15 7

1122	Prevençã cardiovascular estancada: tendencias alarmantes y barreras socioeconômicas persistentes. <b>2010</b> , 63, 1340-1348	9
1121	Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. <b>2010</b> , 375, 481-9	623
1120	Diabetic retinopathy. <b>2010</b> , 376, 124-36	1675
1119	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <b>2010</b> , 375, 1365-74	188
1118	Survival in people with type 2 diabetes as a function of HbA(1c). <b>2010</b> , 375, 438-40	8
1117	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <b>2010</b> , 376, 419-30	914
1116	Survival as a function of HbA(1c) in people with type 2 diabetes. <b>2010</b> , 375, 1433; author reply 1434-5	
1115	Survival as a function of HbA(1c) in people with type 2 diabetes. <b>2010</b> , 375, 1433-4; author reply 1434-5	
1114	Survival as a function of HbA(1c) in people with type 2 diabetes. <b>2010</b> , 375, 1434; author reply 1434-5	1
1113	Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. <b>2010</b> , 375, 2244-53	92
1112	Dapagliflozin, an SGLT2 inhibitor, for diabetes. <b>2010</b> , 375, 2196-8	21
1111	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. <b>2010</b> , 8, 359-72	81
1110	Acute consequences of hypoglycaemia in diabetic patients. <b>2010</b> , 36 Suppl 3, S75-83	17
1109	Epigenetics: mechanisms and implications for diabetic complications. <b>2010</b> , 107, 1403-13	157
1108	Standards of medical care in diabetes--2010. <b>2010</b> , 33 Suppl 1, S11-61	2438
1107	Glucose control in the older patient: from intensive, to effective and safe. <b>2010</b> , 22, 274-80	16
1106	Diabetes, Insulin and Alzheimer's Disease. <b>2010</b> ,	2
1105	Role of Oral Agents in Improving Cardiovascular Prognosis in Diabetes MellitusâReplyâ <b>2010</b> , 85, 99-101	2

1104	Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. <b>2010</b> , 85, 41-6	16
1103	Atherosclerosis, diabetes and lipoproteins. <b>2010</b> , 8, 1015-29	27
1102	Concerns about meta-analysis of glucose control and cardiovascular disease in type 2 diabetes. <b>2010</b> , 152, 63; author reply 63-4	5
1101	Effects of beta-blockers on glucose and lipid metabolism. <b>2010</b> , 26, 615-29	101
1100	Stem Cell Therapy for Diabetes. <b>2010</b> ,	2
1099	Antidiabetic properties and mechanism of action of <i>Gynura procumbens</i> water extract in streptozotocin-induced diabetic rats. <b>2010</b> , 15, 9008-23	69
1098	Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. <b>2010</b> , 44, 37-44	16
1097	Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). <b>2010</b> , 26, 1793-7	36
1096	Ketoconazole enantiomer for the treatment of diabetes mellitus. <b>2010</b> , 19, 185-94	17
1095	Economic impact of hypoglycemia on healthcare in Spain. <b>2010</b> , 10, 649-60	37
1094	Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. <b>2010</b> , 26, 1647-56	27
1093	Management of Global Cardiovascular Risk in Older Subjects with Diabetes Mellitus. <b>2010</b> , 17, 53-58	
1092	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. <b>2010</b> , 17, 73-102	9
1091	Many diabetic patients with recurrent severe hypoglycemia hold a valid driving license. A community-based study in insulin-treated patients with diabetes. <b>2010</b> , 11, 258-62	4
1090	Therapeutic potential of aleglitazar, a new dual PPAR- $\alpha/\gamma$ agonist: implications for cardiovascular disease in patients with diabetes mellitus. <b>2010</b> , 10, 209-16	33
1089	Is insulin treatment a first-line defense against Type 2 diabetes?. <b>2010</b> , 8, 483-5	2
1088	Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. <b>2010</b> , 13, 212-20	14
1087	An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention. <b>2011</b> , 24, 332-8	21

1086	Endocrine and metabolic emergencies: hypoglycaemia. <b>2011</b> , 2, 81-93	10
1085	Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. <b>2011</b> , 7, 753-63	19
1084	Type 2 diabetes and cardiovascular risk factors. <b>2011</b> , 27 Suppl 3, 1-5	14
1083	Special considerations for treatment of type 2 diabetes mellitus in the elderly. <b>2011</b> , 68, 500-9	31
1082	Continuous monitoring of circadian glycemc patterns in patients receiving prednisolone for COPD. <b>2011</b> , 96, 1789-96	124
1081	The ACCORD Study: the devil is in the details. <b>2011</b> , 9, 81-4	1
1080	Sulfonylureas: do we need to introspect safety again?. <b>2011</b> , 10, 851-61	16
1079	The importance of managing diabetes correctly to prevent heart failure. <b>2011</b> , 9, 257-9	4
1078	Evidence-based risk assessment and recommendations for physical activity clearance: diabetes mellitus and related comorbidities. <b>2011</b> , 36 Suppl 1, S154-89	37
1077	What options are available when considering starting insulin: premix or basal?. <b>2011</b> , 13 Suppl 1, S85-92	7
1076	Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. <b>2011</b> , 13 Suppl 1, S25-32	57
1075	Combining basal insulin analogs with glucagon-like peptide-1 mimetics. <b>2011</b> , 13, 873-81	14
1074	Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. <b>2011</b> , 343, d4169	496
1073	Controversies in the cardiovascular management of type 2 diabetes. <b>2011</b> , 97, 6-14	19
1072	Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. <b>2011</b> , 34, 69-77	18
1071	Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. <b>2011</b> , 7, 683-90	127
1070	Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. <b>2011</b> , 18, 813-23	103
1069	Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. <b>2011</b> , 34, 1164-70	140

1068	Disease Prevention in Heart Failure. <b>2011</b> , 610-625	
1067	Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. <b>2011</b> , 27, 897-906	13
1066	Peripheral artery disease. Part 2: medical and endovascular treatment. <b>2011</b> , 8, 429-41	31
1065	Impact of weight gain on outcomes in type 2 diabetes. <b>2011</b> , 27, 1431-8	63
1064	Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. <b>2011</b> , 11, 227-47	59
1063	Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. <b>2011</b> , 124, 1151-9	152
1062	Clinical update on nursing home medicine: 2011. <b>2011</b> , 12, 615-626.e6	5
1061	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. <b>2011</b> , 3, 217-236	1
1060	Critères de choix des analogues du GLP-1 dans le traitement du diabète de type 2. <b>2011</b> , 5, 348	
1059	Le parcours de soin : une solution ou une contrainte supplémentaire ?. <b>2011</b> , 5, S81-S85	1
1058	Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. <b>2011</b> , 86, 128-38	39
1057	End-point selection for acute heart failure trials. <b>2011</b> , 7, 481-95	
1056	Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. <b>2011</b> , 86, 444-56	84
1055	Development and Pilot-Testing of a Brief Psychosocial Group Intervention Protocol for Type 2 Diabetes Self-Management. <b>2011</b> , 35, 287-294	3
1054	Biliopancreatic Diversion with Duodenal Switch in the Treatment of Diabetes: An Argument that a Chance to Cut is a Chance to Cure. <b>2011</b> , 35, 109-114	4
1053	Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. <b>2011</b> , 35, 518-27	3
1052	Overall mortality in diabetes mellitus: where do we stand today?. <b>2011</b> , 13 Suppl 1, S65-74	33
1051	Report of the 20th European Stroke Conference, Hamburg, May 24-27, 2011. <b>2011</b> , 32, 589-613	3

1050	Hypertension artfielle et diabète : nouvelles données apportées par l'étude ACCORD-Blood Pressure (ACCORD-BP). <b>2011</b> , 5, 312-316	
1049	Glycemic targets for elderly diabetic patients need reappraisal. <b>2011</b> , 12, 9-11	2
1048	Diabetes in the Elderly. <b>2011</b> , 35, 13-16	1
1047	L'âthertie thfapeutique dans le diabète de type 2 : la comprendre sans la banaliser. <b>2011</b> , 5, S62-S68	3
1046	« Arrêtez de tirer sur le pianiste ! »* Le point de vue du médecin gñfaliste sur l'âthertie thfapeutique. <b>2011</b> , 5, S69-S75	2
1045	Mechanisms of vascular complications in prediabetes. <b>2011</b> , 95, 309-25, vii	35
1044	Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. <b>2011</b> , 34, 1511-3	64
1043	The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. <b>2011</b> , 13, 813-8	118
1042	Left ventricular structure and function in prediabetic adults: Relationship with insulin resistance. <b>2011</b> , 2, 23-8	6
1041	Predicting the Future Burden of Diabetes in Alberta from 2008 to 2035. <b>2011</b> , 35, 274-281	8
1040	Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. <b>2011</b> , 58, 112-120	6
1039	Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic	95
1038	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force	243
1037	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses,	185
1036	International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. <b>2011</b> , 58, 671-6	22
1035	Physiological aging: window of opportunity. <b>2011</b> , 4, 243-5	3
1034	Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. <b>2011</b> , 58, 331-340	12
1033	Glucocentricity or adipocentricity: A critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus. <b>2011</b> , 58, 541-549	8

1032	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. <b>2011</b> , 58, 112-20	9
1031	[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]. <b>2011</b> , 58, 331-40	11
1030	[Glucocentricity or adipocentricity: a critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus]. <b>2011</b> , 58, 541-9	7
1029	Diabetes and insulin resistance in older people. <b>2011</b> , 95, 615-29, xi-ii	22
1028	Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. <b>2011</b> , 8, 445-456	6
1027	Special considerations on the management of Latino patients with type 2 diabetes mellitus. <b>2011</b> , 27, 969-79	15
1026	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <b>2011</b> , CD008143	51
1025	Introduction to Staged Diabetes Management. <b>2011</b> , 5-16	
1024	Characterization of Glucose Metabolism. <b>2011</b> , 29-39	1
1023	Type 2 Diabetes in Adults. <b>2011</b> , 77-137	3
1022	Complications Associated with Diabetes. <b>2011</b> , 201-249	
1021	Glucose Management in the Hospital Setting. <b>2011</b> , 261-271	
1020	Add-on therapies to metformin for type 2 diabetes. <b>2011</b> , 12, 47-62	14
1019	Type 2 Diabetes and Dementia. <b>2011</b> , 19-38	
1018	Hypoglycaemia and the Older Person. <b>2011</b> , 55-73	
1017	Cardiovascular Risk, Glucose and Targets for Management of Diabetes in Older People. <b>2011</b> , 75-99	
1016	Sitagliptin: a review. <b>2011</b> , 12, 1613-22	30
1015	Should A1C targets be individualized for all people with diabetes? Arguments for and against. <b>2011</b> , 34 Suppl 2, S191-6	14

1014	The surgical treatment of type two diabetes mellitus. <b>2011</b> , 91, 821-36, viii		29
1013	Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. <b>2011</b> , 71, 1281-320		62
1012	Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. <b>2011</b> , 71, 1675-88		63
1011	Clinical Uses of Alginate. <b>2011</b> , 137-184		2
1010	Long-term effects of intensive glucose lowering on cardiovascular outcomes. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 818-28	59.2	732
1009	Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2366-76	59.2	390
1008	Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. <b>2011</b> , 31, 485-93		37
1007	Epigenetic Aspects of Chronic Diseases. <b>2011</b> ,		2
1006	Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?. <b>2011</b> , 28, 935-41		3
1005	Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. <b>2011</b> , 1, 145-156		17
1004	Comprehensive Cardiovascular Medicine in the Primary Care Setting. <b>2011</b> ,		
1003	Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <b>2011</b> , 42, 517-84		1148
1002	Hypoglycémie et effets cardiovasculaires. <b>2011</b> , 5, 399-405		
1001	Characteristics of peripheral arterial disease and its relevance to the diabetic population. <b>2011</b> , 10, 152-66		51
1000	Type 2 diabetes mellitus--current therapies and the emergence of surgical options. <b>2011</b> , 7, 408-19		53
999	Prevention and management of transplant-associated diabetes. <b>2011</b> , 12, 2641-55		9
998	Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. <b>2011</b> , 154, 554-9		259
997	Clinical inertia as a clinical safeguard. <b>2011</b> , 305, 1591-2		62



996	Hypertension and Stroke. <b>2011,</b>	3
995	CKD and hypertension: pogo and pragmatism. <b>2011, 18, 1-2</b>	0
994	L'efficacité thérapeutique dans le traitement du diabète de type 2 : à propos de quelques données. <b>2011, 5, S46-S51</b>	1
993	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. <b>2011, 23, 40-48</b>	
992	A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. <b>2011, 161, 210-219.e1</b>	47
991	No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. <b>2011, 161, 657-663.e1</b>	23
990	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes	95
989	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. <b>2011, 162, 938-948.e2</b>	116
988	Heart failure and diabetes: time to pay attention. <b>2011, 162, 795-7</b>	4
987	Repeated hemoglobin A1C ordering in the VA Health System. <b>2011, 124, 342-9</b>	25
986	Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. <b>2011, 124, S35-53</b>	58
985	Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. <b>2011, 124, 1028-35</b>	114
984	Death during intensive glycemic therapy of diabetes: mechanisms and implications. <b>2011, 124, 993-6</b>	97
983	Insulin therapy in the elderly patient with diabetes. <b>2011, 9, 24-36</b>	18
982	Diabetes is more lethal in Mexicans and Mexican-Americans compared to Non-Hispanic whites. <b>2011, 21, 899-906</b>	18
981	Lipids, lipid-lowering therapy and diabetes complications. <b>2011, 37, 15-24</b>	20
980	Hemoglobin A(1c) proportion, mortality rate, and risk factors for death in diabetic patients with severe hypoglycemia: a multicenter retrospective survey over ten years. <b>2011, 93, 17-20</b>	
979	Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. <b>2011, 93, 328-36</b>	34

978	Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. <b>2011</b> , 94, 284-90	16
977	Reno-cerebrovascular disease: linking the nephron and neuron. <b>2011</b> , 11, 241-9	15
976	Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. <b>2011</b> , 64, 743-8	47
975	Intensive glucose control and cardiovascular outcomes in type 2 diabetes. <b>2011</b> , 20, 647-54	59
974	The association between post-load low insulin level and high mortality rates in patients with no previous diagnosis of diabetes mellitus. <b>2011</b> , 148, 59-63	
973	Screening for overt diabetes by oral glucose tolerance test: stratification by fasting blood glucose and patients' age improve practicability of guidelines in cardiological routine. <b>2011</b> , 150, 201-5	1
972	Glucometabolic responses during Glucose Tolerance Test: a comparison between known diabetes and newly detected diabetes after acute myocardial infarction. <b>2011</b> , 152, 78-82	5
971	Heart rate recovery identifies high risk heart failure patients with intermediate peak oxygen consumption values. <b>2011</b> , 149, 284-285	2
970	I. Stroke in general. <b>2011</b> , 20, S7-30	21
969	Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. <b>2011</b> , 54, e1-31	439
968	The role of insulin growth factor on atherosclerosis and endothelial function: the effect on hyperlipidemia and aging. <b>2011</b> , 88, 425-31	12
967	Management of type 2 diabetes mellitus in the elderly. <b>2011</b> , 70, 151-9	30
966	[Risk factors for lower limbs vascular complications in diabetic patients]. <b>2011</b> , 136, 386-7	
965	Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. <b>2011</b> , 29, 47-70	18
964	Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? The Western New York experience. <b>2011</b> , 21, 504-11	14
963	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. <b>2011</b> , 37, 74-82	1
962	Mitochondria as potential targets in antidiabetic therapy. <b>2011</b> , 331-56	17
961	Correlates of quality of life in older adults with diabetes: the diabetes & aging study. <b>2011</b> , 34, 1749-53	144

960	PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus--study design. <b>2011</b> , 5, 231-9	32
959	What can we learn from the recent blood glucose lowering megatrials?. <b>2011</b> , 2, 1-5	11
958	Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. <b>2011</b> , 2, 56-62	6
957	HbA1c: The lower the better?. <b>2011</b> , 2, 45-7	
956	Therapeutic management of diabetic kidney disease. <b>2011</b> , 2, 248-54	11
955	Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. <b>2011</b> , 63, 943-51	16
954	Cognitive function, dementia and type 2 diabetes mellitus in the elderly. <b>2011</b> , 7, 108-14	265
953	Sugar and stroke: cerebrovascular disease and blood glucose control. <b>2011</b> , 29, e31-42	19
952	Hypoglycaemia and cardiovascular disease. The fatal linkage. <b>2011</b> , 27, 39-41	
951	Estudio descriptivo de la evoluci3n cl3nico-asistencial de la poblaci3n con diabetes tipo 2 en la Comunidad de Madrid. Estudio de seguimiento diab3tico tipo 2 (ESD-2). <b>2011</b> , 27, 53-60	9
950	Dapagliflozin: A Once-Daily Oral Therapy Sodium-Glucose Cotransporter-2 Inhibitor for the Treatment of Adult Patients with Type 2 Diabetes. <b>2011</b> , 3, CMT.S6168	1
949	[Benefits and harms - two sides of the same medal?]. <b>2011</b> , 105, 163-70	1
948	[Development, appraisal and synthesis of complex interventions - a methodological challenge]. <b>2011</b> , 105, 751-61	19
947	Variability of ventricular repolarization during hypoglycemia. <b>2011</b> , 149, 285-286	1
946	Peregrinaje de un antidiab3tico hasta su aprobaci3n por las agencias internacionales del medicamento. Situaci3n actual. <b>2011</b> , 27, 107-114	
945	Tratamiento de la hiperglucemia en la diabetes mellitus tipo 2: Hacia un tratamiento individualizado. <b>2011</b> , 10, 6230-6239	
944	National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. <b>2011</b> , 377, 557-67	2925
943	Ultra-long-acting insulins for a lifestyle-related pandemic. <b>2011</b> , 377, 880-1	1

942	Type 2 diabetes across generations: from pathophysiology to prevention and management. <b>2011</b> , 378, 169-81	614
941	Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. <b>2011</b> , 3, CMT.S6227	1
940	Why hypotheses informed by observation are often wrong: results of randomized controlled trials challenge chronic disease management strategies based on epidemiological evidence. <b>2011</b> , 17, 224-31	2
939	Focus on Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies. <b>2011</b> , 17, 1-4	
938	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. <b>2011</b> , 17 Suppl 2, 1-53	329
937	Coordinated primary and specialty care for type 2 diabetes mellitus, guidelines, and systems: an educational needs assessment. <b>2011</b> , 17, 880-90	16
936	Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management. <b>2011</b> , 35, 264-72	12
935	Bariatric surgery and the role of the clinical endocrinologist: 2011 update. <b>2011</b> , 17, 788-97	3
934	Nutritional Treatment of Diabetic Foot Ulcers - A Key to Success. <b>2011</b> ,	2
933	Organic consequences of ileal transposition in rats with diet-induced obesity. <b>2011</b> ,	
932	The Experience of Hypoglycaemia and Strategies Used For Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review. <b>2011</b> , 9, 2063-2104	
931	Is it possible to apply secondary stroke prevention guidelines to very old populations?. <b>2011</b> , 11, 9-16	2
930	Editorial on management of diabetes mellitus with coronary artery disease. <b>2011</b> , 7, 928-30	7
929	New Onset Diabetes After Solid Organ Transplantation. <b>2011</b> ,	
928	Heart Failure as a Consequence of Diabetic Cardiomyopathy. <b>2011</b> , 408-418	2
927	Hypoglycemia revisited in the acute care setting. <b>2011</b> , 52, 898-908	13
926	Short-term diabetes attenuates left ventricular dysfunction and mortality rates after myocardial infarction in rodents. <b>2011</b> , 66, 1437-42	8
925	The burgeoning public health impact of diabetes: the role of the ophthalmologist. <b>2011</b> , 129, 225-9	6

924	Increasing trend in the number of severe hypoglycemia patients in Korea. <b>2011</b> , 35, 166-72	31
923	Pharmacologie et Thfapeutique Vasculaire. <b>2011</b> , 687-843	
922	Overlapping medication associated with healthcare switching among Korean elderly diabetic patients. <b>2011</b> , 26, 1461-8	21
921	Structured assessments of diabetic residents. <b>2011</b> , 13, 19-25	
920	Using insulin in people with type 2 diabetes. <b>2011</b> , 9, 496-498	
919	Weight considerations in pharmacotherapy for type 2 diabetes. <b>2011</b> , 2011,	21
918	TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT. 35-61	
917	Tissue factor, blood coagulation, and beyond: an overview. <b>2011</b> , 2011, 367284	121
916	New onset diabetes after transplantation (NODAT): an overview. <b>2011</b> , 4, 175-86	149
915	Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. <b>2011</b> , 35, 571-7	36
914	Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. <b>2011</b> , 5, 283-97	9
913	The case for an elderly targeted stroke management. <b>2011</b> , 2, 89	3
912	No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome. <b>2011</b> , 195, 578-9	2
911	Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. <b>2011</b> , 35, 529-35	22
910	Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. <b>2011</b> , 254, 458-63; discussion 463-4	90
909	Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. <b>2011</b> , 22, 55-61	34
908	Susceptibility of LDL and its subfractions to glycation. <b>2011</b> , 22, 254-61	57
907	The oldest gravidas: a review of pregnancy risks in women over 45. <b>2011</b> , 66, 580-90	7

906	What should be the blood pressure target for diabetic patients?. <b>2011</b> , 26, 308-13	9
905	Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008. <b>2011</b> , 12, 714-22	7
904	Ask the Experts: Cardiovascular complications in diabetic patients. <b>2011</b> , 1, 565-570	
903	How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. <b>2011</b> , 7, 433-51	9
902	Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). <b>2011</b> , 29, 309-18	24
901	Glycemic control and cardiovascular mortality. <b>2011</b> , 18, 104-9	12
900	The wrong tool for the job: diabetes public health programs and practice guidelines. <b>2011</b> , 101, 1871-3	
899	Optimal glycemic control in the elderly: where is the evidence and who should be targeted?. <b>2011</b> , 7, 89-96	4
898	Advances in the treatment of type 2 diabetes mellitus. <b>2011</b> , 18, 117-52	112
897	Ideal Blood Glucose Control for Type 2 Diabetes Management: A New Clinical Equipose. <b>2011</b> , 20, 115-118	0
896	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. <b>2011</b> , 1, 615-626	
895	Predicting severe hypoglycemia in the community: a review of recent evidence. <b>2011</b> , 1, 109-128	1
894	Diabetes, hyperglycemia and the management of cerebrovascular disease. <b>2011</b> , 24, 81-8	25
893	Management of type 2 diabetes: more evidence is required to address the clinical and contextual facets. <b>2011</b> , 7, 99-105	2
892	The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. <b>2011</b> , 39, 105-11	147
891	Traitement du diabète en dehors de l'insuline. <b>2011</b> , 8, 1-20	
890	Effects of insulin on the vasculature. <b>2011</b> , 9, 321-32	24
889	Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. <b>2011</b> , 12, 1498-512	12

888	Managing chronic kidney disease in type 2 diabetes in family practice. <b>2011</b> , 103, 952-9	5
887	Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. <b>2011</b> , 2011, 538-540	1
886	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <b>2011</b> , 2011, 6-8	
885	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <b>2011</b> , 2011, 536-538	
884	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <b>2011</b> , 2011, 67-69	
883	FLT3/ITD AML and the law of unintended consequences. <b>2011</b> , 117, 6987-90	49
882	Reducing cardiovascular risk factors in patients with prediabetes. <b>2011</b> , 1, 423-438	1
881	Time for clinically relevant comparative effectiveness studies in type 2 diabetes. <b>2011</b> , 154, 131-2	5
880	Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. <b>2011</b> , 154, 602-13	386
879	Combined assessment of myocardial perfusion and function by ECG-gated myocardial perfusion single-photon emission computed tomography for the prediction of future cardiac events in patients with type 2 diabetes mellitus. <b>2011</b> , 75, 376-82	11
878	Glycemic control is another target of PCI in diabetic patients--to improve clinical outcome from outside the procedure. <b>2011</b> , 75, 773-4	2
877	Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. <b>2011</b> , 6, 539-547	1
876	ACCORD microvascular and Eye substudy: should the results change our practice?. <b>2011</b> , 1, 389-396	
875	Hypoglycemia, diabetes and atherosclerosis: is there a link?. <b>2011</b> , 1, 291-297	1
874	Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. <b>2011</b> ,	0
873	Renal protection and pharmacology. 783-799	
872	Colesevelam for type 2 diabetes mellitus. <b>2011</b> ,	
871	Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. <b>2011</b> , 341, 1-9	26

870	[108th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 2. Therapeutic strategy for diabetic nephropathy]. <b>2011</b> , 100, 2592-8	
869	Rapid-acting insulin glulisine: an update on clinical experience. <b>2011</b> , 6, 527-542	3
868	[Not Available]. <b>2011</b> , 153, 56-63	
867	Meaningful use of information technology: a local perspective. <b>2011</b> , 154, 690-2	5
866	Update in endocrinology: evidence published in 2010. <b>2011</b> , 154, 684-9	
865	Perioperative management of blood glucose during open heart surgery in infants and children. <b>2011</b> , 21, 530-7	7
864	Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. <b>2011</b> , 13, 207-20	55
863	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. <b>2011</b> , 13, 302-12	104
862	Interventions in primary care to improve cardiovascular risk factors and glycated haemoglobin (HbA1c) levels in patients with diabetes: a systematic review. <b>2011</b> , 13, 479-89	18
861	Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. <b>2011</b> , 13, 221-8	248
860	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. <b>2011</b> , 13, 718-25	42
859	High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. <b>2011</b> , 13, 759-64	23
858	New approaches to the treatment of diabetic retinopathy. <b>2011</b> , 13, 784-90	16
857	Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. <b>2011</b> , 13, 869-79	16
856	Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. <b>2011</b> , 13, 921-7	13
855	Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency. <b>2011</b> , 13 Suppl 1, 133-43	14
854	Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. <b>2011</b> , 13, 1020-7	74
853	Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. <b>2011</b> , 13, 1073-87	34



852	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. <b>2011</b> , 13, 1149-57	11
851	Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. <b>2011</b> , 28, 73-80	17
850	Autonomic imbalance: prophet of doom or scope for hope?. <b>2011</b> , 28, 643-51	145
849	R D Lawrence Lecture 2010. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. <b>2011</b> , 28, 141-7	79
848	Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. <b>2011</b> , 28, 876-9	6
847	Alterations in HbA(1c) with advancing age in subjects with normal glucose tolerance: Chandigarh Urban Diabetes Study (CUDS). <b>2011</b> , 28, 590-4	20
846	HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. <b>2011</b> , 28, 1520-4	11
845	Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. <b>2011</b> , 41, 825-32	3
844	Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. <b>2011</b> , 41, 1292-8	8
843	Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline. <b>2011</b> , 164, 2064-72	16
842	The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. <b>2011</b> , 59, 666-72	44
841	Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy. <b>2011</b> , 59, 2263-72	84
840	Patient adherence to medication requirements for therapy of type 2 diabetes. <b>2011</b> , 65, 314-22	165
839	Preventing diabetes complications and the "gluco-centric" dilemma: a word of caution. <b>2011</b> , 65, 225; author reply 226	2
838	Tight glycaemic control-caution in high risk groups. <b>2011</b> , 65, 226-226	
837	Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). <b>2011</b> , 65, 415-9	12
836	Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project]. <b>2011</b> , 65, 1067-75	7
835	Anti-inflammatory therapeutics for the treatment of atherosclerosis. <b>2011</b> , 10, 365-76	197

834	Paradoxical effects of streptozotocin-induced diabetes on endothelial dysfunction in stroke-prone spontaneously hypertensive rats. <b>2011</b> , 589, 5153-65	12
833	Vascular dysfunction in obstructive sleep apnea and type 2 diabetes mellitus. <b>2011</b> , 19, 17-22	34
832	Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. <b>2011</b> , 89, 429-36	2
831	Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. <b>2011</b> , 89, 587-94	8
830	Progress and challenges in translating the biology of atherosclerosis. <b>2011</b> , 473, 317-25	2436
829	Prioritization of care in adults with diabetes and comorbidity. <b>2011</b> , 1243, 69-87	32
828	Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. <b>2011</b> , 1243, 88-102	300
827	4th International Conference on Advanced Technologies and Treatments for Diabetes. <b>2011</b> , 3, 95-102	1
826	Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. <b>2011</b> , 3, 257-60	3
825	Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. <b>2011</b> , 13, 422-30	7
824	Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. <b>2011</b> , 13, 244-51	234
823	Overcoming obstacles in risk factor management in type 2 diabetes mellitus. <b>2011</b> , 13, 613-20	17
822	Glargine prescribing practices for Type 2 diabetes: is there room for improvement?. <b>2011</b> , 3, 352-360	
821	Main characteristics of type 1 and type 2 diabetic patients interested in the use of a telemonitoring platform. <b>2011</b> , 3, 456-468	7
820	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. <b>2011</b> , 60, 1-23	203
819	Management of chronic kidney disease. <b>2011</b> , 39, 407-413	4
818	Concept paper: antihyperglycemic therapy and the diabetic heart--do we really know enough?. <b>2011</b> , 25, 63-72	
817	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. <b>2011</b> , 25, 202-7	12

816	The effort required to achieve and maintain optimal glycemic control. <b>2011</b> , 25, 283-8	12
815	Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. <b>2011</b> , 25, 216-21	67
814	Strict glycemic control and mortality risk among US adults with type 2 diabetes. <b>2011</b> , 25, 289-91	4
813	Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. <b>2011</b> , 25, 362-7	9
812	The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. <b>2011</b> , 25, 355-61	106
811	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. <b>2011</b> , 211, 147-55	12
810	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <b>2011</b> , 10, 969-77	356
809	Intensive glucose lowering and cognition in type 2 diabetes. <b>2011</b> , 10, 949-50	8
808	[Prevention of progression and regression of target organ damage. Future strategies]. <b>2011</b> , 211 Suppl 1, 8-14	0
807	Adequacy of diabetes care for older U.S. rural adults: a cross-sectional population based study using 2009 BRFSS data. <b>2011</b> , 11, 940	18
806	In vitro study of variables relevant to perioperative care of the surgical patient: glucose, osmolarity, and rewarming. <b>2011</b> , 212, 180-6	3
805	Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. <b>2011</b> , 33, 110-20	9
804	Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. <b>2011</b> , 33, 393-407	24
803	Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. <b>2011</b> , 33, 665-78	47
802	Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. <b>2011</b> , 33, 1281-8	16
801	Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. <b>2011</b> , 33, 1868-82	21
800	Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. <b>2011</b> , 33, 1904-13	5
799	Current status of aggressive blood glucose and blood pressure control in diabetic hypertensive subjects. <b>2011</b> , 107, 1856-61	9

798	Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. <b>2011</b> , 108, 3B-24B	212
797	Macrovascular effects and safety issues of therapies for type 2 diabetes. <b>2011</b> , 108, 25B-32B	25
796	Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. <b>2011</b> , 108, 52B-8B	22
795	Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. <b>2011</b> , 108, 59B-67B	16
794	Cardiovascular effects of glucagonlike peptide-1 agonists. <b>2011</b> , 108, 33B-41B	56
793	Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. <b>2011</b> , 108, 1124-8	18
792	A propensity-matched study of the association of diabetes mellitus with incident heart failure and mortality among community-dwelling older adults. <b>2011</b> , 108, 1747-53	10
791	[Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. <b>2011</b> , 43, 202.e1-9	9
790	The ADA focus on diabetes 2011. <b>2011</b> , 32, 119-22	
789	Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011?. <b>2011</b> , 12, 611-23	10
788	The place for glyceemic control in the surgical patient. <b>2011</b> , 12, 405-18	18
787	Intensive glyceemic control and renal outcome. <b>2011</b> , 170, 196-208	13
786	Effects of glucose-lowering drugs on body weight in type 2 diabetes. <b>2011</b> , 22, 32-42	
785	Intensive glycaemic control in type 2 diabetes: where are we now?. <b>2011</b> , 22, 6-8	
784	Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP - at baseline. <b>2011</b> , 123, 436-43	7
783	The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. <b>2011</b> , 396, 941-7	
782	Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. <b>2011</b> , 40, 819-28	79
781	Sekundärprävention bei Patienten mit peripherer arterieller Verschlusskrankheit. <b>2011</b> , 16, 211-220	

- 780 Oral antidiabetic drug therapy in type 2 diabetes mellitus - focus on elderly patients. **2011**, 161, 297-9 4
- 779 [New differential therapy of type 2 diabetes]. **2011**, 52, 395-6, 398-404
- 778 [Cardial target-organ damage in diabetes]. **2011**, 52, 505-17
- 777 [Diabetic retinopathy and maculopathy]. **2011**, 52, 518-32 1
- 776 [Considerations about the efficacy of psychopharmacological drugs]. **2011**, 82, 1425-30 4
- 775 Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. **2011**, 54, 291-9 11
- 774 Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. **2011**, 54, 25-31 110
- 773 1.?????????????????. **2010**, 41, 90-94
- 772 [Clinical guidelines for elderly patients with diabetes mellitus]. **2010**, 47, 517-21
- 771 2.?????????????????????. **2010**, 41, 55S-56S
- 770 Diabetes and the Brain - An Epidemiologic Perspective. **2010**, 73-80
- 769 Peripheral Arterial Disease. **2010**, 196-204.e2
- 768 Management of Type 2 Diabetes Mellitus. **2010**, 897-915
- 767 Diabetes Mellitus: Is the Presence of Nephropathy Important as a Cardiovascular Risk Factor for Cardioneral Syndrome?. **2010**, 145-157
- 766 Diabetic Kidney Disease. **2010**, 319-339
- 765 Antidiabetika. **2010**, 343-365
- 764 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2010**, 250-262
- 763 Thérapeutique des troubles glychiques. **2010**, 119-174

- 762 Diabetes Control, Long-Term Complications, and Large Vessel Disease. **2010**, 959-970
- 761 BARI 2D - where has it taken us to and what the future has in store for us. **2010**, 52, 168-175
- 760 Residual Risk Reduction Initiative: vřva ke snřnřreziduřnřho vaskulřnřho rizika u pacientř dyslipidemiř **2010**, 52, 212-228
- 759 Quels enjeux thřapeutiques chez la personne řđe diabřique ?. **2010**, 194, 819-831
- 758 Peroxisome Proliferator-Activated Receptor-řA Key Regulator of Adipose Tissue Formation, Remodeling, and Metabolism. 441-458
- 757 Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors. **2011**, 3-24
- 756 Diagnosis and Management of Ischemic Stroke. **2011**, 373-390 1
- 755 Potentially dangerous treatment. **2010**, 107, 444; author reply 445
- 754 Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies. **2011**, 165-183
- 753 Pharmacological Prerequisites for Treatment of Complex Patients with Peripheral Artery Disease. **2010**, 10-21
- 752 The Aims of Diabetes Care. 323-333
- 751 Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. **2010**, 3, 243-52
- 750 The Role of Community and Specialist Services. 957-968
- 749 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656 1
- 748 Diabetes in Old Age. 922-939
- 747 How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513
- 746 Congestive Heart Failure. 684-697
- 745 References. **2010**, 149-155

- 744 The Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era. **2010**, 16, 33-38
- 743 Management of Type 2 Diabetes. 79-86
- 742 Point: Metabolic Surgery Plays a Key Role in Endocrinology Practice—The Case for Incorporating RYGB in the Standard Clinical Algorithm to Treat Obesity and Diabetes. **2010**, 16, 39-42
- 741 Macrovascular Disease in Diabetes. 152-160
- 740 Diabetes and Cardiovascular Disease. **2010**, 173-194
- 739 Effectiveness of Individual-Level Interventions to Prevent Vascular Complications. **2010**, 343-372
- 738 Medical Management of Kidney Transplant Recipients. **2011**, 311-332
- 737 Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. **2010**, 3, 387-94 1
- 736 Rossiyskiy konsensus po terapii sakharnogo diabeta u detey i podrostkov. **2010**, 13, 1-8 10
- 735 Optimizatsiya i intensivatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). **2010**, 13, 9-16 9
- 734 Hyperglycemia and Blood Glucose Control. **2011**, 1210-1214
- 733 Antidiabetika. **2011**, 351-375 1
- 732 Primary Prevention of Stroke. **2011**, 242-251
- 731 Diabetes Mellitus. **2011**, 731-755
- 730 [Treatment guide for diabetes]. **2011**, 48, 640-3
- 729 Diabetes in the Elderly. **2011**, 493-496
- 728 The Role of Treatment Adherence in Cardiac Risk Factor Modification. **2011**, 570-578
- 727 The Experience of Hypoglycaemia and Strategies Used For Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review. **2011**, 9, 2063-2104

- 726 Training bij hartfalen. **2011**, 175-184
- 725 Complications cardiovasculaires du diabète. **2011**, 195, 205-211 1
- 724 Diabetes and Cardiovascular Disease. **2011**, 345-370
- 723 What is the Role of Self-Monitoring in Diabetes? Is there a Role for Postprandial Glucose Monitoring? How does Continuous Glucose Monitoring Integrate into Clinical Practice?. 41-55
- 722 Insulin Sensitizers Versus Secretagogues as First-Line Therapy for Diabetes: Rationale for Clinical Choice. 71-78
- 721 HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?. 96-104 1
- 720 Diabetes mellitus and cardiovascular diseases. **2011**, 53, 242-248
- 719 Hemostasis effects of various glucose-lowering medications and angiopathy prevention. **2011**, 10, 66-71
- 718 Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. **2011**, 17, 13-19 1
- 717 Risk Factor Management of Atherosclerotic Peripheral Vascular Disease. **2012**, 175-192
- 716 Diabetes and Coronary Heart Disease. **2012**, 471-484
- 715 Role of Disease Prevention in Health Care Reform. **2011**, 57-72
- 714 Antidiabetika. **2012**, 351-378
- 713 Serum Low-Density Lipoprotein Levels Predict Mid-Term Outcomes of Diabetic Patients After Off-Pump Coronary Artery Bypass Surgery. **2012**, 58, 325-329
- 712 References, Bibliography & Further Reading. **2012**, 287-306
- 711 Stroke Update: Risk Factors and Primary Prevention of Stroke. **2012**, 14, 12 1
- 710 Neurologic Aspects of Kidney Disease. **2012**, 2138-2155
- 709 Diabetes. **2012**, 30-49



708 [Management of the older person with diabetes mellitus]. **2012**, 49, 561-8

707 RECOMENDACIONES EN PREVENCI DEL RIESGO VASCULAR. **2012**, 29-61

706 Chronic Kidney Disease. **2012**, 477-497

705 Peripheral Artery Diseases. **2012**, 1338-1358

1

704 Management Strategies for Diabetes. **2012**, 19-33

703 Public Health - Pages e1-e91. **2012**, e1-e91

702 Literatur. **2012**, 215-227

701 [Early insulin therapy in type 2 diabetes?]. **2012**, 132, 2151-2

1

700 [The risk of diabetic complications in older elderly diabetic patients]. **2012**, 49, 597-601

699 UTICAJ HIPERGLIKEMIJE USLED STRESA NA ISHOD BOLNIOG LENJA BOLESNIKA SA AKUTNIM INFARKTOM MIOKARDA SA ST ELEVACIJOM. **2012**, 18-23

698 Past, Present, and Future of Drug Safety Assessment. **2013**, 157-173

697 Diabetische Nephropathie.

696 Diabetes and the Cardiovascular System. **2013**, 701-714

695 Evidence-Based Glycemic Target for the Prevention of the Complications of Diabetes Mellitus Towards Individualized Therapy. **2013**, 44, 429-430

694 Vascular Complications in Diabetes. **2013**, 313-337

693 Obesity and Diabetes. **2013**, 39-62

692 The outcomes of acute coronary syndrome and complications of acute myocardial infarction in carbohydrate metabolism disorders. **2013**, 4, 11-16

691 The "collateral benefits" of noninsulin therapies for Type 2 diabetes. **2013**, 3, 145-160

- 690 Self-monitoring of blood glucose as a basis for diabetes management. **2013**, 4, 47-54
- 689 Medical therapy for peripheral vascular disease. **2013**, 48-59
- 688 Patient Safety in Outpatient Care. **2014**, 311-325
- 687 Diabetic Nephropathy. **2014**, 455-466 1
- 686 Hypoglycaemia in Diabetes. **2014**, 429-443
- 685 Therapy with Insulin. **2014**, 395-405
- 684 Oral Therapies for Type 2 Diabetes. **2014**, 375-384
- 683 Risks of Intensive Therapy. 145-164
- 682 Mortality, Cardiovascular Morbidity and Possible Effects of Hypoglycaemia on Diabetic Complications. 263-284
- 681 Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus. **2013**, 16, 95-100 1
- 680 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2014**, 265-275
- 679 The Effects of Therapeutic Lifestyle Change on Cardiovascular Disease and Mortality in Diabetic Patients. **2014**, 15, 129 1
- 678 Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?. **2014**, 6, 138-44 8
- 677 Performance Evaluation of the ARKRAY ADAMS Bridge System Comprising Glucose GA-1171 and HbA1c HA-8180 Analyzers. **2014**, 4, 179
- 676 Glycaemic Therapy for Diabetes. **2014**, 43-74
- 675 Prevention of Cardiovascular Disease in Older Adults. **2014**, 1-28
- 674 Vascular Complications of Diabetes Mellitus. **2014**, 1-65
- 673 D'sordres glyc'miques. **2014**, 47-69

- 672 Medical Practice Variations in Diabetes Mellitus. **2014**, 1-40 1
- 671 Prevention and management of diabetic retinopathy. **2014**, 57, 525
- 670 Dřordres glycđmiques et complications diabđtiques : physiopathologie. **2014**, 205-214
- 669 Diabetes Management - Lowering Cardiovascular Risk. **2014**, 9, 7-9 1
- 668 Allgemeine Grundlagen des Diabetes mellitus. **2014**, 1-31
- 667 Contraception and Diabetes. **2014**, 55-68
- 666 The Influence of Admission Hypoglycemia on Clinical Outcomes in Acute Myocardial Infarction Patients with Diabetes Mellitus. **2014**, 87, 565 1
- 665 Diabetes Mellitus. **2014**, 1-21
- 664 Diseđs experimentales en Salud Pđblica: Principales caracterđsticas de los modelos, tđcnicas de anđlisis y casos. es1,
- 663 Glycemia and CVD and Its Management. 116-139
- 662 Hypertension and Cardiovascular Disease and Its Management. 140-164
- 661 Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus. **2014**, 17, 34-40 0
- 660 Self-monitoring of blood glucose as an essential component of exerting total control over diabetes. **2014**, 5, 29-33
- 659 EXPERIENCE WITH THE ROSINSULIN C IN COMBINATION WITH ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN ROUTINE CLINICAL PRACTICE. **2014**, 13, 61-65
- 658 Diabetes. **2015**, 241-250
- 657 Comparison of the efficacy of the herbs for upper medication on glucose tolerance induced by high fat/high sucrose feeding-induced mice. **2014**, 29, 1-8 1
- 656 Conclusion: Time for Medical Reason. **2015**, 121-136
- 655 Endocrine Heart Diseases. **2015**, 571-591

- 654 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. **2015**, 179-202
- 653 Surgical Options in Type 2 Diabetes. **2015**, 111-129
- 652 Self-monitoring of blood glucose in patients with diabetes and cardiac pathology with the Meter Contour TS use. **2014**, 5, 14-19
- 651 Hoofdstuk 8 Acute ontregeling van diabetes mellitus bij de oudere patiënt. **2015**, 61-73
- 650 Cardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?. **2015**, 4, 3
- 649 Diabetes Mellitus: Alterations in Vessel Wall Properties. **2015**, 221-236
- 648 Prevention and Therapy of Steroid-Induced Diabetes. **2015**, 605-610
- 647 Ischemic Stroke. **2015**, 189-202
- 646 Hypoglycemia in Diabetes Mellitus. **2015**, 1-17
- 645 Epidemiology of Coronary Heart Disease in the Elderly. **2015**, 1-12
- 644 Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment. **2015**, 1-19
- 643 Chapter 11. An Elderly Patient with T2DM. **2015**,
- 642 Diseases of Renal Microcirculation: Diabetic Nephropathy. **2015**, 3739-3768
- 641 Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). **2015**, 18, 5-23 8
- 640 Effets de la perte de poids sur la morbidité et la mortalité cardiovasculaires des diabétiques de type 2. **2015**, 199, 823-833
- 639 Diabetes mellitus. **2016**, 89-93
- 638 Surgical and Radiologic Intervention for Prevention of Ischemic Stroke. **2016**, 121-129
- 637 Type 2 Diabetes Mellitus and Skeletal Health. **2016**, 25-43

636 Biomarkers of Diabetic Bone Disease. **2016**, 113-124

635 Biliopancreatic Diversion with Duodenal Switch. **2016**, 187-195

634 Ileal Interposition with Sleeve Gastrectomy for the Treatment of Type 2 Diabetes. **2016**, 197-205

633 Introduction and disease overview. **2016**, 1-9

632 Antidiabetika. **2016**, 301-318

631 Stable Ischemic Heart Disease. **2016**, 1-70

630 Diabetes in the Elderly. **2016**, 1-9

o

629 Coronary Artery Disease and Cardiomyopathy. **2016**, 1-21

628 Treating Type 2 Diabetes Mellitus. **2016**, 1-24

627 Prevention of Microvascular Complications of Diabetes: General Overview. **2016**, 1-9

626 12. Diabetes. **2016**,

625 The Future of Diabetes. **2016**, 1-14

624 Insulin resistance - the body's defence against caloric intoxication?. **2016**, 136, 1015-7

o

623 What news brought last year on oral antidiabetic drugs?. **2016**, 18, 14-18

622 Evolution of the Target Blood Pressure in Diabetes. Analysis of International Experience. **2016**, 1, 40-42

621 Diabetes Mellitus. **2017**, 1649-1668

620 Arterial hypertension and optimal therapy options. **2016**, 15, 141-144

619 English Approaches to Integrated Diabetes Care: The East Cambridgeshire and Fenland Diabetes Integrated Care Initiative: A Multiple Provider Approach. **2017**, 107-130

- 618 Diabetes Integrated Care: Are We There Yet?. **2017**, 233-248
- 617 Neuropathy in Diabetes. **2017**, 443-457
- 616 Cerebrovascular Disease in the Elderly. **2017**, 113-125
- 615 Coronary Artery Disease and Cardiomyopathy. **2017**, 1-21
- 614 Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal. **2017**, 21, 909-918
- 613 Coronary Artery Disease and Cardiomyopathy. **2017**, 637-657
- 612 Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. **2017**, 21, 618-629 2
- 611 Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes. **2017**, 18, 7
- 610 Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy. **2017**, 07, 86-95
- 609 Treating Type 2 Diabetes Mellitus. **2017**, 905-927
- 608 Hypoglycemia in Diabetes Mellitus. **2017**, 367-383
- 607 Perioperative Management of Medical Comorbidities After Bariatric Surgery. **2017**, 167-178
- 606 The Future of Diabetes. **2017**, 999-1012
- 605 Sitosterol Blood Levels are Elevated in Diabetics and may be the Cause of Coronary Artery Disease and Stroke. **2017**, 3, 89-94
- 604 Perspectives on medical treatment of type 2 diabetes mellitus. **2017**, 23, 113-116
- 603 Treating Type 2 Diabetes Mellitus. **2017**, 1-24
- 602 Prevention of Microvascular Complications of Diabetes: General Overview. **2017**, 947-955
- 601 Development of a Pharmaceutical Care Service Model for Patients with Diabetes in Ambulatory Care Settings. **2017**, 27, 1-8 1

600	Comments on current guidelines of type 2 diabetes mellitus treatment. <b>2017</b> , 63, 211-217	1
599	Diabetic Nephropathy: Where do we Stand. <b>2017</b> , 4,	
598	Diabetes Mellitus. <b>2017</b> ,	
597	Cardio Vascular Outcomes Trials (CVOTs) with Anti-Hyperglycemic Agents: Demystifying Statistical Complexities. <b>2017</b> , 4,	1
596	Diabète de type 2 : les médicaments hypoglycémisants et leurs risques cardiovasculaires. <b>2017</b> , 201, 1209-1225	
595	Hypoglycemia-associated In-stent Thrombosis: Are We Doing Too Much?. <b>2017</b> , 9, e1712	3
594	Management of type 2 Diabetes in patients with Chronic Kidney Disease. 053-056	1
593	Second line therapy in type 2 diabetes: legacy effect activation. <b>2017</b> , 20, 356-362	
592	THE ROLE OF GLYCATED HEMOGLOBIN IN THE DIAGNOSIS AND IMPROVED PROGNOSIS OF DIABETES MELLITUS. <b>2017</b> , 48-53	3
591	Fall 56: Prävention â€ 4 Jahre, ?, DM Typ 2, periphere arterielle Verschlusskrankheit, Mikroalbuminurie. <b>2018</b> , 225-228	
590	Fall 63: Therapie â€ 3 Jahre, ?, DM Typ Umstellung auf Insulintherapie. <b>2018</b> , 253-256	
589	: Cardiovascular Disease Prevention in Diabetes. <b>2018</b> , 13, 21-22	0
588	Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy. <b>2018</b> , 10, 493-498	1
587	Fall 57: 73 Jahre, ?, DM Typ 2, Übergewicht, Apoplex Prävention. <b>2018</b> , 229-232	
586	Hypoglycemia. <b>2018</b> , 617-654	1
585	Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience. <b>2018</b> , 08, 152-159	
584	Antidiabetika. <b>2018</b> , 353-368	
583	New Herbal Approaches for the Treatment of Diabetic Kidney Diseases and Its Therapeutic Implications. <b>2018</b> , 321-360	

- 582 Data-Adaptive Estimation in Cluster Randomized Trials. **2018**, 195-215
- 581 Fall 46: Spätschäden â19 Jahre, ?, DM Typ 2 seit 11 Jahren, erhöhter HbA1c, Bluthochdruck von 145 mm Hg, Nierenwerte erhöht, drohende Dialyse. **2018**, 183-185
- 580 Fall 59: Spätschäden â11 Jahre, ?, DM Typ 2, Herzinfarkt- und Schlaganfallrisiko. **2018**, 237-240
- 579 Fall 73: Spätschäden â12 Jahre, ?, DM Typ 2, Surrogatparameter. **2018**, 293-295
- 578 Fall 55: Zielwerte â17 Jahre, ?, DM Typ 2, periphere arterielle Verschlusskrankheit, nichtproliferative Retinopathie und sensorische Neuropathie. **2018**, 221-223
- 577 Fall 53: Zielwerte â18 Jahre, ?, DM Typ 2, Z. n. Herzinfarkt. **2018**, 211-215
- 576 Enfoque terapûtico de la diabetes mellitus tipo 2 en adultos. Mâ allude una meta glucmica. **2018**, 37, 36-46 0
- 575 Glycemic Targets and Prevention of Chronic Complications. **2018**, 421-450
- 574 Fall 23: Spätschäden â13 Jahre, ?, früher Nikotinabusus, periphere arterielle Verschlusskrankheit. **2018**, 89-91
- 573 Diabetes and the Cardiovascular System. **2018**, 131-159
- 572 Hypertension and Diabetes. **2018**, 109-130
- 571 Effective Medical Therapy for Cushing Disease Can Increase the Susceptibility to Relative Hypocortisolism. **2018**, 4, 1-6
- 570 Management of diabetes mellitus. The new period of self-control: detection of glucose trends and patterns. **2017**, 20, 441-448 2
- 569 Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. **2018**, 6, 55 3
- 568 Self-Reported Hypoglycemia in Insulin-Treated Patients with Diabetes: Results from the Philippine Cohort of the International Operations Hypoglycemia Assessment Tool (IO HAT) Study. **2018**, 33, 12-21
- 567 A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018). **2018**, 64, 405-426
- 566 Improving the Understanding of Test Results by Substituting (Not Adding) Goal Ranges: Web-Based Between-Subjects Experiment (Preprint).
- 565 Efficacy, safety and clinical use of newer basal insulins analogs. **2018**, 6,



- 564 Homeostasis Model Assessment (HOMA) and M Value in Daily Profile of Glucose. **2018**, 1, 1-7 1
- 563 Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases. **2018**, 58-64 1
- 562 Cardio-diabetology: New subspecialty and collaborative work to defeat the burden of deadly duo. 081-084
- 561 Prescribing to the Oldest Old. **2019**, 297-304
- 560 Stroke in the Elderly Population. **2019**, 121-135
- 559 LA GENETICA AL LETTO DEL PAZIENTE: COME MIGLIORARE LA SALUTE CARDIOVASCOLARE NEL DIABETE. **2018**, 30,
- 558 Hypertension and Diabetes. **2019**, 1-22
- 557 Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. **2019**, 377-390
- 556 Dřordres glycđmiques et complications diabđtiques : physiopathologie. **2019**, 271-281
- 555 Dřordres glycđmiques. **2019**, 53-90
- 554 Type 2 Diabetes Mellitus (T2DM) in the Arab Society of Israel. **2019**, 1-32 1
- 553 Hypoglycemia. **2019**, 1-38
- 552 Diabetic nephropathy in type 2 diabetes: The frequency and risk factors. **2019**, 10, 118-127
- 551 Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. **2019**, 112, 649-705 5
- 550 Clinical Practice Guidelines, Evidence-Based Medicine, and Diabetes. **2019**, 333-355
- 549 Diabetes and premature death. **2019**, 65, 1-2
- 548 Prise en charge du diabđtique aprđ infarctus du myocarde. **2019**, 469-474
- 547 Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients. **2019**, 20, 233

546 Épidémiologie des états diabétiques. **2019**, 3-11

545 Thérapeutique des troubles glycémiés. **2019**, 141-252

544 Comparison of intensive insulin therapy and conventional glucose management in patients undergoing coronary artery bypass grafting. **2019**, 35, 493-497 2

543 Hypoglycémias in elderly patients with type 2 diabetes mellitus: possible risks and ways to prevent them. **2019**, 22, 109

542 Peripheral Arterial Disease and Diabetes Mellitus. **2019**, 747-763 1

541 Effets des traitements anti-hyperglycémiants sur les complications cardiovasculaires et rénales du patient diabétique de type 2 : leçons des grands essais d'intervention. **2019**, 283-295

540 Treatment Goals for Glycemia in Older Patients with Diabetes Mellitus. **2019**, 20, 220

539 Encouragement of Super-aggressive LDL-lowering Therapies. **2019**, 25, 84-89

538 Diabetes and the Cardiovascular System. **2019**, 1-29

537 De vuelta a la clínica: sin justificación no existe pregunta de investigación que valga. **2019**, 155, 168-175 0

536 The Prevention of Cardiovascular Diseases in Diabetes Mellitus: Role of Glycemic Control. **2019**, 76-79

535 Does insulin signalling decide glucose levels in the fasting steady state?. 0

534 3. Recent Progress in the Treatment of Type 2 Diabetes. **2019**, 108, 460-467

533 The effect of hemodialysis on glycemic variability. **2019**, 73, 53-59

532 Prevalence of Hypoglycemia, Treatment Satisfaction, Adherence and Their Associations with Glycemic Goals in Patients with Type 2 Diabetes Mellitus Treated with Sulfonylureas: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) in Romania. **2019**, 26, 55-64 1

531 A STUDY OF CLINICAL, METABOLIC AND ANTHROPOMETRIC PROFILE AND POSSIBLE ETIOLOGICAL FACTORS AMONG NEWLY DETECTED TYPE 2 DM IN NORTH KERALA. **2019**, 8, 907-914

530 A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus. **2019**, 65, 289-294 2

529 Management and control of type 2 diabetes mellitus in Lebanon: Results from the International Diabetes Management Practices Study Wave 6. **2019**, 10, 249-259 1

528 Trans-omic analysis reveals allosteric and gene regulation-axes for altered glucose-responsive liver metabolism associated with obesity.

527 Quels objectifs glycémiqes pour les patients diabétiques ? Ce que GERODIAB nous apporte actuellement. **2019**, 13, 280-287

526 Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis. **2019**, 16, 96-103

1

525 Managing type 2 diabetes mellitus: Role of family physicians in successful treatment goal achievement. **2019**, 16, em146

524 Pharmacotherapy of Diabetes Focused on Stroke. **2019**, 37, 235-250

523 Age-Dependent Hemoglobin A1c Therapeutic Targets Reduce Diabetic Medication Changes in the Elderly. **2019**, 7, 46

1

522 Specialist Advice Does Not Modify the Risk of Death of Diabetic 2 Patients. **2019**, 1-10

521 Predictive approaches to heterogeneous treatment effects: a systematic review.

520 The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. **2019**, 98-111

3

519 Cardiovascular complications in diabetes mellitus: the role of hyperglycemia. **2019**, 2019, 102-112

518 Membrane Free Stem Cell Extract from Adipose Tissue Enhances Glucose Uptake in 3T3-L1 Cells. **2019**, 19, 89-96

1

517 Hypoglycemia and the Risk of Cardiovascular Events: Causality or (Just) an Epidemiological Association?!. **2019**, 26, 341-344

516 Diabetes Mellitus and Chronic Kidney Disease (Stages 1&2). **2020**, 175-196

515 Inflammatory Mechanisms in Diabetic Kidney Disease. **2020**, 437-455

514 What glycemic control target best balances risks and benefits in the geriatric diabetic population?. **2020**, 23, 1-2

513 Incretin-based treatment of diabetes and cardiovascular complications. **2020**, 66, 74-80

512 Relationship of type 2 diabetes mellitus and cardiovascular pathology: significance of glycemic control on the way to solving the problem. **2020**, 22-28

511 Exercise based assessment of cardiac autonomic function in type 1 versus type 2 diabetes mellitus. **2020**,

510 Die diabetische Angiopathie. **2020**, 18, 200-207

509 Delay Early CKD with Lifestyle Intervention in African Americans with Diabetic Kidney Disease: A Pre-Post Pilot Study (Preprint).

508 Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries. **2021**, 8, 742072

2

507 Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. **2021**, 12, 3201-3215

1

506 Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. **2021**, 10, e021230

505 Optimizing glucose control for diabetic patients undergoing percutaneous coronary intervention. **2021**, 36, 1320-1322

504 Versorgungssituation und Mortalität von Patienten in Deutschland innerhalb und außerhalb des DMP Typ-2-Diabetes: eine kritische Analyse. **2021**, 16, 55-62

503 Driver versus navigator causation in biology: the case of insulin and fasting glucose. **2020**, 8, e10396

0

502 Proatherogenic Changes in the Blood Lipid Profile in Patients with Cerebrovascular Disease and Type 2 Diabetes. **2020**, 46, 840-844

501 Glycemic Control and Future Perspectives for Treatment. **2021**, 73-86

500 Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. **2020**, 44, 785-801

499 Prevention of Ischemic Stroke. **2021**, 581-609

498 Value of Doppler ultrasound in early detection of diabetic kidney disease: A systematic review and meta-analysis. **2021**, 29, 141-149

497 Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. **2020**, 26, 5953-5968

0

496 Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. **2020**, 26, 5637-5649

4

495 Nutritional and metabolic management of the diabetic patient with chronic kidney disease and chronic renal failure. **2022**, 805-827

494 Prevention and management of cardiovascular disease in kidney disease and kidney failure. **2022**, 207-223

493 Amyloidogenicity of peptides targeting diabetes and obesity. **2022**, 209, 112157

1

- 492 GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact. **2020**, 695-704
- 491 Diabetes mellitus and the kidney. **2020**, 4975-4987
- 490 Standard Pharmacological Treatment of Diabetes Based on the Guidelines. **2021**, 179-187
- 489 Clinical Impact of Diabetes Mellitus in Cardiovascular Diseases. **2021**, 43-49
- 488 Chronic Care Management. **2020**, 501-513
- 487 Diabetes mellitus, glycemic traits, and cerebrovascular disease: a Mendelian randomization study. **2020**, 1
- 486 Hypoglycemia. **2020**, 615-652
- 485 Antidiabetika. **2020**, 339-358
- 484 Management of Type 2 Diabetes. **2020**, 79-84
- 483 Cardiovascular Impact of Newer Diabetes Medications. **2020**, 735-745
- 482 Techniques for the Lateral Thoracolumbar Approach. **2020**, 211-218
- 481 Diabetic kidney disease: seven questions. **2020**, 63, 6
- 480 Hypertension and Diabetes. **2020**, 109-130
- 479 Diabetes and the Cardiovascular System. **2020**, 131-159
- 478 Cardiovascular Disease in Women Part 2: Prevention, Identification, and Treatment of Cardiovascular Disease. **2020**, 361-374
- 477 Treatment of Diabetes and Heart Failure. **2020**, 719-733
- 476 Safety of Flash Glucose Monitoring System using Free Style Libre Pro<sup>®</sup> in Patients with Diabetes in the Clinic. **2020**, 51, 51-55
- 475 What Is the Role of Self-Monitoring in Diabetes? Is There a Role for Postprandial Glucose Monitoring? How Does Continuous Glucose Monitoring Integrate into Clinical Practice?. **2021**, 87-100

- 474 Choosing Medications for Type 2 Diabetes âWhat Weighting Should Be Given to Cardiovascular Risk Reduction?. **2021**, 174-186
- 473 Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. **2021**, 2
- 472 Prevalence and associated factors of diabetic retinopathy among type 2 diabetes mellitus patients in Brunei Darussalam - A cross-sectional study. **2021**, 0
- 471 Characterising frailty, metrics of continuous glucose monitoring, and mortality hazards in older adults with type 2 diabetes on insulin therapy (HARE): a prospective, observational cohort study. **2021**, 2, e724-e735 2
- 470 Assessing the quality of the evidence underlying recommendations in type 2 diabetes' commonly used clinical practice guidelines. **2020**, 19,
- 469 New Herbal Approaches for the Treatment of Diabetic Kidney Diseases and Its Therapeutic Implications. 368-406
- 468 Inpatient Diabetic Hypoglycemia: Economic and Clinical Impact. **2010**, 1, 1-48
- 467 Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included.
- 466 Contraception and Diabetes. **2014**, 55-68 0
- 465 Letter: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65). **2020**, 44, 775-776
- 464 [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines]. **2020**, 60, 122-133
- 463 Effect of Glycemic Control During Follow-up on Late Target Lesion Revascularization After Implantation of New-Generation Drug-Eluting Stents in Patients With Diabetes - A Single-Center Observational Study. **2020**, 2, 479-489 1
- 462 Glycated Haemoglobin and Outcomes of Percutaneous Coronary Intervention Among Type Two Diabetic Patients in Saudi Arabia. **2020**, 12, e11278
- 461 Diabetes mellitus Typ 2: Diagnose, Behandlungsziele und Therapie. **2020**, 1, 99-118
- 460 SOP Einstellung mit Insulin in der Hausarztpraxis. **2020**, 1, 10-15
- 459 Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?. **2021**, 53, 75-84 1
- 458 Primary Prevention of Coronary Artery Disease. **2021**, 81-123
- 457 Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. **2021**, 295-313

456	[Measurement of pupillary diameter in diabetic and non-diabetic patients: a case-control study]. <b>2020</b> , 43, 770-773	
455	Sulfonylurea derivatives and risk of hypoglycaemia in type 2 diabetic patients. <b>2020</b> , 66, e35-e42	
454	Treating hyperglycemia and diabetes with insulin therapy: transition from inpatient to outpatient care. <b>2008</b> , 10, 216; quiz 216	4
453	Update on the Canadian Diabetes Association 2008 clinical practice guidelines. <b>2009</b> , 55, 39-43	38
452	Reasons to exercise caution when considering a screening program for type 2 diabetes mellitus. <b>2009</b> , 84, 34-6	2
451	Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. <b>2009</b> , 84, 38-42	13
450	Is tight glycemic control in type 2 diabetes really worthwhile? Yes. <b>2009</b> , 55, 580, 582, 584, 586, 588	6
449	Is tight glycemic control in type 2 diabetes really worthwhile? No. <b>2009</b> , 55, 581, 583, 585, 587, 588	2
448	Complementary and alternative medicine for the treatment of type 2 diabetes. <b>2009</b> , 55, 591-6	78
447	Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians. <b>2009</b> , 55, 803-4	7
446	A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus. <b>2009</b> , 34, 368-78	2
445	Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's, Nfld. <b>2010</b> , 56, e13-9	16
444	Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. <b>2008</b> , 3, 13-30	3
443	Incretin agents in type 2 diabetes. <b>2010</b> , 56, 639-48	30
442	Thiazolidinediones: a 2010 perspective. <b>2010</b> , 14, 64-72	24
441	Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. <b>2010</b> , 35, 498-529	15
440	Diabetes & coronary heart disease: current perspectives. <b>2010</b> , 132, 584-97	27
439	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. <b>2010</b> , 3, 155-63	10

438	To test or not to test? Self-monitoring of blood glucose in patients with type 2 diabetes managed without insulin. <b>2010</b> , 4, e114-6	1
437	Glycemia and cardiovascular risk: challenging evidence based medicine. <b>2011</b> , 15, 199-204	3
436	Diabetes in the frail elderly: individualization of glycemetic management. <b>2012</b> , 58, 543-6	11
435	Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. <b>2012</b> , 37, 687-96	9
434	Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. <b>2012</b> , 6, e62-74	14
433	The case for intervention bias in the practice of medicine. <b>2013</b> , 86, 271-80	19
432	Management of Diabetic Nephropathy in the Elderly: Special Considerations. <b>2012</b> , 2,	
431	An inpatient hypoglycemia committee: development, successful implementation, and impact on patient safety. <b>2013</b> , 13, 407-12	6
430	Use of Glycated Hemoglobin in the Diagnosis of Diabetes Mellitus and Pre-diabetes and Role of Fasting Plasma Glucose, Oral Glucose Tolerance Test. <b>2013</b> , 4, 1025-9	26
429	Type 2 diabetes and hemoglobin A1c targets. <b>2013</b> , 59, 1193	
428	Heart failure: epidemiology and prevention in India. <b>2010</b> , 23, 283-8	64
427	Microvascular benefits of hypertension and glucose control in type 2 diabetes. <b>2008</b> , 19, 179-80	
426	Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction. <b>2014</b> , 125, 281-91; discussion 291-2	8
425	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <b>2014</b> , 18, 617-23	6
424	Editorial on the original article entitled "Changes in diabetes-related complications in the United States, 1990-2010" published in the New England Journal of Medicine on April 17, 2014. <b>2014</b> , 2, 118	
423	Complications of diabetes: progress, but significant challenges ahead. <b>2014</b> , 2, 120	8
422	Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. <b>2014</b> , 2,	22
421	Cardiovascular safety profile of currently available diabetic drugs. <b>2014</b> , 14, 616-32	27



420	Effect of glycated hemoglobin on heart function of the patients with revascularization of coronary artery. <b>2015</b> , 8, 7181-8	1
419	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. <b>2015</b> , 126, 62-76	4
418	Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. <b>2016</b> , 8, 2450-8	13
417	Approach to preventive care in the elderly. <b>2016</b> , 62, 717-21	5
416	[Aborder les soins prventifs chez les a n s]. <b>2016</b> , 62, e508-13	
415	Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study. <b>2016</b> , 6, 153-162	3
414	Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease. <b>2014</b> , 3, 15-20	14
413	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. <b>2017</b> , 19, D163-D189	
412	Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. <b>2016</b> , 5, 92-101	2
411	X Marks the Spot: Mapping Similarity Between Clinical Trial Cohorts and US Counties. <b>2017</b> , 2017, 1110-1119	1
410	Preventing hypoglycemia with novel technology and flexible therapy. <b>2011</b> , 108, 113-7	
409	Hypoglycemia Safety Initiative: Working With PACT Clinical Pharmacy Specialists to Individualize HbA Goals. <b>2018</b> , 35, S14-S17	1
408	Feature Selection in Predictive Modeling: A Systematic Study on Drug Response Heterogeneity for Type II Diabetic Patients. <b>2019</b> , 2019, 295-304	1
407	Effects and mechanisms of glucose-insulin-potassium on post-procedural myocardial injury after percutaneous coronary intervention. <b>2020</b> , 17, 554-560	
406	3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy. <b>2020</b> , 8, 1345	2
405	Burnt Out? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease. <b>2020</b> , 37, 580-585	
404	Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting. <b>2020</b> , 24, 1-8	
403	Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema - Pan-Indian survey of retina specialists. <b>2021</b> , 69, 3273-3278	

402	Risk factors and pharmacological therapy in patients with vascular disease. <b>2022</b> , 11-24	
401	Metabolic and endocrine diseases - is our approach always rational?. <b>2021</b> , 67, 399-403	
400	Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial. <b>2021</b> ,	0
399	Blutdrucksenkende pleiotrope Effekte antidiabetischer Medikamente. <b>2021</b> , 25, 356-362	
398	Association of glycated hemoglobin A levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. <b>2021</b> , 20, 223	2
397	Hypoglycemia-induced changes in complement pathways in type 2 diabetes. <b>2021</b> ,	
396	Hypoglycaemia combined with mild hypokalaemia reduces the heart rate and causes abnormal pacemaker activity in a computational model of a human sinoatrial cell. <b>2021</b> , 18, 20210612	0
395	The role of sulfonylureas in the treatment of type 2 diabetes. <b>2021</b> , 1-17	1
394	Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers. <b>2021</b> , 1	4
393	Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortality. <b>2021</b> ,	3
392	SUR1-E1506K mutation impairs glucose tolerance and promotes vulnerable atherosclerotic plaque phenotype in hypercholesterolemic mice. <b>2021</b> , 16, e0258408	1
391	Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review. <b>2021</b> , 12, 1856-1874	1
390	Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer mortality. <b>2021</b> , e3512	
389	Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. <b>2022</b> , 65, 14-36	3
388	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. <b>2021</b> , 10,	0
387	Diabetes is still a CAD risk equivalent, now what?. <b>2021</b> , 1	0
386	Implications of remote monitoring Technology in Optimizing Traditional Self-Monitoring of blood glucose in adults with T2DM in primary care. <b>2021</b> , 21, 222	0
385	Nonlinear relationship between HbA1c and coronary artery calcium score progression: a secondary analysis based on a retrospective cohort study. <b>2021</b> , 13, 136	

- 384 Evolution of Glycemic Targets in Management of Diabetes. **2021**, 11, 208-220
- 383 Diabetic Nephropathy and Diabetic Kidney Disease. **2021**, 11, 359-377 0
- 382 Evolution in Understanding of Cardiovascular Outcomes in Diabetes. **2021**, 11, 378-387
- 381 Principles of Diabetes Care and Lifestyle Modification. **2021**, 83-107
- 380 Diabetes. **2021**, 1-24
- 379 Historical Background of Diabetic Kidney Disease. **2022**, 1-19
- 378 Glycemic Control. **2022**, 443-467
- 377 Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes.. **2022**, 4
- 376 A prospective multicentre open label study to assess effect of Teneeligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study).. **2022**, 16, 102394 0
- 375 Relationship between hemoglobin A1C and characteristics of plaque vulnerability in stable coronary disease: an optical coherence tomography study.. **2022**, 1 1
- 374 The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.. **2022**, 0
- 373 The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases.. **2021**, 62, 85-96 7
- 372 Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations.. **2021**, 434, 120117 0
- 371 Krankheitsparameter auf dem Prüfstand: Dogmatisierung des HbA1c.
- 370 Lungenfibrose: Eine Komplikation des Diabetes?.
- 369 Senioren mit Diabetes: Lebensqualität vor strenger Blutzuckereinstellung.
- 368 3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy. **2020**, 8, 1345-1345 2
- 367 Glycaemic Control in Diabetes. **2021**, 47

- 366 Antidiabetika. **2021**, 241-260
- 365 Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.. **2021**, 28, 337-346 0
- 364 A Lifestyle Intervention to Delay Early Chronic Kidney Disease in African Americans With Diabetic Kidney Disease: Pre-Post Pilot Study.. **2022**, 6, e34029 1
- 363 HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.. **2022**, 21, 13 1
- 362 Depressive symptoms improve over 2 years of type 2 diabetes treatment via a digital continuous remote care intervention focused on carbohydrate restriction.. **2022**, 1 0
- 361 JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. **2022**, 86, 3
- 360 Initial Diagnosis and Management of Type 2 Diabetes Mellitus. **2022**, 353-367
- 359 Association of total VLDL particle concentrations with elevated blood viscosity in patients with type 2 diabetes.. **2021**, 183, 109180 0
- 358 Protective Effects of Transient Glucose Exposure in Adult .. **2022**, 11, 1
- 357 Takotsubo syndrome in the context of severe hypoglycemia. **2022**, 158, 192-192
- 356 Exercise is medicine for type 2 diabetes: An interview with Dr. Sheri R. Colberg.. **2022**, 1
- 355 Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.. **2022**, 2
- 354 Antihypertensive Therapies. **2022**, 499-520
- 353 Prevalence of cardiovascular disease risk factors in Chinese patients with type 2 diabetes mellitus, 2013-2018.. **2022**, 1-10
- 352 Significantly Increased Risk of All-Cause Mortality Among Type 2 Diabetes Patients Living Alone.. **2022**, 9, 782751
- 351 Trends in the Incidence of Hospitalization for Major Diabetes-Related Complications in People With Type 1 and Type 2 Diabetes in Australia, 2010-2019.. **2022**, 2
- 350 Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.. **2022**, 108132 0
- 349 Adherence to the ADA's Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001-2018.. **2022**, 2

348	Dysglycemia and High Natriuretic Peptides: The Prelude to Heart Failure.. <b>2021</b> ,	1
347	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <b>2022</b> , 24, 143-168	7
346	Heterogeneity of Treatment Effects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven Subgroup Analysis in SPRINT and ACCORD.. <b>2022</b> , 9, 778756	
345	The prime type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus.. <b>2022</b> , 1-32	0
344	Changes in fat mass and lean body mass and outcomes in type 2 diabetes mellitus.. <b>2022</b> , 1	0
343	Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms.. <b>2022</b> , 22, 65	1
342	Diabetes and Kidney Disease. <b>2022</b> , 23-33	
341	GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.. <b>2022</b> , 34, 418-440	0
340	Separating the direct effects of traits on atherosclerotic cardiovascular disease from those mediated by type 2 diabetes.. <b>2022</b> , 1	1
339	Systematic Heritability and Heritability Enrichment Analysis for Diabetes Complications in UK Biobank and ACCORD Studies.. <b>2022</b> ,	0
338	Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.. <b>2022</b> , 100, 93-106	2
337	SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.. <b>2022</b> , 24, 183	1
336	The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.. <b>2022</b> , 13, 367	1
335	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.. <b>2022</b> ,	1
334	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study.. <b>2021</b> , 11,	0
333	A validated analysis pipeline for mass spectrometry-based vitreous proteomics: new insights into proliferative diabetic retinopathy. <b>2021</b> , 18, 28	2
332	Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.. <b>2021</b> , 11,	7
331	Treatment of diabetic polyneuropathy. <b>2022</b> , 299-311	

- 330 Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.. **2022**, 13, 20420188221081601 1
- 329 Oral Therapies for Type 2 Diabetes. **2022**, 325-334
- 328 Insulin Therapy. **2022**, 345-353
- 327 Diabetic Nephropathy. **2022**, 397-409
- 326 Hypoglycaemia in Diabetes. **2022**, 375-386
- 325 The Role of Glycated Albumin as a Biomarker of Glycemic Control in Diabetes and Chronic Kidney Disease. **2022**, 1-25
- 324 Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.. **2022**, 5, 132 0
- 323 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. **2022**, 0
- 322 Low Use of Guideline Recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-Sectional Study of Persons with Type 2 Diabetes. **2022**, 0
- 321 Enhanced Differentiation Capacity and Transplantation Efficacy of Insulin-Producing Cell Clusters from Human iPSCs Using Permeable Nanofibrous Microwell-Arrayed Membrane for Diabetes Treatment.. **2022**, 14, 0
- 320 Glucose-derived posttranslational modification in cardiovascular disease.. **2022**, 101084 0
- 319 Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease.. **2022**, 17, e0264568
- 318 Perioperative care in open aortic vascular surgery: A Consensus Statement by the Enhanced Recovery after Surgery (ERAS<sup>®</sup>) Society and Society for Vascular Surgery.. **2022**, 2
- 317 The efficacy of pioglitazone for renal protection in diabetic kidney disease.. **2022**, 17, e0264129 0
- 316 Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.. **2022**, 79, 593-604 0
- 315 Identification of Sorafenib as a Treatment for Type 1 Diabetes.. **2022**, 13, 740805
- 314 Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte. **2022**, 25, 19-30
- 313 3-Hydroxybutyrate Ameliorates the Progression of Diabetic Nephropathy.. **2022**, 11, 1

312	Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults.. <b>2022,</b>	0
311	Glucose variability and predicted cardiovascular risk after gastrectomy.. <b>2022,</b> 1	
310	Below which threshold of glycemic variability is there a minimal risk of hypoglycemia in people with type 2 diabetes ?. <b>2022,</b>	0
309	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now.. <b>2022,</b>	0
308	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.. <b>2021,</b>	
307	Using an Electronic Health Record and Deficit Accumulation to Pragmatically Identify Candidates for Optimal Prescribing in Patients With Type 2 Diabetes.	
306	Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus.. <b>2022,</b> 46, 165-180	0
305	Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.. <b>2022,</b>	0
304	Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.. <b>2022,</b>	0
303	Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study.. <b>2022,</b>	2
302	Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review.. <b>2022,</b> 11,	
301	Is Lower Better?. <b>2022,</b>	
300	Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models.. <b>2022,</b> 101161CIRCOOUTCOMES121008487	1
299	Polyphenol Extracts From Germinated Mung Beans Can Improve Type 2 Diabetes in Mice by Regulating Intestinal Microflora and Inhibiting Inflammation.. <b>2022,</b> 9, 846409	1
298	Should Hemoglobin A1c Targets Be Re-Evaluated?. <b>2022,</b>	
297	Impact of Baseline and Trajectory of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus.. <b>2022,</b> 13, 858209	0
296	Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease.. <b>2022,</b>	1
295	Autonomic Dysregulation in Diabetes: CAN We Prevent Heart Failure?. <b>2022,</b>	

294	The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study.. <b>2022</b> , 1	0
293	Vascular hyperacetylation is associated with vascular smooth muscle dysfunction in a rat model of non-obese type 2 diabetes.. <b>2022</b> , 28, 30	2
292	Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.. <b>2022</b> , 13, 651	
291	Canagliflozin and Dapagliflozin Attenuate Glucolipotoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1.. <b>2022</b> , 5, 216-225	1
290	Potential Over-Treatment and Over-Testing among Older Adults with Type-2 Diabetes across Canada: An Observational Retrospective Cohort Study. <b>2022</b> ,	
289	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19.. <b>2022</b> ,	2
288	L. Leaves: A Valuable Source of Bioactive Compounds with Multiple Pharmacological Effects.. <b>2022</b> , 27,	1
287	Hemoglobin A1C Monitoring Practices Prior to Lower Extremity Bypass in Patients with Diabetes Vary Broadly and Do Not Predict Outcomes.. <b>2022</b> ,	1
286	The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.. <b>2022</b> , 109824	0
285	Endothelial Dysfunction and Diabetic Cardiomyopathy.. <b>2022</b> , 13, 851941	4
284	On the survival of individuals diagnosed with type 2 diabetes mellitus in the United Kingdom: A retrospective matched cohort study. <b>2022</b> , 6, 100065	0
283	Does optimal HbA1c in diabetes differ according to drug treatment? An evaluation of national electronic database in Malta.. <b>2022</b> , 16, 102475	
282	Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events (MACE) in people with type 2 diabetes: primary care cohort study.. <b>2022</b> ,	0
281	Association of Polygenic Risk Score With Blood Pressure and Adverse Cardiovascular Outcomes in Individuals With Type II Diabetes: Insights From the ACCORD Trial.. <b>2022</b> , HYPERTENSIONAHA12218976	0
280	Stress, hypoglycemia, and the autonomic nervous system.. <b>2022</b> , 240, 102983	0
279	Hyperlipidemia management in diabetes: First line or supportive therapy?. <b>2022</b> , 16, 102470	1
278	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <b>2022</b> , 21, 50	1
277	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.. <b>2022</b> , 14, eabj9625	3



276	Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. <b>2022</b> , 162, 110804	
275	J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention.. <b>2021</b> , 20, 234	1
274	Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER.. <b>2021</b> , 13, 251	0
273	6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.. <b>2022</b> , 45, S83-S96	39
272	Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. <b>2021</b> ,	1
271	Prescribing, monitoring, and deprescribing drugs in geriatric DM patients. <b>2021</b> , 69, 282-285	0
270	Optimal Type 2 Diabetes Mellitus Management and Active Ageing. <b>2021</b> , 2, 523-539	0
269	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.. <b>2021</b> , 68, 741-750	
268	Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial. <b>2021</b> , 13, 161	
267	13. Older Adults: Standards of Medical Care in Diabetes-2022.. <b>2022</b> , 45, S195-S207	11
266	Protective Effects of Eicosapentaenoic Acid on the Glomerular Endothelium via Inhibition of EndMT in Diabetes.. <b>2021</b> , 2021, 2182225	0
265	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.. <b>2021</b> , 20, 241	3
264	Renal Tubular Handling of Glucose and Fructose in Health and Disease.. <b>2021</b> , 12, 2995-3044	1
263	On the survival of individuals diagnosed with type 2 diabetes mellitus in the United Kingdom: a retrospective matched cohort study.	
262	Effect of Clinical Inertia on Diabetes Complications among Individuals with Type 2 Diabetes: A Retrospective Cohort Study.. <b>2021</b> , 58,	0
261	Individualizaci3n del tratamiento de la diabetes mellitus tipo 2. <b>2021</b> , 13, 2688-2697	
260	Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.. <b>2021</b> , 12, 759262	0
259	Rationale and design of the effects of EMPagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.. <b>2021</b> , 23,	0

- 258 Hospital utilization for hypoglycemia among patients with type 2 diabetes using pooled data from six health systems.. **2021**, 9, 0
- 257 Management of Hyperglycemia in Older Adults with Type 2 Diabetes.. **2021**, 39, 39 1
- 256 Financial Risk Management using Machine Learning Method. **2021**,
- 255 Vascular Cognitive Impairment (VCI).. **2021**, 1 4
- 254 Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.. **2022**,
- 253 Study on the Correlation between TyG, SAA and Atherosclerosis in Diabetic Nephropathy Patients. **2022**, 12, 2535-2540
- 252 Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes.. **2022**, 1
- 251 Severe Iatrogenic Hypoglycemia Modulates the Fibroblast Growth Factor Protein Response.. **2022**,
- 250 High incidence of undetected low sensor glucose events among elderly patients with type 2 diabetes more than a decade on after the ACCORD study.. **2022**, 1-8 0
- 249 Hypoglycemia: A closer look at a community pharmacist's impact in optimizing diabetes care.. **2022**,
- 248 Data\_Sheet\_1.pdf. **2019**,
- 247 Data\_Sheet\_1.docx. **2019**,
- 246 DataSheet\_1.pdf. **2020**,
- 245 DataSheet\_2.pdf. **2020**,
- 244 DataSheet\_3.pdf. **2020**,
- 243 Data\_Sheet\_1.XLSX. **2019**,
- 242 Presentation\_1.PDF. **2019**,
- 241 Burnt Out? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease. **2020**, 37, 580-585 1

240 Hypoglycemia: Elucidating its circadian propensity and recovery time based on clinical parameters.. **2022**, 13, 29-37

239 Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. **2014**, 18, 617

7

238 Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting. **2020**, 24, 1-8

237 The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.. **2022**,

236 Diabetes Mellitus. **2022**, 7017-7043

235 Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes.. **2022**, 13, 890907

0

234 Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.. **2022**, 9, 876795

233 Sarco/Endoplasmic Reticulum Ca ATPase 2 Activator Ameliorates Endothelial Dysfunction; Insulin Resistance in Diabetic Mice.. **2022**, 11,

0

232 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. **2022**, 21, 3235

11

231 Novel  $\alpha$ -Amylase Inhibitor Hemi-Pyocyanin Produced by Microbial Conversion of Chitinous Discards. **2022**, 20, 283

1

230 European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 239698732211000

5

229 Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.. **2022**, 21, 58

0

228 Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease.. **2022**,

1

227 Recent advances in the pharmacotherapeutic management of diabetic kidney disease.. **2022**, 23, 791-803

0

226 Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials.. **2022**,

225 Secondary Prevention of Atherosclerotic Cardiovascular Disease. **2022**, 475-482

224 The effect of type 2 diabetes mellitus on early postoperative cognitive functions. **2022**, 6, 1-1

223 Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.. **2022**,

- 222 Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).. **2022**, 10, 0
- 221 Concomitant treatment with insulin and sodium-glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score-matched analysis.. **2022**, 0
- 220 Effect of Preablation Glycemic Control on Outcomes of Atrial Fibrillation Patients With Diabetes Mellitus Following Valvular Surgery Combined With the Cox-Maze IV Procedure. **2022**, 9,
- 219 Metabolic syndrome, hyperglycemia, and type 2 diabetes. **2013**, 436-462
- 218 Echocardiography in Nutritional and Metabolic Disorders. **2017**, 724-743
- 217 Intensive glycaemic control and macrovascular, microvascular, hypoglycaemia complications and mortality in older (age ≥80years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. 1
- 216 Implementation of Precision Genetic Approaches for Type 1 and 2 Diabetes. **2022**, 111-129
- 215 Precision Medicine Approaches for Management of Type 2 Diabetes. **2022**, 1-52
- 214 Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. 7
- 213 Type 2 Diabetes mellitus treatment intensification and deintensification in primary care: a retrospective cohort study.
- 212 Management of Diabetic Nephropathy. **2022**, 671-690
- 211 The Relationship between Hypoglycaemic Episodes and Arrhythmias in Type 2 Diabetes Subjects after Acute Myocardial Infarction with ST-Segment Elevationâ Case Series. **2022**, 12, 141-152
- 210 Giving Insulin Is Not a Guessing Game: Insulin Replacement Therapy in Type 2 Diabetes Mellitus. **2022**, 6, 868-880
- 209 A Contemporary Insight of Metabolomics Approach for Type 1 Diabetes: Potential for Novel Diagnostic Targets. Volume 15, 1605-1625
- 208 Estimating the replicability of highly cited clinical research (2004-2018).
- 207 Status of glycemic excursions and hypoglycemia in patients with type 1 diabetes 2 months after first initiation of intermittently scanned continuous glucose monitoring: a pilot study.
- 206 Real-world risk factors of confirmed or probable COVID -19 in Americans with diabetes: A prospective, community-based study ( iNPHORM ). 0
- 205 Glyoxalase 1 knockdown induces age-related ßcell dysfunction and glucose intolerance in mice.

- 204 Validation of the WATCH-DM and TRS-HF DM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. ○
- 203 Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. **2022**, 108225
- 202 Investigating the relationship between harm and over- or under-treatment of frail patients living with diabetes, admitted to hospital. **2022**, 39, 23
- 201 Cardiovascular events after a dramatic reduction of HbA1c in hospitalized subjects with type 2 diabetes and high long-term glucose exposure. **2022**, 108234 ○
- 200 The expanding role of primary care providers in care of individuals with kidney disease. **2022**, 114, S10-S19
- 199 A retrospective study of diabetes treatment in older adults: what should we AIM for?. 1-5
- 198 Utilizing the Probation Office as an Opportunity to Screen for Cardiometabolic Outcomes: A Feasibility Study. ○
- 197 Altered Caffeine Metabolism Is Associated With Recurrent Hypoglycemia in Type 2 Diabetes Mellitus: A UPLC-MS-Based Untargeted Metabolomics Study. 13,
- 196 Effects of an exercise-based lifestyle intervention on systemic markers of oxidative stress and advanced glycation endproducts in persons with type 2 diabetes: Secondary analysis of a randomised clinical trial. **2022**, 1
- 195 Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology. ○
- 194 Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. **2022**, 5, 1
- 193 Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. ○
- 192 Diabetes Mellitus and its impact on Quality of life. 205-210
- 191 Anti-Hyperglycemic Medication Adherence and Health Services Utilization in People with Diabetes: A Longitudinal Study of Alberta's Tomorrow Project. Volume 16, 1457-1467
- 190 Prescribing Antidiabetic Drugs. **2022**, 322-356
- 189 New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. 13,
- 188 Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis.
- 187 A comprehensive risk assessment for nocturnal hypoglycemia in geriatric patients with type 2 diabetes: A single-center case-control study. **2022**, 108239

- 186 Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling. **2022**, 10, e002636
- 185 Management of Diabetes in the Elderly. **2022**, 23, 128-132 1
- 184 Associations between glycated hemoglobin and the risks of incident cardiovascular diseases in patients with gout. **2022**, 21, 0
- 183 Cardiovascular protection by SGLT2 inhibitors –do anti-inflammatory mechanisms play a role?. **2022**, 101549 1
- 182 Prognostic value of 1,5-anhydro-d-glucitol incorporating syntax score in acute coronary syndrome.
- 181 Association of hemoglobin A1c time in range with risk for diabetes complications. **2022**, 10, e002738 0
- 180 Low-dose nifedipine rescues impaired endothelial progenitor cell-mediated angiogenesis in diabetic mice.
- 179 Glycated Hemoglobin Levels and Risk of All-cause and Cause-specific Mortality in Hemodialysis Patients with Diabetes. **2022**, 110016
- 178 GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. **2022**, 2, 386-398
- 177 Retinal microvascular associations with cardiometabolic risk factors differ by diabetes status: results from the UK Biobank. 0
- 176 Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. **2022**, 199-229
- 175 Hypoglycemia in type 2 diabetes mellitus patients –cerebral, cognitive, psychosocial and clinical aspects. **2022**, 25, 288-298
- 174 The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control. 0
- 173 Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial. 0
- 172 A Novel Architecture for Diabetes Patients’s Prediction Using K-Means Clustering and SVM. **2022**, 2022, 1-9 1
- 171 Time-in-range: a promising glycemic control metric for bariatric surgery. **2022**,
- 170 Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. 1-16 0
- 169 Acute Ischemic Stroke Comorbid with Type 2 Diabetes: Long-Term Prognosis Determinants in a 36-Month Prospective Study for Personalized Medicine. **2022**, 26, 451-460

- 168 Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial. **2022**, 12, e054100
- 167 Does sugar control arrest complications in type 2 diabetes? Examining rigor in statistical and causal inference in clinical trials.
- 166 Association of Hypoglycemia with Biomarkers of Oxidative Stress and Antioxidants: An Observational Study. **2022**, 10, 1509
- 165 MiRNA and associated inflammatory changes from baseline to hypoglycemia in type 2 diabetes. 13, 1
- 164 Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21 st century assessment. 0
- 163 Revisiting "intensive" blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials. 0
- 162 Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. **2022**, 21, 1
- 161 Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly. 0
- 160 Hypoglycaemia in diabetes. **2022**,
- 159 Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy "Subanalysis of the REAL-CAD Trial " **2022**,
- 158 Prognostic significance of Systolic Blood Pressure Time in Target Range in Patients with Type 2 Diabetes Mellitus.
- 157 DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. **2022**, 9, 0
- 156 A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial. **2022**, 36, 108287
- 155 The association between long-term glycemic control and all-cause mortality is different among older versus younger patients with diabetes mellitus and maintenance hemodialysis treatment. **2022**, 191, 110033
- 154 Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. **2022**, 106, 154389
- 153 Joint effect of visit-to-visit variability in LDL-cholesterol, HDL-cholesterol and HbA1c on cardiovascular and total mortality in patients with diabetes. **2022**, 14, 0
- 152 Relationship among Insulin Therapy, Insulin Resistance, and Severe Coronary Artery Disease in Type 2 Diabetes Mellitus. **2022**, 2022, 1-6 0
- 151 Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. 1-7 0

- 150 Long-term glycemic variability and risk of adverse health outcomes in patients with diabetes: A systematic review and meta-analysis of cohort studies. **2022**, 192, 110085 ○
- 149 Accelerated brain aging in individuals with diabetes: Association with poor glycemic control and increased all-cause mortality. **2022**, 145, 105921 1
- 148 CLINICAL GUIDELINES AND EVIDENCE REGARDING PERIOPERATIVE MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS. **2012**, 35-39 ○
- 147 Herz und Diabetes. **2022**, 1-14 ○
- 146 Robust Methods for Quantifying the Effect of A Continuous Exposure from Observational Data. **2022**, 1-10 ○
- 145 Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets. **2022**, 12, 1402 ○
- 144 Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. **2022**, 21, ○
- 143 Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study. **2022**, 21, 1
- 142 Stratified proportional win-fractions regression analysis. ○
- 141 Extent of Role: Anti-Diabetic Medications. **2022**, 23, 153-156 ○
- 140 The Role of Glycated Albumin as a Biomarker of Glycemic Control in Diabetes and Chronic Kidney Disease. **2023**, 513-537 ○
- 139 Effect of Glucose Levels on Cardiovascular Risk. **2022**, 11, 3034 ○
- 138 Associations of Age at Diagnosis and Duration of Diabetes With Morbidity and Mortality Among Older Adults. **2022**, 5, e2232766 ○
- 137 Reversion and remission are promising targets for patients with type 2 diabetes mellitus. **2022**, 3, 7-16 ○
- 136 Time course of the triglyceride glucose index accumulation with the risk of cardiovascular disease and all-cause mortality. **2022**, 21, ○
- 135 Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia. **2022**, 17, e0275032 ○
- 134 Assessment of Disparities in Diabetes Mortality in Adults in US Rural vs Nonrural Counties, 1999-2018. **2022**, 5, e2232318 ○
- 133 Time trends (2012-2020) in glycated hemoglobin and adherence to the glycemic targets recommended for elderly patients by the Japan Diabetes Society/Japan Geriatrics Society Joint Committee among memory clinic patients with diabetes mellitus. ○



132	The Clinical Effect of Dapagliflozin in Patients with Angiographically Confirmed Coronary Artery Disease and Concomitant Type 2 Diabetes Mellitus. <b>2022</b> , 30, 35-43	0
131	Day-to-day fasting plasma glucose variability on the short-term prognosis of ST-segment elevation myocardial infarction: A retrospective cohort study.	0
130	Diabetic kidney disease treatment: new perspectives. <b>2022</b> , 41, S63-S73	1
129	Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease. 13,	0
128	The severity and duration of Hypoglycemia affect platelet-derived protein responses in Caucasians. <b>2022</b> , 21,	1
127	Longitudinal Adherence to Diabetes Quality Indicators and Cardiac Disease: A Nationwide Population-Based Historical Cohort Study of Patients With Pharmacologically Treated Diabetes. <b>2022</b> , 11,	0
126	Diabetes and Cardiovascular Disease. <b>2022</b> , 1393-1414	0
125	Behavioral Medicine Treatments for Heart Failure. <b>2022</b> , 1171-1205	0
124	â Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Serviceâ <b>2022</b> , 16, 117954682211336	0
123	A Health Care Professional Delivered Low Carbohydrate Diet Program Reduces Body Weight, Haemoglobin A1c, Diabetes Medication Use and Cardiovascular Risk Markersâ A Single-Arm Intervention Analysis. <b>2022</b> , 14, 4406	0
122	Racial and ethnic subgroup reporting in diabetes randomized controlled trials published from 2000 to 2020: A survey.	0
121	Gender-specific differences in central blood pressure and optimal target blood pressure based on the prediction of cardiovascular events. 9,	1
120	Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).	0
119	Optimal Cardiometabolic Health and Risk of Heart Failure in Type 2 Diabetes: An Analysis from the Look AHEAD Trial.	1
118	PlateletâNeutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches. <b>2022</b> , 11,	0
117	Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. <b>2022</b> , 54, 3039-3051	0
116	Psychometric and biomedical outcomes of glycated haemoglobin target-setting in adults with type 1 and type 2 diabetes: Protocol for a mixed-methods parallel-group randomised feasibility study. <b>2022</b> , 17, e0275980	0
115	Continuous glucose monitoring reveals a novel association between duration and severity of hypoglycemia and small nerve fiber injury in patients with diabetes. <b>2022</b> ,	0

114	Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus—Results from the TRIUMPH randomised controlled trial.	0
113	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. <b>2022</b> , 100513	0
112	Modifiable predictors of type 2 diabetes mellitus and roles of insulin resistance and $\beta$ cell function over a 6-year study and 30-year follow-up.	0
111	Intensive versus conservative glycemic control in patients undergoing coronary artery bypass graft surgery: A protocol for systematic review of randomised controlled trials. <b>2022</b> , 17, e0276228	0
110	Comprehensive assessment of cardiovascular complications in a patient with type 1 diabetes mellitus, chronic kidney disease and diabetic neuroosteoarthropathy. <b>2022</b> , 50, 205-215	0
109	Time in range, assessed with continuous glucose monitoring, is associated with brachial-ankle pulse wave velocity in type 2 diabetes: A retrospective single-center analysis. 13,	0
108	Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. <b>2022</b> , 101405	0
107	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <b>2022</b> , 102, S1-S127	8
106	Type 2 diabetes. <b>2022</b> ,	5
105	Diametrical Effects of Glucose Levels on Microvascular Permeability of Peripheral Nerves in Type 2 Diabetes Patients With and Without Diabetic Neuropathy.	0
104	Pharmacotherapy of type 2 diabetes: An update and future directions. <b>2022</b> , 137, 155332	3
103	Editor's Pick: How Can We Develop More Effective Strategies for Type 2 Diabetes Mellitus Prevention? A Paradigm Shift from a Glucose-Centric to a Beta Cell-Centric Concept of Diabetes. 46-52	0
102	Recent Trends in Diabetes-Associated Hospitalizations in the United States. <b>2022</b> , 11, 6636	0
101	Derivation and Validation of a High Sensitivity Troponin-T HEART Pathway. <b>2022</b> ,	0
100	Present and future directions in diabetic kidney disease. <b>2022</b> , 108357	1
99	Preventable risk factors for type 2 diabetes can be detected using noninvasive spontaneous electroretinogram signals.	0
98	Association of a Multi-Ancestry Genome-Wide Blood Pressure Polygenic Risk Score with Adverse Cardiovascular Events.	0
97	Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. <b>2022</b> , 23, 13749	0

96	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <b>2022,</b>	0
95	Hypertension. <b>2022,</b> 329-353	0
94	Secondary Diseases of the Kidney. <b>2022,</b> 366-399	0
93	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <b>2022,</b> 18, 40-53	0
92	Epidemiology of Diabetes. <b>2022,</b> 1-49	0
91	Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. <b>2023,</b> 195, 110206	0
90	Neovascular Glaucoma in Proliferative Diabetic Retinopathy. <b>2022,</b> 37-55	0
89	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-glucose Co-transporter-2 Inhibitors. <b>2022,</b> 18, 106	0
88	Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes. <b>2022,</b> 21,	0
87	Pre-Operative Medical Management. <b>2022,</b> 64-76	0
86	Economic Burden of Severe Hypoglycemia Among Patients With Diabetes Mellitus. <b>2022,</b>	0
85	Pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among people with type 2 diabetes. <b>2022,</b>	0
84	MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes. <b>2022,</b> 23, 14696	1
83	6. Glycemic Targets: Standards of Care in Diabetes 2023. <b>2023,</b> 46, S97-S110	1
82	Efficiency et précision du contrôle glycémique dans le diabète : symphonie inachevée ?. <b>2022,</b>	0
81	Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.	1
80	13. Older Adults: Standards of Care in Diabetes 2023. <b>2023,</b> 46, S216-S229	2
79	Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. <b>2022,</b>	0

- 78 Effectiveness of the chronic care model for adults with type 2 diabetes in primary care: a systematic review and meta-analysis. **2022**, 11, ○
- 77 Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: Insights from the ACCORD trial. ○
- 76 Control of blood glucose levels by an artificial pancreas in patients with severe coronavirus disease 2019 pneumonia. ○
- 75 Assessing how clinicians and staff would use a diabetes artificial intelligence prediction tool (Preprint). ○
- 74 Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol. **2022**, 22, ○
- 73 Renal Disease in Patients with Type 2 Diabetes: Magnitude of the Problem, Risk Factors and Preventive Strategies. **2022**, 104159 ○
- 72 Benefits of Intensified Reductions in Blood Glucose and in Blood Pressure for Patients with Type 2 Diabetes. **2022**, 104160 ○
- 71 Caring for Patients With Diabetes in Stroke Neurology. ○
- 70 Machine learning for the prediction of minor amputation in University of Texas grade 3 diabetic foot ulcers. **2022**, 17, e0278445 ○
- 69 Cardiovascular outcomes in type 1 and type 2 diabetes. 1
- 68 Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. **2023**, 67-138 ○
- 67 Preventable risk factors for type 2 diabetes can be detected using noninvasive spontaneous electroretinogram signals. **2023**, 18, e0278388 ○
- 66 Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. **2023**, 153, 40004 ○
- 65 Évolution des cibles glycémiques chez le patient diabétique de type 2 au cours des dernières années. **2023**, ○
- 64 Control of Blood Glucose and Cardiovascular Risk Profile. **2023**, 451-469 ○
- 63 The Mediating Effect of Acceptance Action in the Relationship between Diabetes Distress and Self-stigma among Old Adults with Diabetes in South Korea. **2022**, 33, 446 ○
- 62 Diabetes mellitus. **2022**, 267-285 ○
- 61 Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight. ○

60	Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. <b>2023</b> , 18, 95-110	0
59	The association of glycosylated hemoglobin A1c with coronary artery disease, myocardial infarction, and severity of coronary lesions. 108155892211405	0
58	Revert diabetes. 2, 5	0
57	Individual or familial diabetes in relation to eight cardiovascular diseases: A two-sample Mendelian randomization study. <b>2023</b> ,	0
56	Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999-2020.	0
55	The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature. <b>2023</b> , 13, 241	0
54	Modern principles of the diabetic macular edema management. <b>2020</b> , 13, 51-65	0
53	Remission with an Intervention. <b>2023</b> , 52, 65-88	0
52	Annual trends in glycemic control and prescribing patterns in diabetic treatment according to age in Japanese patients with type 2 diabetes between 2012 and 2019 (JDDM 71). <b>2023</b> , 198, 110599	0
51	Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial. <b>2023</b> , 13,	0
50	Intensive glucose control and recurrent cardiovascular events: 14-year follow-up investigation of the ACCORDION study.	0
49	Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2. <b>2023</b> ,	0
48	Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study.	0
47	Glycaemic control in people with diabetes following acute myocardial infarction. <b>2023</b> , 199, 110644	0
46	Geriatric Syndromes in Older Adults with Diabetes. <b>2023</b> , 52, 341-353	0
45	Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review.	0
44	Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Volume 15, 137-149	0
43	Long-Term Visit-to-Visit Glycemic Variability as a Predictor of Major Adverse Limb and Cardiovascular Events in Patients With Diabetes. <b>2023</b> , 12,	1

- 42 Impact of diabetes mellitus severity, treatment regimen and glycaemic control on atrial fibrillation prevalence. A report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. ○
- 41 Metabolic Control, Diabetic Complications and Drug Therapy in a Cohort of Patients with Type 1 and Type 2 Diabetes in Secondary and Tertiary Care between 2004 and 2019. **2023**, 20, 2631 ○
- 40 Mean HbA 1c , HbA 1c Variability, and All-cause and Cardiovascular Disease related Mortality in Older Men with Type 2 Diabetes, a Retrospective cohort study: A Focus on Early Glycemic Control. ○
- 39 Vascular ageing: moving from bench towards bedside. 1
- 38 Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. **2023**, 12, 1382 ○
- 37 Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients?. 31-38 ○
- 36 GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ○
- 35 Long-term increase in fasting blood glucose is associated with increased risk of sudden cardiac arrest. **2023**, 22, ○
- 34 Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study. **2023**, 28, 107424842311563 ○
- 33 The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond. ○
- 32 ACSL1: A preliminary study that provides a new target for the treatment of renal fibrosis could bring new insights in diabetic kidney disease. **2023**, ○
- 31 Persistent post-bariatric-surgery hypoglycemia: A long-term follow-up reassessment. **2023**, ○
- 30 Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-11 ○
- 29 Longer time in blood pressure target range improves cardiovascular outcomes among patients with Type 2 diabetes: A secondary analysis of a randomized clinical trial. **2023**, 198, 110600 ○
- 28 Performance of the European Society of Cardiology 0/1-Hour Algorithm With High-Sensitivity Cardiac Troponin T Among Patients With Known Coronary Artery Disease. **2023**, 8, 347 ○
- 27 Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes. **2023**, 22, ○
- 26 Data-driven classification of health status of older adults with diabetes: The diabetes and aging study. ○
- 25 Association between hemoglobin glycation index and diabetic kidney disease in type 2 diabetes mellitus in China: A cross-sectional inpatient study. 14, ○

- 24 Paradigm shift of the medical care in diabetes. **2023**, 19, 32-41 ○
- 23 A framework for perioperative care for lower extremity vascular bypasses: A Consensus Statement by the Enhanced Recovery after Surgery (ERAS<sup>®</sup>) Society and Society for Vascular Surgery. **2023**, 77, 1295-1315 ○
- 22 Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22, ○
- 21 Cardiovascular Autonomic Neuropathy. **2023**, 203-220 ○
- 20 Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?. ○
- 19 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 18 Evaluation of glycosylated albumin levels in tears and saliva as a marker in patients with diabetes mellitus. **2023**, 110637 ○
- 17 Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. **2018**, 252-265.e1 ○
- 16 Deletion of smooth muscle O-GlcNAc transferase prevents development of atherosclerosis in western diet-fed hyperglycemic ApoE<sup>-/-</sup> mice in vivo. ○
- 15 Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. **2023**, 22, ○
- 14 Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction. **2023**, 221-232 ○
- 13 Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335 ○
- 12 Future perspectives for diabetic retinopathy management. **2024**, 265-295 ○
- 11 Management of diabetic kidney disease: where do we stand?: A narrative review. **2023**, 102, e33366 ○
- 10 Effect of optimized germination technology on polyphenol content and hypoglycemic activity of mung bean. 10, ○
- 9 Association of hemoglobin A1c stability with mortality and diabetes complications in older adults with diabetes. **2023**, 11, e003211 ○
- 8 Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study. **2023**, 58, 101934 ○
- 7 Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy. **2023**, 6, ○

- 6 Effects of glyceimic control on frailty: a multidimensional perspective. 1-11 ○
- 5 Trends in dietary patterns over the last decade and their association with long-term mortality in general US populations with undiagnosed and diagnosed diabetes. **2023**, 13, ○
- 4 Assessing How Clinicians and Staff Would Use a Diabetes Artificial Intelligence Prediction Tool (Preprint). ○
- 3 Geriatri sche Aspekte bei Diabetes mellitus (Update 2023). **2023**, 135, 307-318 ○
- 2 Diabetes Management and Outcomes among Patients with Type 2 Diabetes Attending a Renal Service. **2023**, 2023, 1-10 ○
- 1 Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023). **2023**, 135, 201-206 ○